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In white matter, axonal energy homeostasis critically depends on glial support. Failure in glial-
mediated delivery of metabolic substrates into the axonal compartment results in axonal 
energy deficit and may anticipate axonal degeneration observed in myelin disorders and 
several neurodegenerative diseases. In mice, transgenic expression of an ATP-sensor in neurons 
allowed us to visualize axonal energy content in acutely isolated optic nerves while 
simultaneously performing electrophysiological compound action potentials (CAP) recordings. 
The real-time monitoring of activity-dependent axonal ATP revealed a strong correlation 
between axonal energy fluctuations and nerve conduction. Importantly, upon pharmacological 
inhibition of endogenous lactate metabolism while under continuous glucose supply, ATP-CAP 
correlation was disrupted, suggesting that the axonal glycolysis products alone were 
insufficient to maintain axonal mitochondrial energy metabolism during spiking activity. To 
determine possible metabolic consequences of myelin defects we monitored ATP and CAP in 
Plp1-null optic nerves. Genetic ablation of Plp1, encoding a myelin membrane protein, serves 
as a model of spastic paraplegia type-2, where functional but structurally destabilized myelin 
sheaths lead to secondary axonal loss. We found that the energy metabolism of myelinated 
axons of Plp1-null optic nerves is perturbed long before the onset of clinical symptoms and 
major pathological changes. These observations motivated us to assess the metabolic 
properties of spinal cord fibres in vivo to allow long-term studies involving demyelination and 
remyelination models. The parallel monitoring of axonal ATP and CAP is a powerful tool to 
study white matter metabolism and metabolic support mechanisms under physiological 





1.1 Cellular metabolism and ATP production 
Metabolism is the series of biochemical reactions used by living beings for maintaining their structure 
and molecular organization in a quasi-stable state which is maintained by a steady state flux through 
metabolic pathways. Metabolism can theoretically be divided into two processes: anabolism and 
catabolism. Anabolism is the process of arranging smaller molecules into macromolecules essential 
to maintain cellular activity, by consuming or, less often, storing energy. Catabolism is the process 
that disintegrates organic molecules and macromolecules such as proteins, lipids and carbohydrates 
to release energy in its biochemical form, ATP. The main catabolic process happening in the brain is 
the oxidation of glucose, one of the simplest carbohydrate, into six molecules of CO2. The conversion 
of glucose into energy can be summarized as: 
𝐶6𝐻12𝑂6(𝑔𝑙𝑢𝑐𝑜𝑠𝑒) +  6𝑂2  →  6𝐶𝑂2  +  6𝐻2𝑂 +  𝐸𝑛𝑒𝑟𝑔𝑦 
The energy released by catabolic reactions can be stored in phosphoric acid anhydride bonds 
using adenosine nucleotide molecules as substrates, thus generating ADP and ATP. The opposite 
process, the hydrolysis of phosphoric acid anhydride bonds from ATP, yields ADP and phosphates, 
or AMP and pyrophosphate, as a result of an exergonic reaction releasing  7.3 kcal/mol or 
10.9 kcal/mol, respectively (Stryer, 1995). For its role in energy exchange between metabolic 
pathways, ATP is often referred to as the cell energy currency. ATP is generated by brain cells from 
glucose mainly via two metabolic pathways: glycolysis in the cytosol and the oxidative 
phosphorylation (OX-PHOS) in the mitochondrion, the latter mostly in combination with the 
production of NADH from the citric acid cycle (TCA).  
In order to generate ATP in the brain, glucose is initially uptaken by glial cells from the blood 
stream through the blood-brain barrier using GLUT-1 (McAllister et al., 2001). Within glial cells 
glucose is partially phosphorylated to glucose-6-phosphate by hexokinase, using one molecule of 
ATP. This is the first of the 10 reactions of glycolysis and during this preparatory phase, an additional 
ATP is consumed by phosphofructokinase to phosphorylate fructose 6-phosphate to fructose 1,6-
phosphate. The subsequent phase of glycolysis is the payoff phase that starts with the production of 
NADH by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and yields a total of four ATP, two 
NADH and two pyruvate molecules.  
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The fate of pyruvate is essential to understand whether a cell can metabolically support 
neighboring cells or whether its metabolism doesn’t allow for that. Pyruvate can be either reduced 
to lactate and released, or further oxidized in the mitochondrial TCA (Figure 1). Both lactate and 
pyruvate, can be endogenously produced or obtained exogenously from the extracellular space, and 
both can feed mitochondrial TCA/oxidative-phosphorylation, bypassing glycolysis. Consequently, 
pyruvate and lactate are intermediate metabolites, linking anaerobic and aerobic ATP production 
either within single cells or between cells, as a consequence of metabolic support. Lactate released 
by a glycolytic cell can be caught by a neighboring cell and converted into pyruvate, which can then 
be co-transported with a proton into the mitochondrial matrix and generate ATP.  
In the mitochondrial matrix, pyruvate undergoes decarboxylation to acetyl-CoA, along with 
reduction of NAD+ to NADH, by action of pyruvate dehydrogenase which uses coenzyme-A (CoA) as 
cofactor. Acetyl-CoA can also be provided by other metabolic pathways involving e.g., the catabolism 
of fatty acids (β-oxidation). Acetyl-CoA can enter the TCA cycle and be converted to citrate, a six-
carbon molecule, by citrate synthase which uses the four-carbon molecule oxaloacetate as substrate 
for the reaction. As a net gain for the cell, TCA cycle produces three molecules of NADH, one ATP 
and one QH2 (or one FADH2) along with two molecules of CO2 (waste) and regenerates oxaloacetate 
for the next cycle. All NADH molecules produced, either by glycolysis (which enter the mitochondrial 
matrix through the malate-aspartate shuttle) or by TCA, are used in the electron transport chain (ETC) 
as electron-donors. The process of oxidation of NADH to NAD+ and H+ is coupled, by mitochondrial 
complexes I-IV, to the transfer of protons across the inner mitochondrial membrane. The 
establishment of an electrochemical proton gradient drives the production of ATP, starting from ADP 
and inorganic phosphate, by the ATP synthase (Cooper & Hausman, 2007).  
Although total concentration of ATP has been estimated in brain tissue (i.e. 2.3 μmol/g of 
frozen murine brain tissue; Beis & Newsholme 1975), little is known about its steady state and its 
kinetics in single brain cell types under physiological conditions. It is predicted that for each molecule 
of glucose which gets fully oxidized in the cell, 29-30 molecules of ATP are produced by the 
combined activity of glycolysis and mitochondria respiration (Rich, 2003). In the brain, the 
maintenance of proper ATP homeostasis seems to be essential for neurons.  Alterations in ATP 
management have been described in a mouse model for Rett syndrome, suggesting a link between 
impaired ATP homeostasis and increased susceptibility to epileptic seizures (Toloe, Mollajew, Kügler, 
Introduction 
3 
& Mironov, 2014). The process of glucose oxidation is not always complete, yielding around 30 ATP 
molecules: pyruvate can in fact be transformed by lactate dehydrogenase (LDH) into lactate. Despite 
its inefficiency in ATP generation, this process of lactate formation can be used to quickly regenerate 
NAD+ (Keith Chenault & Whitesides, 1989) and to maintain high rates of anaerobic consumption of 
glucose via glycolysis, process relevant in cancer and known as Warburg effect (Liberti & Locasale, 
2016; Warburg, 1925).  
Lactate can consecutively be released and used to fuel ATP production by nearby cells: the 
process can be seen as metabolic support and is facilitated by transporters termed monocarboxylate 
transporters (MCTs). Four different types of MCTs, encoded by the SLC16A family of genes, are 
responsible for the proton-coupled transport of several monocarboxylates such as pyruvate, lactate 
or ketone bodies (acetoacetate and β-hydroxybutyrate): MCT1, MCT2, MCT3 and MCT4 (Morris & 
Felmlee, 2008). Different cell types express different MCTs: neurons express mainly MCT2 while glial 
cells, astrocytes and oligodendrocytes, express mainly MCT1-4 (Pérez-Escuredo et al., 2016; Pierre & 
Pellerin, 2005). The transporters differ mainly for their affinities to the substrates, having different Km 
values. For lactate MCT1 has a calculated Km of 3.5 – 10 mM, while MCT2 Km is between 0.5 – 0.75 
mM (Halestrap, 2012). This implies that, assuming a null cytosolic concentration for lactate, a cell that 
expresses MCT1 will uptake lactate in an extracellular sub-millimolar concentration very slowly, while 
a cell that expresses MCT2 will be more reactive in its uptake. Along with the knowledge of different 
glycolytic states, the expression of different MCTs poses the basis for the concept of metabolic 
support that uses lactate as a supporting metabolite both in gray and white matter (J. Hirrlinger & 





Figure 1. Main metabolic pathways in a living cell.  
Metabolic pathways contribute to generate ATP and maintain the structural and molecular organization of the cell (entire 
pathways are highlighted in red). Transporters allow substrates for the metabolic pathways to enter, and be released by, 
the cell. Glycolytic enzymes provide anaerobic production of ATP and are located in the cytoplasm. The glycolytic process 
is coupled to mitochondrial tricarboxylic acid cycle (TCA) and oxidative phosphorylation (OX-PHOS) mainly by pyruvate 
and the reducing equivalent NADH. Mitochondrial activity requires oxygen as electron acceptor in the electron transport 
chain (ETC) and relies on the electrochemical gradient of protons (H+) to generate ATP through the ATP synthase. 
Estimates calculate a production of 29 to 30 molecules of ATP per each molecule of glucose fully oxidized.  
Key enzyme are indicated in blue italics, HK: hexokinase; G6PD: glucose 6-phosphate dehydrogenase; LDH: lactate 
dehydrogenase; PDH: pyruvate dehydrogenase; SCOT: succinyl-CoA-3-oxaloacid CoA transferase; ACAT: Acyl-CoA 
cholesterol acyl transferase; BDH: beta hydroxybutyrate dehydrogenase. Entire metabolic pathways are indicated in red, 
PPP: pentose phosphate pathway; TCA: tricarboxylic acid cycle; ETC: electron transport chain. Reducing equivalent are 
labeled in green: NAD(P): Nicotinamide adenine dinucleotide (phosphate). Substrates: ATP: adenosine triphosphate; β-
HB: beta hydroxybutyrate; AcA: Acetoacetate; d-6GPL: 6-phosphoglucono-delta-lactone; R5P: Ribulose 5-phosphate. 




1.2 Metabolic support in gray matter – ANLSH 
The great metabolic demand of neurons is matched by a precise local regulation of blood flow 
and pressure (Magistretti, 2006). In the late 70s, it was possible to identify a coupling between 
neuronal activity and glucose consumption using 18-fluoro-DG imaging of glucose consumption by 
positron emission tomography (PET) (Sokoloff et al., 1977). Providing that neurons are never in 
contact with the vasculature, and a selective barrier is controlling the delivery of glucose and other 
metabolites, it is evident that glial cells are working as mediators for metabolism. More recently it 
has been shown that astrocytes can control the blood supply, possibly as the initial step for the 
metabolic support of neurons (Mulligan & MacVicar, 2004). In order to maximize this support, 
astrocytes are capable of perceiving and responding to synaptic activity by shuttling the metabolites 
uptaken from the blood stream. The detailed mechanisms through which astrocytes support neurons 
have been described by Pellerin & Magistretti in 1994 in a model that defines this neurometabolic 
coupling as the astrocyte-neuron lactate shuttle hypothesis (ANLSH).  
Starting from the classic 'bipartite' communication between the pre- and postsynaptic neurons, 
the intimate association of astrocytes with synapses has introduced the concept of the ‘tripartite 
synapse’, i.e. the functional integration of pre and post synapse with the neighboring astrocyte. 
According to the ANLSH astrocytes are capable of sensing the neuronal activity and, by increasing 
their own anaerobic metabolism, release lactate to support the perceived higher demand for 
substrates. This neurometabolic coupling mediated by astrocytes starts with the release of glutamate 
neurotransmitters from the pre-synapse, following with the arrival of an action potential. The 
astrocytes processes that are surrounding the synapse remove the glutamate by taking it up via 
sodium co-transport. The cytosolic increase in sodium concentration activates the Na/K ATPase 
which pumps out three Na+ by hydrolyzing one molecule of ATP. The sudden increase in ATP 
consumption triggers the astrocytes to enhance the local uptake of glucose from the vascular lumen. 
The fate of glucose taken up in a glutamate-dependent way, is mainly lactate production, indicating 
an activation of aerobic glycolysis in astrocytes (Pellerin & Magistretti, 1994). A modulator-signal 
from astrocytes seems to be responsible for the metabolic adaptation of neurons: ascorbic acid. 
Ascorbic acid is the reduced form of vitamin-C and it is highly concentrated in the human brain (14 
mg/100 g of wet tissue; Hornig, 1975). Besides its well-known function as antioxidant, ascorbic acid 
has been reported to regulate metabolism in cultured neurons (Beltrán et al., 2011; Castro et al., 
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2007; Castro, Beltrán, Brauchi, & Concha, 2009). After its release by astrocytes, triggered by glutamate 
stimulation, ascorbic acid is taken up by the neurons in a sodium dependent co-transport. The rise 
in intracellular sodium in neurons stimulates lactate and inhibits glucose uptake (Castro et al., 2007, 
2009). Gray matter astrocytes are thus fulfilling several tasks with the common aim of keeping 
neuronal transmission efficient at the synaptic level: I) cleaving neurotransmitters from the synaptic 
cleft (Stobart & Anderson, 2013; Swanson, 2004; Y. Zhang & Barres, 2010), II) control local blood 
supply (Mulligan & MacVicar, 2004) and lactate delivery (Magistretti, 2006; L Pellerin & Magistretti, 
1994) and III) signaling neighboring neurons to metabolically switch towards more aerobic ATP 
production derived from mitochondrial oxidation of lactate (Castro et al., 2007, 2009). 
The ANLSH implies that neurons, especially under conditions of synaptic activation, are 
producing ATP mainly by oxidative phosphorylation, while astrocytes are mainly glycolytic and 
provide lactate as energy substrate to neurons (Magistretti, 2006; L Pellerin & Magistretti, 1994; Luc 
Pellerin, 2003). Although this hypothesis originally based on in vitro studies fits many in vivo 
observations using PET, fMRI, and MRS (Figley & Stroman, 2011; Lin, Gao, Duong, & Fox, 2010) it still 
remains a matter of debate. For example, evidence suggests that cultured glutamatergic cerebellar 
neurons seem to preferentially use glucose and not lactate during synaptic activation via NMDA (Bak 
et al., 2009) and that lactate, compared to glucose, has an inferior influence on maintaining ATP 
homeostasis (Lange et al., 2015). Furthermore, the overall glucose, lactate and oxygen balance in the 
brain is not favoring the ANLSH (Dienel, 2012). Along this line and in opposition to the ANLSH, the 
evidence of an increased neuronal NADH:NAD+ ratio in the stimulated brain of awake mice, seems 
to corroborate the idea of a preferential anaerobic metabolism in neurons in response to increased 
energy demand by neuronal activation, independent from lactate support by neighboring glial cells 
(Díaz-García et al., 2017). A recent study however showed the existence of a lactate gradient between 
astrocytes and neurons in awake mice (Mächler et al., 2016). Therefore, lactate metabolism and 
neuro-glia metabolic adaptations in the brain seem to be rather intricate, with results varying based 





1.3 Metabolic support in white matter 
 Although white matter consumes on average less glucose than gray matter does (3.80 
mg/100 g per min, white matter, 8.05 mg/100 g per min, gray matter; Reivich et al., 1979), white 
matter neuronal axonal projections require considerable metabolic support from neighboring glial 
cells. The main energy consuming tasks for established projecting fibers are the maintenance of 
membrane potential, the AP propagation, and other housekeeping activities, such as the axonal 
transport of proteins, vesicles and organelles to the pre-synaptic terminals. Together with other 
housekeeping processes, axonal transport accounts for about 25% of energy consumed (calculated 
in 6.88 ∙ 1022 ATP molecules/m3/s; Harris & Attwell, 2012) and requires continuous microtubule 
polymerization (GTP-dependent process) which offers a solid track along which molecules can move 
through the ATP-powered activity of motor proteins (e.g. kinesin and dynein; Stryer, 1995). Any 
perturbation of this process contributes to pathological events that lead to neurodegeneration, as 
observed in multiple diseases such as amyotrophic lateral sclerosis (ALS) and hereditary spastic 
paraplegia (HSP; Millecamps & Julien, 2013). The propagation of action potentials along axons is also 
an ATP-dependent process: in order to maintain the ability of conducting action potentials (APs) 
axons need to maintain a negative membrane potential (around -70 mV) by establishing and keeping 
ion gradients across the membrane by action of Na/K-ATPase. The maintenance of the membrane 
resting potential and the constant transfer of APs, combined account for most of the remaining 
axonal energy needs (Harris & Attwell, 2012). At each AP propagation, voltage dependent ion 
channels let the ions follow their respective gradient generating current (i.e. flux of electric charges): 
initially, sodium ions flow into the axonal compartment and at the AP peak (depolarization) the 
potassium ions exit the axon, thereby inverting the current and repolarizing the membrane. By the 
end of the AP, the gradients of both ions have to be restored by Na/K-ATPase to allow propagation 
of a second AP.  
 In myelinated axons, less energy is needed compared to unmyelinated fibers (Stiefel, 
Torben-Nielsen, & Coggan, 2013). The lower energy requirement for AP propagation introduced by 
myelin, comes from the electrical insulation which allows saltatory AP conduction instead of wave-
propagation, i.e. AP are localized events at the Nodes of Ranvier (Harris & Attwell, 2012; Hartline & 
Colman, 2007; Waxman, 1977). However, a disadvantage of the insulation provided by myelin is the 
physical barrier it represents for the axon, limiting its free-access to extracellular substrates and 
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energy supply. In white matter, most of the surface of the axon is in fact ensheathed by several layers 
of lipid membranes, leaving only a few percent of ‘naked axon’ in correspondence of the Node of 
Ranvier (Nave, 2010). Therefore, while myelin provides both, the benefit of an enhanced velocity of 
AP propagation and energy-saving saltatory conduction, it restricts the transfer of substrates from 
the extracellular reservoir of metabolites into the axon (J. Hirrlinger & Nave, 2014). However, this 
restriction might be overcome by the supply of energy substrates directly from oligodendrocytes 
and their myelin to the axon. 
 In a series of pivotal experiments addressing energy metabolism in acute optic nerve 
preparations as a model system for white matter tracts, it has been reported that axonal AP 
propagation, measured as compound action potentials (CAP; the integrated activity of all axons 
within the nerve), can be fueled by several different substrates including glucose, fructose, lactate 
and pyruvate (Brown, Wender, & Ransom, 2001). Furthermore, when the nerves were challenged by 
high frequency stimulation or by ischemic conditions mimicked via oxygen-glucose-deprivation 
(OGD) the functional conduction could be maintained for a short time window thanks to glycogen, 
stored in astrocytes and mobilized as lactate, which could be conveyed to axons for energy 
production (Brown, Baltan Tekkök, & Ransom, 2004; Brown, Tekkök, & Ransom, 2003; Tekkök, Brown, 
Westenbroek, Pellerin, & Ransom, 2005). When provided in replacement of glucose, lactate was able 
to sustain optic nerve’s CAP indicating that this metabolite can supply mitochondrial TCA and ATP 
production in axons bypassing glycolysis (Brown et al., 2003, 2001). Remarkably, several other 
substrates that could be used by cells to produce energy (e.g. octanoate, sorbitol, alanine, aspartate, 
and glutamate) failed to support axonal function. Among these substrates also β-hydroxybutyrate, 
normally produced by the liver under ketogenic conditions, unexpectedly failed to maintain CAP in 
isolated optic nerves (Brown et al., 2001). 
 Besides astrocytes, it was recently discovered that also oligodendrocytes metabolically 
support axons by providing lactate to the axons they ensheath (Fünfschilling et al., 2012) and the 
failure of this support mechanism leads to a progressive loss in small caliber axons, as displayed by 
the MCT1+/- mutant mice, a model for amyotrophic lateral sclerosis (ALS; Lee et al., 2012). This opens 
to two possible scenarios where oligodendrocytes are leading the metabolic support using their 
myelin as a functional bridge for the delivery of substrates: I) lactate in particular, provided by 
glycolytic astrocytes, might reach oligodendrocytes via gap junctions and be shuttled to the axon, 
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thereby avoiding the bottle neck of the transport at the nodes of Ranvier (J. Hirrlinger & Nave, 2014); 
II) lactate is produced by glycolytic oligodendrocytes themselves to fuel axons (Fünfschilling et al., 
2012). The importance of oligodendroglial support to axons is emphasized by the axonal loss 
described in in PLP1 knock out mice. In PLP1KO mice the genetic ablation of PLP/DM20, thought to 
influence myelin sheath stability (Duncan, Hammang, Goda, & Quarles, 1989) affects primarily 
oligodendrocytes but leads to axonal pathology with described impairment of fast axonal transport 
(Edgar et al., 2004) and morphological defects. The axonopathy parallel between PLP1KO and MCT1het 
(Lee et al., 2012), is reminiscent of that shown by mouse models of mitochondrial diseases 
(Ferreirinha et al., 2004; Tarrade et al., 2006), suggesting that energy failure in the axons is a crucial 
aspect of disease progression in vivo.  
 A metabolic support from oligodendrocytes also implies a regulation mechanism to 
maximize energy production and communication between axons and oligodendrocytes, and vice 
versa, seems to be required (Micu, Plemel, Caprariello, Nave, & Stys, 2018). Although authors often 
refer to it as “axo-glia” or “axo-myelinic” synapse (Stys, 2011), the mechanisms through which axons 
communicate to oligodendrocytes and astrocytes, substantially differ from those observed in gray 
matter and theoretical models are still at their infancy. Neurons can release neurotransmitters (NTs) 
via vesicles fusion along the axonal membrane, without a specialized synaptic apparatus (Fields, 
2011). The released NTs activate specific ionotropic and metabotropic receptors on the adaxonal side 
of myelin. The vesicular release of NTs exhibit low rates of spontaneous release (Bergles, Roberts, 
Somogyi, & Jahr, 2000) and can happen in activity-dependent manner (Stevens & Fields, 2000), as 
demonstrated by the astrocytes depolarization in response to retinal stimulation (Orkand, Nicholls, 
& Kuffler, 1966). Interestingly the axonal vesicular release of NTs seems to play a role in development, 
during white matter myelination-initiation by oligodendrocytes precursors cells (De Biase, Nishiyama, 
& Bergles, 2010). The evidence of neuronal vesicular NT release, in activity-dependent manner, 
influencing myelination was provided by interfering with synaptic vesicle release of 
neurotransmitters: Tetanus toxin, by inhibiting axonal vesicular fusion and NT release, directly impairs 
myelination (Mensch et al., 2015). Vice versa, artificial stimulation of neuronal activity increases 
myelin sheath formation (Mensch et al., 2015).  Besides the role in controlling and establishing 
myelination, the axonal NT release controls the trophic support of axons by modulating glial 




Figure 2. Proposed axo-glia metabolic coupling in white matter.  
Following myelination, oligodendrocytes contribute to support axonal energy homeostasis by shuttling metabolites 
(mainly lactate) into the axonal compartment, following functional activation of oligodendrocytic NMDAR facing the 
periaxonal space. The signaling cascade triggered by NMDAR likely involves Ca2+ and drives the insertion of GLUT1 into 
oligodendrocytes’ plasma membrane. The inserted GLUT1 increase glucose flow into the oligodendrocyte and support 
the anaerobic production of lactate via glycolysis, which can be shuttled into the active axon. Astrocytes are connected 
via gap junctions to oligodendrocytes and take part to this metabolic interplay by supporting the axons at the nodal 
regions. Glc: glucose; pyr: pyruvate; lac: lactate; glt: glutamate; MCT: monocarboxylate transporter; GLUT: glucose 
transporter; GJ: gap junction; OX-PHOS: oxidative phosphorylation; NMDAR: N-Methyl-D-aspartate receptor. ATP: 
adenosine triphosphate. Adapted with permission from Hirrlinger & Nave, 2014.  
 
 
 A step towards the understanding the link between the contribution of oligodendrocytes 
to axonal metabolic support (Fünfschilling et al., 2012) and the role of axonal NT release in 
modulating was represented by the findings that: I) oligodendrocytes mobilize their GLUT1 glucose 
transporter upon NMDAR stimulation; II) myelinated optic nerves from cNR1KO (oligodendrocyte-
conditional NMDA receptor knock-out), challenged with oxygen-glucose deprivation (OGD), fail to 
recover when returned to oxygen-glucose but are indistinguishable from wild-type when provided 
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with oxygen-lactate; III) NMDA preincubation of isolated optic nerves enhances their functional 
integrity (Saab et al. 2016).  
 In most of these studies, axonal energy status has been estimated indirectly by analyzing 
CAP-maintenance or morphological damage as functional readout, linked to energy maintenance 
and failure. Although it is logical to think to a correlation between conduction and energy state in 
white matter, the latter is better defined by the cellular redox state and ATP content. Other factors in 
fact, can influence the functional readout represented by nerve conduction and direct conclusions 
on the ATP content or redox state of axons might not be as trivial. To provide a better in depth 
understanding of white matter energetics, we imaged axonal ATP directly, by taking advantage of 
the genetically encoded fluorescent sensor for ATP “ATeam1.03YEMK” (Imamura et al., 2009). 
Transgenic mice with neuronally-targeted expression of this sensor were generated and used to 
simultaneously monitored CAPs and ATP in excised optic nerves ex vivo.  
 
1.4 Genetically encoded FRET sensors for metabolites 
Fluorescence resonance energy transfer (FRET) is a non-radiative mode of energy transfer via 
dipole-dipole interaction between two different fluorophores termed FRET pairs. The FRET pairs 
consist in the donor and the acceptor fluorophores and these have to be closely associated in space, 
usually within few nanometers (Pawley, 2006). The donor fluorophore, upon excitation, releases 
energy while the acceptor absorbs part of this energy. The emission spectrum of the donor typically 
overlaps with the excitation of the acceptor fluorophore. The amount of non-radiative energy 
transmission is described by the quantum yield Φ, which can be defined via transfer rate constants 
of the different decay channels k: 
Φ𝑑𝑜𝑛𝑜𝑟 =
k𝑑𝑜𝑛𝑜𝑟,𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑣𝑒
k𝑑𝑜𝑛𝑜𝑟,𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑣𝑒  +  k𝑑𝑜𝑛𝑜𝑟,𝑛𝑜𝑛−𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑣𝑒
 
The acceptor thus, acts as a quencher and the closer the acceptor comes to the donor, the 
more energy can be transferred non-radiatively, altering the donor quantum yield: 
Φ𝑑𝑜𝑛𝑜𝑟,𝑎𝑐𝑐𝑒𝑝𝑡𝑜𝑟 =
k𝑑𝑜𝑛𝑜𝑟,𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑣𝑒




This defines the efficiency of FRET (EFRET) as a dimensionless value that measures what fraction 
of the transferred energy is conveyed via non-radiative dipole-dipole interaction: 




FRET efficiency is maximal when the dipole moments are in the same plane and aligned. What 
ultimately drives the energy transfer is thus the electromagnetic interaction between the emission 
and absorption dipole moments of donor and acceptor, respectively (Pawley, 2006).  
Genetically encoded metabolite sensors are chimeric proteins that take advantage of FRET 
between a donor and an acceptor fluorophores. The strategy to genetically assemble these fusion 
peptides, is to genetically modify a protein that normally binds the metabolite of interest (e.g. for 
ATP, the bacterial ε subunit of the FoF1-ATP synthase from Bacillus subtilis; Imamura et al., 2009) and 
link it to FRET-pairs at N- and C- termini. In order to correlate changes in concentration of the 
metabolite of interest the construct has to satisfy the following requirements: I) the binding to the 
metabolite of interest has to happen within the biologically-relevant concentration range of the 
target metabolite (i.e. the binding affinity of the sensor has to be as close as possible to the 
physiological concentration of the target metabolite); II) upon binding of the metabolites to its core, 
the sensor has to undergo a conformational change which results in a spatial repositioning of the 
FRET pairs; III) the dipole moments of the FRET pairs have to be oriented in parallel and correctly 
spaced in order to maximize FRET and the conformational change of the sensor has to determine a 
change in the orientation of the dipoles (the larger the change in dipoles orientation, the better the 
signal-to-noise of the sensor). Most FRET pairs used so far for genetically encoded metabolite 
sensors are CFP-YFP variants, but recently also red-shifted combination (e.g. mClover3/ mRuby3 
provide wide FRET dynamic range; Bajar, Wang, Zhang, Lin, & Chu, 2016) have been described. 
Different FRET pairs carry different advantages/ disadvantages. A special combination of FRET pairs 
occurs when the acceptor is a dark fluorophore (e.g. YFP mutants, REACh (resonance energy-
accepting chromoprotein, originally engineered as acceptors for EGFP; Ganesan, Ameer-Beg, Ng, 
Vojnovic, & Wouters, 2006), i.e. a fluorophore with very low quantum yield that are employed in 
FRET-FLIM. Dark acceptors offer, in this imaging technique, the considerable advantages of I) 
diminishing the bleed-through from the acceptor into the donor emission channel; II) improving 
FRET dynamic range; III) reducing phototoxicity as result of less excitation needed; IV) introducing 
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the possibility of using more fluorophores of different colors simultaneously as consequence of a 
narrower spectrum required by the FRET pairs (Bajar et al., 2016).  
The first genetically encoded sensor for a molecule involved in energy metabolism was a 
glucose sensor based on a modified bacterial periplasmic glucose/galactose-binding protein: several 
sensors with different binding affinities for glucose were described (FLIP series; Fehr, Lalonde, Lager, 
Wolff, & Frommer, 2003). The glucose sensor was quickly followed by genetically encoded sensors 
for glutamate (FLIPE, iGluSnFR; Marvin et al., 2013; Okumoto et al., 2005), ATP (ATeam, GO-ATeam, 
PercevalHR; Imamura et al., 2009; Nakano et al., 2011; Tantama et al., 2013), NADH/NAD+ (Peredox; 
Hung, Albeck, Tantama, & Yellen, 2011), lactate (Laconic; San Martín et al., 2013) and pyruvate 
(Pyronic; San Martín et al., 2014). 
The ATeam series were the first FRET sensors described for ATP: ATeam1.03 (Kd = 3.3 mM), 
ATeam3.10 (Kd = 7.4 μM), ATeam1.03
YEMK (Kd = 1.2 mM) and AT3.10
MGK (Kd = 14 μM). The ATeam 
sensors with higher affinity (low Kd) derived from a construct which employed a different ε subunit 
(PS3; about 70% homology from the ε subunit used in the ATeam1.03 series) of the FoF1-ATP synthase 
from Bacillus subtilis. The YEMK and MGK amino acid substitution around residues 60th and 132nd 
respectively of the N-terminal β-sandwich domain and C-terminal α-helical domain of the ε subunit, 
helped to tune the affinity for ATP (Imamura et al., 2009). GO-ATeam is a red-shifted ATP variant of 
the ATeam series, in which green fluorescent protein (GFP, mEGFP) and orange fluorescent protein 
(OFP, mKOκ) substituted the mseCFP and mVenus FPs. GO-ATeam is reported to have less affinity 
for ATP than all ATeam sensors, with a Kd = 7.2 mM and showed improved pH tolerance in more 
acidic environments, in addition, the red-shifted FRET pairs allowed less phototoxic wavelengths 
(Nakano et al., 2011). Finally, PercevalHR (Tantama et al., 2013) is an improved (in terms of sensitivity 
range and fluorescence response) version of the original Perceval (Berg, Hung, & Yellen, 2009). 
Perceval are single cpFP sensors for ADP:ATP ratio and have fixed isosbestic point for absorbance at 
455 nm. By exciting Perceval above (550 nm) and below (420 nm) it is possible to determine the 




1.5 FLIM – FRET detection 
Fluorophores are excitable biomolecules that emit light particles (photons) upon de-excitation 
from an excited state caused by photon absorption. The emitted photon has less energy than the 
absorbed one and this produces a wavelength shift (Stokes shift). Intensity-based measurements of 
FRET ratio in living tissues carry one pitfall which is represented by the nature of FRET itself, i.e. the 
donor and acceptor fluorophores’ different emission wavelengths λ. Photons with higher frequencies 
(shorter λ) are scattered more than photons with lower frequencies (long λ): this phenomena is known 
as “Rayleigh scattering” which relates the amount of scattering to 1/λ. In microscopy, the higher the 
scattering of fluorescent light through a phase, the less the photon yield (or count) at the detector. 
It follows that, assuming constant conformation of a FRET probe, by moving the focus along the z-
axis while imaging a tissue, donor’s fluorescence intensity is lost faster than acceptor’s fluorescence 
at increasing depth, resulting in an artefactual change of the calculated FRET ratio and misleading 
data interpretation. Therefore, in biological context, Rayleigh scattering effect during FRET intensity-
measurements, poses an additional problem when a calibration of the probe is required.  
In order to translate a biologically-relevant ratio into a define concentration of substrate, for 
which the FRET-probe is sensitive, the FRET probe should undergo a calibration procedure and any 
artifact contribution, caused by e.g. the Rayleigh scattering, should be accounted for when fitting the 
calibration curve to the measured data. The relationship of FRET-ratio and substrate binding is 
described by the Hill equation (Figure 3B). In order to reconstruct the relationship between 
ratiometric fluorescence intensity and substrate concentration, it is customary to expose the FRET 
probe to a range of substrate concentrations around its dissociation constant. In cells, the calibration 
is achieved by equilibrating the extracellular solution with the cytosol of the cell and, depending on 
the sensed metabolite, by blocking its production and/or consumption. Many metabolites have their 
dedicated transporter (e.g. glucose, lactate, glutamate) which can be used for this purpose. However, 
ATP and other molecules relevant for metabolism, have no dedicated transporter and their 
equilibration in the cell requires cell membrane permeabilization. The calibration procedure will also 
require equilibration of the metabolites of interest in the same environment of the experimental 
condition to avoid artifact contribution. However, permeabilization of the phospholipid membranes 
in a highly organized tissue can be arduous as often results in considerable damage and lading to 
an altered structural organization and consequently, undesired changes in the focal plane. Also, any 
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attempt of calibration in cells will make the calibration curve not-usable for complex tissue in view 
of the mentioned Rayleigh effect. We therefore used an alternative imaging method which is 
relatively insensitive to photobleaching and photon scattering: fluorescence lifetime imaging 
microscopy (FLIM; Marx, 2017). FLIM measures the characteristic decay curves of fluorophores from 
which the corresponding lifetimes can be extracted. Taking ATeam1.03YEMK as example for a FRET 
sensor, in FRET-FLIM analysis the relevant moiety of the sensor is the donor (mseCFP, for 
ATeam1.03YEMK) and its quenched state is reported as an indirect measure of the proximity of the 
acceptor (i.e. FRET). In correspondence of high FRET (e.g. ATeam1.03YEMK saturated by ATP and in 
“close” conformation) the donor fluorophore is highly quenched by the acceptor and its lifetime 𝛵av-
w is very short: this condition occurs when a cell is in its resting state and a lot of ATP is present (in 
mM order, Pathak et al., 2015; Rangaraju, Calloway, & Ryan, 2014). FLIM provides a quantitative way 
of expressing FRET and, given its relative independence to phenomena such as the Rayleigh 
scattering, calibration curves obtained in cells can be used to derive ATP concentrations in tissue 











The general aim of this thesis is to study white matter metabolism with a special focus on the 
underlying mechanisms of axo-glia metabolic coupling. What is the correlation between metabolism 
and axonal ability of transmitting action potentials to the synaptic terminals? How are glial cells 
contributing to the functional integrity of axons in white matter? This study aims at contributing to 
the answer to those questions and aims at understanding the functional link that connects 
metabolism to the axonal activity.  
To achieve these goals a white matter model is used: the optic nerve. The optic nerve can be 
isolated and used as an ex-vivo system that preserves white matter structure. Two state of the art 
techniques are combined to allow the synchronized monitoring of nerve conduction and axonal ATP 
as readout for metabolism. 
Thus, by simultaneously monitoring optic nerve CAP and axonal ATP, our aims can be 
summarized: I) describe the axo-glia metabolic coupling under physiological conditions; II) test the 
hypothesis that designates lactate as the central metabolite for metabolic coupling; III) understand 
the role of glial cells in providing support during phases of transient energy deprivation and identify 
the possible metabolic pathways involved in axonal ATP homeostasis; IV) identify the pathological 
implications of  impaired axonal metabolism in models of neurodegeneration where the axo-glia 








3.1 Ateam1.03YEMK and ThyAT transgenic mouse line 
Genetically encoded ATP-sensor ATeam1.03YEMK reports ATP levels with very high spatial and 
temporal accuracy (Imamura et al., 2009). We used ATeam1.03YEMK to track axonal ATP for studying 
white matter metabolism and the contribution of glial cells to axonal energy homeostasis during 
electrical activity. ATeam1.03YEMK binds directly to ATP via the bacteria-derived ε-subunit of the FoF1-
ATP synthase. The binding produces a conformational change of the sensor resulting in a spatial 
relocation of the genetically linked fluorophores (FRET-pairs) mseCFP and mVenus at the N- and C 
terminus of the ε-subunit, respectively (Figure 3A). In absence of ATP, ATeam1.03YEMK is in its “open” 
configuration, permitting poor FRET between the two fluorophores. The binding of ATP molecules 
to the sensor produces a reorientation of the fluorophores’ dipoles in the FRET pairs and 
consequently an increase in FRET. The binding kinetics of ATeam1.03YEMK are described by the Hill 
equation (Figure 3B), following the typical sigmoidal course of a positively cooperative binding, 
having its Kd (apparent dissociation constants) equal to 1.2 mM (Imamura et al., 2009).  
 
Figure 3. ATeam1.03YEMK is a genetically encoded FRET sensor for ATP 
(A) Binding of ATP induces a conformational change in the genetically encoded ATP-sensor ATeam1.03YEMK thus increasing 
the FRET effect (YFP emission upon CFP excitation) and simultaneous decreased emission of CFP (upon CFP excitation). 
The ratio between FRET and CFP can thus be correlated to the concentration of ATP present in the cell. 
(B) ATP-binding kinetic of ATeam1.03YEMK reported as FRET/CFP (F/C) ratio, follows a positively cooperative binding with 
a calculated Kd of 1.2 mM and n (Hill coefficient) of 2.1 (Imamura et al., 2009). 
 
 
We generated transgenic mice for pan-neuronal in vivo expression of this sensor driven by 
the murine Thy1.2 promoter (Caroni, 1997). Upon pronuclear microinjection into the fertilized mouse 
oocytes, 21 copies of the transgene were inserted into the mouse genome, creating a new line [B6-
Tg(Thy1.2-ATeam1.03YEMK)AJhi, also referred to as ThyAT]. The transgenic ThyAT mouse line 
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displayed widespread neuronal expression (Figure 4). In the retina, fluorescence marked ganglion 
cells and their axons (Figure 4G-H) project to the thalamic lateral geniculate nucleus through the 
optic nerve (Figure 4I-K). 
 
 
Figure 4. Characterization of the expression pattern of the newly generated B6-Tg(Thy1.2-ATeam1.03YEMK)AJhi (ThyAT)-
mouse line.  
(A) Sagittal section of the brain highlights broad ATeam1.03YEMK expression in neurons in almost all brain regions with the 
exception of the olfactory bulb. Scale bar: 1 mm. (B), (C) ThyAT expression pattern in coronal brain sections revealing 
sensor expression e.g. in thalamus, hypothalamus, amygdala, cortex and hippocampus Scale bar: 1 mm. Abbreviations 
used in panels A-C are: AV: arbor vitae; BLA: basolateral amygdalar nucleus, anterior; CA1: CA1 region of the 
hippocampus; cc: corpus callosum; Cf: columns of the fornix; CN: cerebellar nuclei; Cp: cerebral peduncle; CPu: caudate 
putamen; Fi: fimbria; IC: inferior colliculus; ic: internal capsule; LH: lateral area of the hypothalamus; M: medulla; opt: 
optic tract; P: pons; S: subiculum; SC: superior colliculus; SMA: somato-motor area (Cortex); SN: substantia nigra; st: stria 
terminalis; T: thalamus; Zi: zona incerta (thalamus). Scale bar for B, C: 1mm. (D) Within the cortex, neurons expressing 
ATeam1.03YEMK are clearly visible including their processes. Note the lack of ATP-sensor localization to the nucleus. Scale 
bar: 100 μm. (E) Also in the hippocampus neurons strongly express ATeam1.03YEMK. Scale bar: 100 μm. (F) In the 
cerebellum, Purkinje cells express the ATP-sensor. In addition, incoming mossy fibers strongly express ATeam1.03YEMK. 
Scale bar: 100 μm. Images in panels A, D-F are obtained on brain slices from a 4 month old animal, images in panels B and 
C are from mice at the age of 2 month. (G) Expression pattern of the ATP-sensor in the retina. Thy1.2 promoter drives 
the expression of ATeam1.03YEMK in ganglion cells. Scale bar: 1 mm. (H) Magnified view of neurons and axons in the retina 
expressing ATeam1.03YEMK. Scale bar: 100 μm. (I), (J), (K) Representative images of optic nerve axons showing the YFP 
channel (I), FRET channel (J) and CFP channel (K). The ATeam1.03YEMK expression is present in different axons independent 
of their diameter. Scale bar: 10 μm.  
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To initially assess functionality of the genetically encoded ATP FRET-reporter in the ThyAT 
line, we prepared primary mixed cultures from mouse E-13 embryos. Subsequently, we monitored 
the ATeam1.03YEMK signal in transgenic expressing neurons (Figure 5) while inducing intracellular ATP 
changes using a live-imaging epifluorescence microscope. We challenged neuronal energy 
metabolism by exposing neurons to glutamate, different concentrations of potassium, Na/K-ATPase 
block and inhibitors for glycolytic flux/TCA cycle while monitoring intracellular neuronal ATP levels. 
Under glutamate and potassium stimulation the intracellular ATP concentration has been previously 
reported to be considerably affected (Foo, Blumenthal, & Man, 2012). We found consistent decreases 
under all mentioned treatments. The strongest effect was observed under simultaneous exposure to 
1 mM iodoacetic acid and 5 mM azide (blockers of glycolysis and OX-PHOS respectively, Figure 5B-
C). Notably, after 10 min of glutamate stimulation, the ATeam1.03YEMK ratio dropped by 60% from its 
baseline value. This factor was comparable to that reported by Foo et al. (2012) where ATP was found 
to be reduced of about 50%, when neurons where exposed to 50 μM glutamate for 60 min. However, 
given the sample number was limited (n = 1, 4 neurons), additional experiments are necessary in 





Figure 5.  The ATP sensor Ateam1.03YEMK in cultured neurons detects ATP fluctuations during different treatments.  
Primary neuronal cultures were prepared from transgenic mice expressing the ATP sensor Ateam1.03YEMK in neurons and 
ATP levels were monitored using live cell fluorescent imaging. Soma and processes from neurons are indicated in dark-
gray and orange respectively. (A) ATP responses to subsequent increase/decrease in extracellular potassium and 
increase/decrease in extracellular sodium (K+ = 20 mM/ Na+ = 147 mM and K+ = 1 mM/ Na+ = 166 mM, red box and blue 
box respectively) from the physiological sodium-potassium concentrations (161 mM and 5.4 mM respectively) followed 
by exposure to 100 μM ouabain (Na/K-ATPase blocker). (B) Blockade of ATP production with exposure to iodoacetic acid 
(1 mM, irreversible glycolysis blocker) and azide (5 mM, reversible OX-PHOS inhibitor) produces a fast and steep decay in 
the FRET-ratio. (C) Neuronal ATP fluctuates under subsequent exposure to glutamate/lactate, glutamate/glucose and 
iodoacetic acid/azide. Traces represent single experiments (neurons from a single mixed culture) variable number of cells 
(2-6 cells, 3-9 processes). 
 
 
Nevertheless, given the consistency of the decay of ATeam1.03YEMK signal in correspondence 
to each of the treatments, we proceeded to investigate ATP dynamics in white matter. Given our 
primary aim of correlating axonal energy metabolism during electric activity, we acutely isolated optic 
nerves from adult ThyAT mice, assessing axonal ATP levels by confocal microscopy while 





Figure 6. Imaging of ATP combined with electrophysiology in acutely isolated optic nerves of ThyAT-mice.  
(A) Schematic representation of the set-up to acquire evoked CAPs in the optic nerve and to simultaneously investigate 
relative ATP levels by electrophysiology and confocal imaging, respectively. (B) Transition of the CAP waveform, acquired 
every 30 s, from baseline (dashed line) to exposure to MB + GD). The shaded area indicates the area under the CAP wave 
form considered for analysis. (C) Time course of fluorescence intensity recorded in the YFP, FRET and CFP- channels during 
application of mitochondrial blockage (MB) and glucose deprivation (GD) for 2.5 min. Values are normalized to YFP 
intensity prior to application of MB + GD (n = 3 nerves). Time resolution: 10.4 s. (D) The combination of MB and GD is a 
fast and reliable way to deplete ATP in axons of the optic nerve. ATP depletion is measured as a decrease in FRET and 
increase in CFP, calculated as ratio between fluorophore intensity during MB + GD, over fluorophore intensity at baseline 
condition (MB + GD/Baseline). Notably, YFP emission upon YFP excitation remains unchanged (n = 5 nerves). (E) FRET/CFP 
ratio values (not normalized) during baseline and MB + GD. The boxplots show summarized data of n = 19 nerves, lines 
in between boxplots show changes in the FRET/CFP ratio of all 19 individual nerves. (F) Ratiometric images displaying the 
FRET/CFP ratio of the ATeam1.03YEMK sensor in the axons of the optic nerve during ATP depletion following MB + GD. The 
phases before (Baseline) and after (Recovery) are also shown. Scale bar: 10 μm.   
Asterisks in (E) indicate significant differences among conditions: ***p < 0.001; Welch’s t test. 
 
 
Expression of the ATP-sensor in myelinated axons appeared robust in all recorded channels 
(Figure 4 I-K; see methods for imaging acquisition details). To verify sensor function also in the ex 
vivo preparations of optic nerve, we subjected the nerve to mitochondrial OX-PHOS blockade and 
simultaneous glucose removal (MB + GD). An immediate drop of the FRET signal (gray trace, Figure 
6B) and an increase in CFP emission (blue trace) indicated that ATP levels in axons dropped. Changes 
in pH can modulate YFP-fluorescence (Nagai, Yamada, Tominaga, Ichikawa, & Miyawaki, 2004), thus 
provoking an artefactual change in the recorded FRET channel. Even though ATeam1.03YEMK has been 
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reported to be almost insensitive to pH variations within the physiological range (Imamura et al., 
2009; Surin et al., 2014) we systematically monitored the acceptor fluorescence by direct 
excitation/emission during all reported experiments. During MB + GD the acceptor fluorescence was 
unchanged (Figure 6B-C, yellow trace), suggesting that pH changes are not the cause of altered FRET 
signals under this condition. 
The ratio of FRET/CFP fluorescence (F/C-ratio) was calculated as a measure of cytosolic ATP 
concentration (Figure 6D) by dividing the average intensity of the corresponding channels for each 
frame and every time point (unless differently noted). The baseline F/C-ratio (control condition; 10 
mM glucose) was calculated as the average F/C-ratio during the last 5 min of the initial baseline 
imaging time series (variable between 15-20 min). F/C-ratio was found to be similar and stable 
between the different nerves analyzed (Figure 6D), while after 2 min of MB + GD treatment, the ratio 
was reduced by 35.1% ± 1.7% (n = 19 nerves; Figure 6D). In further experiments, F/C-ratios were 
normalized between one (10 mM glucose) and zero (MB + GD; Figure 7A). As expected, during MB 
+ GD the decrease in axonal ATP was mirrored by a decay of CAPs, reflecting conduction blocks 
(Figure 7B-C). Strikingly, also the relative decline rates of axonal ATP and conductivity were similar 
(Figure 7D).  
 
Figure 7. ATP and CAP Area recordings during simultaneous mitochondrial blockade and glucose deprivation.  
(A) To assess ATP variations, the ratio of the fluorescence intensities of the FRET and CFP-channel was calculated 
(FRET/CFP ratio) and normalized to baseline (set as 1) and MB + GD (set as 0). The red dashed line visualizes the slope of 
ATP decay at the point of maximal velocity of ATP decay during mitochondrial blockage (MB + GD, n = 3). (B) Evoked 
compound action potential (CAP) area is given as the normalized curve integral during MB + GD. The black dashed line 
represent the slope at the point of maximal velocity of CAP changes during MB + GD treatment (n = 3). (C) Stripe plot 
describing CAP (black) and ATP (red) kinetics, expressed as maximal variation per s, during MB + GD (p = 0.39, n = 3, 
Welch’s t-test). Dots show individual data points, bars and lines represent the mean of all data. Red and black shaded 




3.2 Models of energy deprivation 
We compared ATP and CAP dynamics in response to different modes of energy deprivation (Table 
1; Figures 8-11). The paradigms used for energy deprivation included: glucose withdrawal (also 
referred to as aglycemia, GD; Figure 8), inhibition of mitochondrial OX-PHOSby pharmacological 
inhibition (MB, 5 mM azide; Figure 9A-C), through oxygen replacement with nitrogen in the aCSF (N2 
or anoxia; Figure 9D), through MB + GD (combination of these, Figure 10A) and through oxygen 
glucose deprivation (OGD, a combination of hypoxia and aglycemia; Figure 8B).  
 
Condition Short description Effect Figure(s) 
GD Glucose deprivation 
ATP is not generated from glucose, however 




Mitochondria complex IV 
inhibition by 5 mM azide 
Fast inhibition of OX-PHOS and mitochondrial ATP 




Hypoxic condition created by 
replacement of O2 with N2 in the 
incubating chamber 
Oxygen is replaced by N2 in the incubation 
chamber: OX-PHOS efficiency is strongly reduced 
7D; 9C 
MB + GD 
Simultaneous inhibition of 
mitochondrial activity by 5 mM 
azide and glucose deprivation 
No OX-PHOS, no glycolytic production of NADH 





Simultaneous hypoxic condition 
and glucose deprivation 
Strong reduction of OX-PHOS, no glycolytic 
production of NADH and ATP from glucose 
8B; 9A-B, 
9D-F 




3.2.1 Glucose deprivation 
During glucose deprivation we observed a slow loss of ATP and CAP starting at about 13 
minutes after the removal of glucose from the aCSF (Figure 8C). After 45 minutes of exposure the 
loss of CAP was complete and no response could be elicited (Figure 8A), ATP signal followed the 
kinetics of the CAP, reaching its relative zero by the end of the treatment (Figure 8C). Interestingly, 
at the end of GD, we found changes in fluorescence intensities in each of the three channels (Figure 
8B) comparable to those observed during MB + GD (Figure 6D).  
 
Figure 8. Impairment of axonal ATP and CAP by glucose removal from the aCSF (glucose deprivation, GD, 45 min). 
(A) Single CAP waveform obtained under control conditions (baseline, dashed line) and during exposure of GD (total 45 
min), Single waveforms are separated by 330 s and progressively decay in amplitude. The shaded area indicates the range 
of the CAP waveform set to quantify the CAP area for the baseline condition, the same time window was used for analysis 
of CAPs at subsequent time points. Under all conditions, no CAP could be elicited any longer by electrical stimulation at 
the end of the energy-depleting paradigm. (B) Changes of the fluorescence signal, relative to baseline, during glucose 
deprivation (GD). Fluorescence intensities of the three recorded channels between 44.75 min and 45 min of incubation 
with GD, were averaged (n = 4 nerves). (C) GD (45 min, gray-shaded box) induces similar ATP (red) and CAP (black) decays 
starting at around 13 min after onset of the treatment. Red and black dashed, straight lines represent the maximum 
velocity of ATP and CAP decay (see Figure 9 for quantification). When 10 mM glucose is restored in the circulating aCSF, 
CAP recovery precedes ATP restoration (n = 4 nerves). 
Black and red shaded areas adjacent to each trace represent SEM for CAP and ATP measurements, respectively. 
 
 
When nerves were reperfused with aCSF containing 10 mM glucose, following 45 min of 
aglycemia, CAPs recovered with a delay of about 3 min and the recovery of CAPs preceded the 
restore of ATP levels by several minutes (Figure 8C and 11D for quantification; GD). These data 
suggest that optic nerves, in absence of external substrates can keep on producing ATP, presumably 





3.2.2 Mitochondrial inhibition by azide or hypoxia 
We inhibited mitochondrial OX-PHOS using azide (5 mM for 5 minutes; Figure 9A-C; MB) 
while leaving glucose available in the circulating aCSF. MB produced very quick changes in ATP and 
CAP (Figure 9C), comparable with those observed during MB + GD (Figure 7A-C and Figure 10A). 
Within few minutes loss of ATP and CAP was complete, indicating the prominent role of mitochondria 
in energy production in white matter. However, when the optic nerves were deprived of oxygen after 
its substitution with N2 (gas mixture of 95% N2, 5% CO2; Figure 9D), the ATP signal, instead of 
decaying over time as predicted by the MB exposure, was found to increase by approximately 20-
30% (after 45 min) mirroring a decrease in nerve conduction (about 60% decrease from baseline; 
Figure 11A-B).  
 
Figure 9. Effects of mitochondrial blockade by azide (MB) and hypoxia (N2) on axonal ATP and nerve CAP. 
(A) Single CAP waveform obtained under control conditions (baseline, dashed line) and during application of MB (total 5 
min). Single waveforms are separated by 30 s and their amplitude progressively decays during MB exposure. The shaded 
area indicates the range of the CAP waveform set to quantify the CAP Area for the baseline condition, the same time 
window was used for analysis of CAPs at subsequent time points. Under all conditions, no CAP can be elicited any longer 
by electrical stimulation at the end of the energy-depleting treatment. Compare waveform changes with figure 4B and 
6A for data with GD and MB respectively. (B) Changes of the fluorescence signal, relative to baseline, during mitochondrial 
blockage (MB). Fluorescence intensities of the three recorded channels between 4.75 min and 5 min of incubation with 
MB were averaged (n = 4 nerves). Compare channel intensity analysis in figure 4D and 6B for data with GD and MB 
respectively. In all cases, fluorescence in the CFP channel increased, while fluorescence in the FRET channel decreased. 
Of note, YFP emission upon direct YFP excitation remains stable in all condition. (C) Blockade of mitochondrial respiration 
by azide (MB, 5 min gray-shaded box) produces a fast decay in ATP (red) and CAP (black) starting at 1.8 min after beginning 
of treatment. When azide is removed, CAP and ATP are promptly restored, with CAP recovery preceding the ATP increase 
(n = 4 nerves).   (D) Hypoxia is produced in the optic nerve by substitution of oxygen with nitrogen (N2) in the gas-mixture 
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which enriches the aCSF solution as well as in the incubation chamber. The N2 treatment lasts 45 min (gray-shaded box) 
during which a slow increase in ATP (red trace) is matched by a decrease in conduction (CAP, black trace). n = 4 nerves. 
Black and red shaded areas adjacent to each trace represent SEM for CAP and ATP measurements, respectively. Red and 




3.2.3 Simultaneous glucose depletion and mitochondrial inhibition 
In order to deplete the optic nerve of all its energy, we tested two different paradigms, used 
to simulate, in ex-vivo preparations, ischemic condition where blood supply is drastically reduced 
along with glucose and oxygen absence in the affected tissue. The treatment with MB + GD 
(prolonged to 5 min compared to 2.5 min of exposure used previously; Figure 6B-F and Figure 7) 
induced an immediate and fast decline of ATP, followed by an equally fast decline in CAP (Figure 
10A). MB + GD had similar kinetics to MB treatment but much faster kinetics than GD, supporting 
the hypothesis that axonal ATP production strongly depends on mitochondrial respiration, and 
axonal glycolysis alone is insufficient to maintain ATP levels, even in the virtual absence of electrical 
activity (baseline recording conditions with 0.033 Hz stimulation frequency).  
 
 
Figure 10. Impairment of axonal ATP and CAP during glucose deprivation and simultaneous inhibition of mitochondrial 
activity by azide (MB + GD) or hypoxia (OGD).  
(A) Simultaneous removal of glucose and blockade of mitochondrial respiration with azide (MB + GD, 5 min gray-shaded 
box) produces a fast decay in ATP (red) preceding CAP decay (black), starting already 0.5 min after onset of treatment. 
Following azide removal and replenishment of glucose, CAP and ATP are restored (n = 4 nerves). Red and black dashed, 
straight lines represent the maximum velocity of ATP and CAP decay (see Figure 9 for quantification and comparison with 
other conditions). (B). ATP and CAP are monitored during OGD treatment (simultaneous hypoxic condition lead by N2 
and glucose deprivation). After initial increase, both signals decay very quickly, reaching values close to zero within the 
30 min OGD exposure. After the reintroduction of glucose and oxygen ATP and conduction are quickly restored. n = 3 
nerves. Red and black dashed straight lines in (A) and (B) represent the maximum velocity of ATP and CAP decay (see 
Figure 9 for quantification). Black and red shaded areas adjacent to each trace represent SEM for CAP and ATP 
measurements, respectively.  
Results 
29 
A second treatment that aimed at mimicking ischemic conditions is oxygen-glucose 
deprivation (OGD; Figure 10B), a combination of GD and hypoxia induced by nitrogen. ATP and CAP 
kinetics during OGD were much slower than those observed for MB + GD (Figure 10A), suggesting 
an incomplete blockade of mitochondrial activity by the exposure to low oxygen concentration 
caused by nitrogen. Interestingly, at the beginning of OGD we observed an increase in ATP signal, 
similar in amplitude to that observed during hypoxia in the presence of glucose (N2; Figure 9D), 
followed by a sudden decrease of both ATP and CAP. The decrease onset was comparable with the 
one observed during GD (Figure 11A) suggesting a role of glial glycogen as energy reservoir, also 
during OGD. Another parallelism with GD was observed for the recovery onset of ATP: following 
reperfusion with oxygen and glucose, the ATP signal recovery was in fact following behind the nearly 
instantaneous CAP recovery onset. 
 
3.2.3.1 Comparison between energy-deprivation conditions in the optic nerve 
With the exception of hypoxia, during all treatments, the nerve CAP waveform attenuation 
was similar, though with significantly different time courses for GD and OGD (Figure 8A and data not 
shown). Similarly, with the exception of hypoxia, for ATeam1.03YEMK, we found similar changes in 
fluorescence intensities in all three channels (Figure 6D, Figure 8B and Figure 9B and data not shown). 
By the end of GD, MB, MB + GD and OGD we observed an increase in CFP fluorescence, 
concomitantly with a decrease in YFP fluorescence upon donor excitation (FRET) indicating the 
transition of ATeam1.03YEMK to a conformation where ATP is not bound and FRET is consequently 
reduced. Pointing at the specificity of the effect, YFP fluorescence was found to be unchanged upon 
direct excitation (i.e. of the acceptor). The processed signals obtained from the integration of the 
evoked CAP waveform and from the normalized fluorescent intensity ratio FRET/CFP (F**/C, see 
methods for details) were plotted against time to describe the conduction properties of the optic 
nerve (CAP) and the axonal ATP, respectively. We further analyzed different time courses of the ATP/ 
CAP signals to all energy-deprivation treatments of the optic nerve. In particular, we analyzed several 
time-dependent parameters (decay and recovery onset, decay and recovery speed) to quantitatively 
describe the kinetics of the two signals during the energy deprivation models (Figure 11A-B, D-E). 
The total relative signal reversed after reperfusion with control aCSF was also considered (Figure 11F). 
From the comparative analysis it is clear that direct interference with mitochondrial OX-PHOS by 
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blockade of cytochrome c oxidase (complex IV) function in the electron transport chain (ETC), leads 
to a complete loss of ATP and CAP, which plateau at zero within a few minutes after the addition. 
The mechanism by which ATP and CAP were lost within such short time, seems to be independent 
on the presence of glucose in the media as indicated by the similar kinetics of MB and MB + GD 
(Figure 11A-B, D-E). The short exposure to azide lead to an almost full recovery after azide was 
washed out and glucose reintroduced (Figure 11F). On the opposite side, the kinetic of glucose 
deprivation was found to be very slow (Figure 11B,E), but eventually ATP reached values close to 
relative zero within the 45 minutes of aglycemia, and no CAP could be elicited. The recovery, likely 
due to the prolonged time course, was found to be partial (68% for CAP and 40% for ATP, Figure 
11F, GD). Noteworthy, after glucose was restored in the aCSF, the CAP recovery preceded that of ATP 
by 9.5±1.2 min (Figure 11D; GD). We found a similar difference in the onset of recovery between CAP 
and ATP during glucose-oxygen reperfusion following OGD where ATP signal rescue followed behind 
that of CAP by 7.3±1.4 min. ATP-rescue latency might be explained by the axonal incapability of 
restoring the ATP pool immediately after the energy-deprivation ceased (see discussion section for 
further interpretation). Another notable finding was the un-expected low-impact of hypoxia as 
energy deprivation paradigm as indicated by a partial loss of CAP (56.1%± 8.2%) by the end of the 
45 minutes of nitrogen (N2) exposure, and an increase in ATP signal (132.7%±22.8% from its baseline 
value). The dual response of CAP (decrease) and ATP (increase) might also be explained by the 
combined consequences of oxygen diffusion within the nerve and the nature of the measurements 
themselves. In fact, imaging samples axons at the very surface of the nerve, while CAP recordings are 
comprehensive of most of the fibers. These results, although apparently in contrast, might be 




Figure 11. Quantification and comparison of CAP and ATP signals during all energy-failure paradigms. 
Analysis includes glucose deprivation (GD), mitochondrial blockage (MB), the combination of both (MB + GD) and OGD. 
Hypoxia (C; N2) is considered separately for its very different effect/ kinetics. (A) Time of onset of the ATP and CAP decay. 
The slowest decay induction was observed during glucose deprivation (GD) and OGD. (B) Velocity of maximal signal 
change, after decay onset, for ATP and CAP during all treatments. (C) Maximal signal variation during hypoxia treatment 
with N2. Unlike nerve conduction (CAP), there is no loss in axonal ATP, whose signal increases over time. (D) Time of onset 
of ATP or CAP recovery after the energy-failure paradigm is ended and the optic nerves are reperfused with control aCSF 
containing 10 mM glucose and oxygen. (E) Rate of recovery of both ATP and CAP during reperfusion of the nerves with 
aCSF containing 10 mM glucose and oxygen after the indicated treatments. (F) Comparison of ATP and CAP area overall 
recovery after individual treatments. Data is presented as stripe plots, with dots representing individual data points, bars 
and lines showing the mean. Asterisks indicate statistically significant differences between ATP and CAP under the same 
condition (*p < 0.05, **p < 0.01; one-way ANOVA with Newman-Keuls post-hoc test). 
 
 
3.3 Electrical stimulation at high frequency 
It is known that maintaining axonal conductivity ex vivo depends on energy-rich substrates 
while high frequency stimulation of axons causes CAPs to decrease (Brown et al., 2005, 2001). 





Figure 12. Comparison of axonal ATP and nerve CAP dynamics during high frequency stimulation.  
(A) HFS protocol consisted in bursts of 100 stimuli at a given frequency (16, 50 and 100 Hz) with evoked CAP (E-CAP) 
recordings in-between. The time that divides the burst and the evoked CAP is set at 150 ms, after which 300 ms gap 
separates the following burst of stimuli. (B) The CAP area decreases over time during high frequency stimulation (HFS). 
The decay amplitude deviates from the absence of HFS, indicated by the dashed line (0.1 Hz, used for normalization to 
1.0), and increases progressively with the increase in stimulation frequency (16 Hz, 50 Hz, 100 Hz). Traces from one 
representative nerve incubated in aCSF containing 10 mM glucose are shown. (C) Axonal ATP levels also decrease with 
increasing stimulation frequency, reaching a new steady state level which depends on the stimulation frequency. Same 
experiment as in panel B. (D) ATP and CAP traces of optic nerves stimulated with gradually increasing frequencies (RAMP). 
RAMP consists in subsequent 45 s steps of continuous stimulation at 1 and 4 Hz, followed by 6 burst-like stimulation steps 
at 7, 15, 25, 50, 75 and 100 Hz. RAMP stimulation produces a progressive loss of ATP and CAP followed by prompt signal 
recovery when the stimulation ceases. Black and red shaded areas adjacent to each trace represent SEM for CAP and ATP 
measurements, respectively. (E) RAMP single-frequency quantification of ATP (red) and CAP (black) signal amplitude (1 
to 100 Hz and following recovery). The dashed line at 1.0 indicates ATP and CAP values at 0.1 Hz stimulation frequency, 
which are used for respective normalization. Black and red y-error bars represent SEM for CAP and ATP measurements, 
respectively.  HFS and RAMP responses were recorded in optic nerves (n = 4) incubated in 10 mM glucose aCSF. 
 
 
The electrical stimulation provides a method to change the relative energetic demand of 
axons. Unlike the previously described energy failure paradigms, electrical stimulation doesn’t 
directly interfere with axonal ATP production. Instead, it allows to experimentally manipulate its 
consumption by forcing the axons to quickly restore the ion gradient after the stimulus-evoked 
depolarization. Two different paradigms of electrical stimulation were used to study ATP dynamics: 
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high frequency stimulation (HFS) and continuously increasing stimulation frequencies (RAMP). HFS 
consisted in a series of three burst-like, fixed-high-frequency stimulations (16, 50 and 100 Hz; Figure 
12A), each lasting 2.5 min, separated by 7.5 min of recovery time, i.e. low stimulation frequency, from 
the next train of stimuli (see method section for details). RAMP is a progressive 8-steps increase in 
frequency, each lasting 45-60 s, ranging from 1 to 100 Hz (see methods for details). 
ThyAT optic nerves were subjected to HFS to study axonal ATP dynamics and correlate this 
with conduction responses. Both nerve CAP and ATP signal dropped in a stimulation frequency 
dependent manner (for CAP: 16 Hz: 94.9% ± 1.5%; 50 Hz: 79.6% ± 0.4%; 100 Hz: 66.4% ± 1.0%; for 
ATP: 16 Hz: 91.6% ± 1.0%; 50 Hz: 82.3% ± 1.4%; 100 Hz: 68.9% ± 2.8%; n = 5 nerves; Figure 12 B-C 
and Figure 13A-B). The forced HFS thus produced progressive block along with slowing of 
conduction, likely because of the incapability of a subset of fibers to sustain the repolarization at the 
given stimulation. Strikingly, to the observed loss of conduction, didn’t contribute the first peak of 
the CAP waveform which was stable even at the highest tested frequency (Figure 13A-B).   
 
 
Figure 13. Example of progression of CAP waveform changes during high frequency stimulation (HFS). 
(A) The three peaks recognizable in the baseline trace (dashed line) are differently affected by increasing stimulation 
frequency and for CAP analysis only the first two are considered. Shown are single traces obtained prior to stimulation 
(baseline) as well as at the end of a 2.5 min stimulation period at different stimulation frequencies (16 Hz, 50 Hz, 100 Hz) 
of a nerve incubated in aCSF containing 10 mM glucose. (B) Example of progression of CAP from baseline (dashed line) 
during stimulation of an optic nerve at 100 Hz incubated in ACSF containing 10 mM glucose for a total stimulation time 
of 2.5 min. Single traces are separated by 37.5 s. The shaded area indicates the area under the CAP wave form used for 
CAP quantification for the baseline condition (green) and after 150 s of HFS (red). Grey shading results from the overlay 




This indicates that the fast component of the CAP response can tolerate, within the tested 
time course, the HFS paradigm. At the same time, the loss in axonal ATP signal indicated higher ATP 
consumption in the fibers. Maximal ATP changes and maximal loss of conductivity correlated over 
stimulation frequencies (Figure 14C, magenta scatter plot/ linear regression); however, the causal 
relations are very likely more complex (see discussion below). Finally, both the rates of ATP decay 
and recovery correlated with the amplitude of ATP changes (Figure 16B, D; magenta scatter plot/ 
linear regression).  
 
Figure 14. Quantification and correlation of CAP and ATP signals of optic nerve’s axons stimulated at 16, 50 and 100 Hz 
(HFS) while supplied with different glucose concentrations (2, 3.3 and 10 mM). 
(A) Remaining CAP area at the end of the HFS (overall decay amplitude) during incubation of nerves in different glucose 
concentrations quantified during the last 30 s of HFS. The stripe plot shows summarized data from n = 5, 5, or 4 nerves 
for 10 mM, 3.3 mM and 2 mM glucose, respectively. The dashed line at 1 shows CAP size at 0.1 Hz stimulation frequency, 
which was used for normalization. (B) Quantification of ATP decay amplitude during incubation of the same nerves as in 
(A) in different glucose concentrations. The dashed line at 1 shows ATP levels at 0.1 Hz stimulation frequency. (C) 
Correlation of the amplitude of ATP and CAP decay during HFS of nerves bathed in aCSF containing the glucose 
concentrations indicated. Data points are very close to the diagonal of the graph indicating that ATP and CAP change by 
similar factors. (D) Ratio of ATP and CAP drop during HFS in the presence of glucose in the concentrations indicated. If 
both parameters change by the same factor, this ratio remains equal to one. Data in (A-B) is presented as stripe plots, 
with dots representing individual data points and bars and lines showing the mean. Asterisks in (A-B) and (D) indicate 





Next, we asked whether lower physiological glucose concentrations have an impact on nerve 
conduction and axonal ATP levels when nerves are challenged with different spiking frequencies 
(HFS, Figure 14, 16). In presence of 10 mM and 3.3 mM glucose, CAP performance and ATP levels 
dropped similarly with increasing stimulation frequencies. However, when only 2 mM glucose were 
applied, both CAP and ATP levels were substantially decreased (Figure 14; yellow graphs), resulting 
in a very variable ATP/CAP ratio (Figure 14D). CAP waveforms were also significantly altered by low 
glucose with each peak being strongly reduced at the end of the HFS (2 mM vs 3.3 and 10 mM; 
Figure 15A-C). Single channels were also analyzed since these show the specific effect of ATP loss at 
each glucose condition.  The largest divergence between donor and acceptor fluorescence was seen 
for 2 mM glucose (Figure 15D-F). 
 
Figure 15. Example of CAP waveforms’ and ATP sensor fluorescence intensities’ changes during high frequency stimulation 
(HFS) of optic nerves incubated with aCSF containing different glucose concentrations. 
Shown are mean CAP waveforms (n = 3 nerves for each condition) incubated in ACSF containing 10 mM glucose (A), 3.3 
mM glucose (B) and 2 mM glucose (C) prior to high frequency stimulation (“baseline”; dashed lines) or at the end of the 
2.5 min HFS (100 Hz) period (solid lines). Grey areas indicate SEM. (D-F) Changes of the fluorescence signal at the end of 
the 2.5 min HFS (100 Hz) period relative to the baseline signal prior to stimulation of optic nerves incubated in ACSF 
containing 10 mM glucose (D), 3.3 mM glucose (E) and 2 mM glucose (F). During HFS, fluorescence in the CFP channel 
increased, while fluorescence in the FRET channel decreased. Of note, YFP emission upon direct YFP excitation remains 





This data suggests that 2 mM glucose is insufficient to keep viable ATP steady-states and a 
proper nerve conduction under the challenge of HFS in our ex vivo experimental settings. Further 
evidence of the sub-threshold provision of substrate, represented by 2 mM glucose condition, is 
given by its slower recovery rate following the cessation of HFS, when compared to axonal ATP 
recovery at higher glucose concentrations (0.21% ± 0.01% vs 0.40% ± 0.09% signal/s respectively for 
2 mM glucose and for the averaged recovery rate at higher glucose concentrations, Figure 16D, 
yellow scatter plot/ linear regression). Remarkably, we found that after HFS cessation, both axonal 
ATP and CAP recovery rates increased with the increase in frequency stimulation and the amplitude 
of signal loss, indicating the presence of adaptive mechanisms (see discussion 4.3). 
 
 
Figure 16. Correlation of the rates and amplitudes of CAP and ATP changes during HFS in different glucose concentrations. 
(A) Correlation of the velocity of the initial decay of CAP at the beginning of HFS and the amplitude of CAP decay at the 
end of HFS. The faster the CAP drops, the larger the CAP amplitude is. (B) Same analysis for ATP as for CAP area in panel 
A: the faster ATP consumption at the beginning of HFS correlates with a larger decrease in ATP signal amplitude. (C) 
Correlation between rates of CAP area recovery and the amplitudes of CAP changes after the cessation of stimulation, 
for different glucose concentrations. The velocity of CAP recovery increases with larger amplitude of CAP decay during 
stimulation. (D) Same analysis as in C for ATP: ATP recovery rates are strongly depending on the amplitude of ATP decrease 
during HFS at 10 mM and 3.3 mM glucose, but much less in the presence of 2 mM glucose. The graph summarizes data 




We also investigated how substrates other than glucose can act as the sole extracellular 
energy source for catabolic pathways downstream of glycolysis. It has been previously shown how 
lactate and pyruvate can maintain conduction, in the same manner as glucose, within 2 hours of 
continuous perfusion at baseline stimulation (Brown et al., 2001). We tested optic nerves with high 
frequency stimulation while providing glucose, lactate or pyruvate (each at 10 mM concentration) 
under aerobic conditions. We found optic nerve conduction was maintained equally well with all the 
substrates (Figure 17), in agreement with the earlier findings (Brown et al., 2001), Presumably because 
absolute axonal ATP consumption is likely unaffected by the type of metabolic support.  
 
Figure 17. Comparison between glucose, lactate and pyruvate as exogenous energy substrates shows energy metabolism 
of axons is better maintained in the presence of glucose at higher frequencies. 
(A) The comparison between CAP area decay of optic nerves incubated in aCSF containing 10 mM glucose (n = 5 nerves) 
versus optic nerves incubated either in 10 mM lactate or 10 mM pyruvate (n = 3 nerves) during HFS, shows no significant 
differences among the three substrates in maintaining the conduction (p > 0.05, Welch’s t test). (B) By contrast, analysis 
of axonal ATP levels indicates that at higher frequencies glucose is a better substrate to maintain axonal ATP. Same 
experiments described in panel A. (C) Correlation of ATP and CAP decay amplitude during HFS of nerves bathed in aCSF 
containing glucose, lactate or pyruvate (each 10 mM) as energy substrates. (D) ATP to CAP amplitude ratio, calculated for 
nerves bathed in aCSF containing lactate (10 mM) or pyruvate (10 mM) as energy substrates during HFS. The ratio remains 
almost equal to one for all conditions supporting the concept that both ATP and CAP change by a similar factor. n = 5, 3, 
3 for glucose, lactate and pyruvate, respectively.  




However, at the highest frequency 100 Hz, the relative decrease in axonal ATP levels was 
larger with lactate (or pyruvate) than with glucose (glucose: 68.9% ± 2.8%; lactate: 56.3% ± 2.8%; 
pyruvate: 47.4% ± 2.8%; p = 0.05 and p = 0.01, respectively; n = 3 nerves; Figure 17B), showing that 
glucose maintains axonal ATP production better than lactate or pyruvate, at equimolar exogenous 
concentrations. Noteworthy, the linear 1:1 correlation for the observed changes in ATP and CAP 
parameters at increasing frequencies is maintained also for pyruvate and lactate. 
 
 
3.4 CAG-GO-ATeam optic nerves: ATP and CAP responses to energy deprivation and 
comparison with ThyAT  
In collaboration with Akiyo Natsubori at Keio University (Tokyo), optic nerves from CAG-GO-
ATeam mice were analyzed. Transgenic mice were generated in Japan by targeting the genetically 
encoded GO-ATeam ATP sensor, under the CAG promoter, to the ROSA-26 locus (Natsubori et al., 
unpublished). The mice were transported to the Max Planck Institute for Experimental Medicine for 
analysis and in-deep characterization of the GO-ATeam sensor during different WM energy 
deprivation paradigms. GO-ATeam is a red-shifted version of the original ATeam1.03: GO-ATeam 
carries a green (cp173-mEGFP) and orange (mKOκ) FPs as donor and acceptor, respectively (Nakano 
et al., 2011). CAG-GO-ATeam mice were expected to express the red shifted ATP sensor in most cells 
and axons; however, only sparse labeling expression was observed in LSM z-stack analysis (Figure 
18B-D). The optic nerves were initially challenged with RAMP stimulation frequencies (1-100 Hz, total 
7.8 min in 3.3 mM glucose aCSF) and ATP was monitored as previously described (Figure 6) after 
excitation and emission channels were adjusted to GO-ATeam (Figure 18A; see methods for more 
details). ATP was found to decay of about 15% after the max frequency (Figure 18E, RAMP - 100 Hz) 
was applied. However, during RAMP stimulation the amplitude of CAP decay was similar to that 
described for ThyAT. During 35 min of glucose deprivation (GD) ATP decayed sooner than CAP and 
reached a plateau after 80% of decay was reached (Figure 18F). This plateau at the end of GD was 
observed also in ThyAT optic nerves where, in contrast, the amplitude of ATP signal decay was nearly 




Figure 18. CAG-GO-ATeam responses to energy deprivation paradigms  
(A) GO-ATeam is a red-shifted version of ATeam1.03 carrying a green donor (cp173-EGFP) and orange acceptor (mKOκ) 
for FRET. Excitation and emission maxima are shown for both FPs. (B), (D) GO-ATeam is expressed under the CAG 
promoter in mice, leading to multiple cell type labelling in the optic nerve, as shown by 20 μm z-projection in the three 
channels: ORG (orange, (B)) as result of excitation at 543 nm and emission at 590 ± 25 nm; FRET (C) with excitation at 488 
nm and emission at 590 ± 25 nm; GFP as result of excitation at 488 nm and emission at 525 ± 25 nm. (E) CAG-GO-ATeam 
optic nerves subjected to RAMP stimulation (7.8 min, 8 step frequencies between 1 and 100 HZ): CAP signal decay was 
similar to that observed in ThyAT optic nerves but ATP decay was barely visible compared to the large response observed 
in ThyAT optic nerves. (F) CAG-GO-ATeam optic nerves exposed to glucose deprivation (GD, 35 min) showed a similar 
time-course for CAP than ThyAT; ATP decay anticipated CAP’s, plateau at 20% and its rescue was instantaneous after 
glucose was reintroduced (panel (H) for comparison between CAG-GO-ATeam and ThyAT). (G) Short exposure to MB +GD 
(4 min) induced a quick and transient loss in ATP and CAP in CAG-GO-ATeam optic nerves. (H) Comparison between CAG-
GO-ATeam and axonal ThyAT ATP responses after glucose reperfusion (following 45 and 35 min glucose deprivation 
respectively): the rescue was instantaneous and preceded CAP’s, in CAG-GO-ATeam optic nerves; the opposite situation 
is described in ThyAT optic nerves. (I) box plot of fluorescent signal change from baseline within the last 15 s of GD 
treatment: mKOκ acceptor fluorescence decreased only as specific FRET effect (ORG vs FRET indicating ATP loss) while 
GFP donor fluorescence increased as result of decreased FRET efficiency (i.e. ATP loss), the ratio between FRET and Green 
fluorescence is calculated  as F/G. (J) Box plot analysis of fluorescence signal change from baseline within the last 15 s of 
MB+GD treatment: ATP loss caused the same FP and ratio responses observed in (I). Scale bar in B-D: 20 μm. 
 
 
ATP also recovered immediately as soon as glucose was restored: this instantaneous rescue 
preceded that of CAP and was not observed in ThyAT under similar treatment (Figure 8C; GD, 45 
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min). This instantaneous ATP rescue in CAG-GO-ATeam optic nerves originates non-specifically from 
all cell types and could indicate a higher ATP demand or a reduced glycolytic capacity in axons, if 
compared to the delayed ATP rescue described for the axonal-specific ATP signal (ThyAT, Figure 18H) 
(see discussion 4.3). Moreover, MB+GD treatment successfully induced ATP and CAP loss in CAG-
GO-ATeam optic nerves with ATP decay slightly anticipating CAP’s (Figure 18G; MB+GD, 4 min). The 
specificity of the FRET effect was observed in single-channel fluorescence intensity analysis for GD 
and MB+GD treatments (Figure 18I and 18G, respectively) similarly for the reported FRET effect 
observed in ThyAT optic nerves (Figure 6C-D and Figure 8B). 
 
 
3.5 Ketogenic diet impact on B-Hydroxybutyrate metabolism in the optic nerve 
Another substrate that can fuel mitochondrial TCA/OX-PHOS in the optic nerves is diacetic 
acid. Under physiological conditions, diacetic acid exists as its conjugate base acetoacetate which is 
normally produced in the liver starting from acetoacetyl-CoA and released into the bloodstream. 
Acetoacetate is the second ketone body circulating the bloodstream in terms of concentration, after 
β-hydroxybutyrate (β–HB), also produced in the liver. The interconversion of β–HB and acetoacetate 
is catalyzed by 3-hydroxybutyrate dehydrogenase and requires NAD+/ NADH. In the brain, the 
mitochondrial enzyme SCOT activates acetoacetate to acetoacetyl-CoA, by adding one –CoA group,   
acetoacetyl-CoA can finally be broken down by a thiolase enzyme into two molecules of acetyl-CoA 
that fuel the TCA cycle and generate ATP.  
We tested acetoacetate under HFS and monitored ATP and CAP dynamics of the nerve. 
Surprisingly, in presence of 20 mM acetoacetate in the aCSF, the nerve was unable to maintain ATP 
and conduction even during the lowest stimulation frequency (16 Hz, Figure 19A) and no recovery 
was observed. We hypothesized that, under normal circumstances, the carbohydrate-enriched diet 
of the mice leads to poor systemic production of ketone bodies. These are then likely inefficiently 
absorbed and catabolized by CNS and white matter tracts to generate energy. Therefore, to push the 
CNS tissue to metabolically adapt to ketone bodies oxidation, we treated the mice for 4 weeks with 
a ketogenic diet (KD) after overnight starvation. We monitored ketone levels in the blood once a 
week and by the end of the 4-weeks KD treated mice showed increased levels of β-hydroxybutyrate 
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(β–HB; Figure 19B), likely as a consequence of the β-oxidation in high amounts of fatty acids and 











Figure 19. Ketone bodies as energy substrate in optic nerves.  
(A) HFS at 16 Hz produces strong alteration in ATP (red line) and CAP 
(black line) in optic nerves (ND) perfused with 20 mM acetoacetate 
which is leading to recovery failure after the cessation of the stimulus. 
(B) ThyAT mice were treated for 4 weeks with KD (high-fat diet) and 
glucose and ketone (β-hydroxybutyrate, β-HB) were monitored: 
blood levels of glucose and β-HB at the end of the KD (green boxplot) and normal diet (ND, black boxplot). β-HB levels 
were enhanced in KD-treated mice (C) optic nerves were isolated and exposed to aCSF containing 20 mM β-HB as well as 
α-glucosidase I and II (glycogen-degradation) blockers 1,4-Dideoxy-1,4-imino-D-arabinitol (20 μM, DAB) and 1-
Deoxynojirimycin (20 μM, DNJ). CAP and ATP were monitored during the 45 min exposure to β-HB supplied aCSF, showing 
similar decay-kinetics to glucose deprivation (fig. 5), however recovery was more prompt than GD and CAP recovery was 
almost complete in optic nerves from KD-treated mice. n = 4 nerves (ND, black and red traces for CAP and ATP 
respectively), n = 2 nerves (KD, green traces).  
 
 
We proceeded to test our hypothesis of a beneficial effect of ketogenic diet on white matter 
capability of processing ketone-bodies for energy production. Optic nerves from KD and normal diet 
fed (controls, ND) mice were isolated and superfused with aCSF containing only 20 mM β–HB for 45 
min. β–HB was used instead of acetoacetate to maintain the continuity with the most abundant 
ketone body found in the blood (β–HB is on average 2.0 ± 0.5 fold more abundant than acetoacetate 
in the blood; Tanda, Hinokio, Washio, Takahashi, & Koseki, 2014). Optic nerve CAP and axonal ATP 
were tracked using baseline stimulation at 0.1 Hz during baseline (glucose/ β–HB), β–HB only and 
recovery (glucose/ β–HB). To avoid glycogenolysis from glial stores, which may have been affected 
in KD treated mice, we supplied all the aCSF solutions with α-glucosidase I and II (glycogen 
breakdown) inhibitors. No overall differences were observed between KD and ND treated optic 
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nerves during the 45 min exposure to β–HB (Figure 19C and Figure 20A-B). Conversely, after glucose 
was re-introduced in the aCSF, optic nerve CAPs from KD treated mice showed an enhanced recovery 
(91.2 ± 2.8% vs 65.4% ± 8.7% of ND condition; Figure 20C). This result was not surprising since 
previous evidences suggests the ketogenic diet to have neuroprotective effects under different 
insults and disorders (reviewed by Prins, 2008). Nevertheless, given the low number of nerves tested 
(n = 4, n = 2 respectively for ND and KD conditions), conclusions should be taken with caution.  
 
 
Figure 20. Quantification of CAP and ATP signals during the different phases of β-hydroxybutyrate exposure in KD 
treated mice.  
(A) ATP and CAP in optic nerves from KD and ND treated mice show similar relative decays after the perfusion with 20 
mM β-HB. (B) ATP and CAP signals in optic nerves from KD and ND during recovery after β-HB is substituted with 
glucose. (C) Quantification of the overall recovery of ATP and CAP signals after reperfusion with 10 mM glucose. (D) 
Time (min) of decay and recovery onset. n = 4 nerves (ND, black and red traces for CAP and ATP respectively), n = 2 
nerves (KD, green traces). 
 
 
3.6 Lactate metabolism in white matter 
Following the systematic screening of substrates and concentrations that can be used by axons 
of the optic nerve to generate energy and maintain conduction, we aimed at understanding whether 
these axons require a pyruvate/lactate metabolism also in presence of glucose as the only energy 
substrate available. To address this question, we monitored optic nerves conduction and axonal ATP 
levels while pharmacologically interfering with endogenous lactate metabolism. To serve this 
purpose we supplemented low-glucose (3.3 mM) aCSF with D-lactate and AR-C155858. D-lactate is 
the optical isomer of its metabolizable form L-lactate and competes with it at the MCT transport site. 
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In addition, D-lactate interferes with lactate dehydrogenase (LDH) activity. AR-C155858 is a selective 
MCT1/ MCT2 blocker (Ovens, Davies, Wilson, Murray, & Halestrap, 2010).  
At the highest frequency, D-lactate slightly reduced CAPs (20 mM, Figure 21A) but had a significantly 
stronger effect on axonal ATP (at 100 Hz: Glc: 57.6% ± 2.0%; Glc + D-Lac: 31.8% ± 0.5%; p = 0.009; n 




Figure 21. Endogenous production of lactate from glucose the optic nerve is essential to maintain ATP during HFS. 
(A) In the presence of glucose (3.3 mM; n = 5 nerves) as exogenous energy substrate, inhibition of lactate metabolism by 
D-lactate (20 mM; competitive inhibitor of endogenous L-lactate metabolism at MCTs and LDH, n = 6) or AR-C155858 (10 
µM; MCT1 and MCT2 selective inhibitor, n = 6) does not significantly affect CAPs. (B) Analysis of ATP under the same 
conditions as in (A): ATP levels undergo a strong decrease at higher frequencies in the presence of D-lactate or AR-
C155858. (n = 5 nerves for all conditions). The dashed lines in panels A-B at 1 show CAP size or ATP levels at 0.1 Hz 
stimulation frequency used for normalization. (C) Inhibition of metabolism of endogenously produced L-lactate in the 
presence of glucose as the sole exogenous energy substrate shifts the correlation of ATP and CAP to the upper left 
showing that ATP changes more strongly than CAP. (D) The ratio of ATP and CAP drop decreases significantly in the 
presence of inhibitors of lactate metabolism, confirming that ATP changes more strongly than CAP. 





Similarly, when MCT1/MCT2-mediated lactate transport was inhibited using the specific 
inhibitor AR-C155858, relative axonal ATP levels were strongly affected (10 μM, at 100 Hz: 25.2% ± 
2.7%; p = 0.004; n = 3 nerves), but with little effect on CAP performance (at 100 Hz: Glc = 76.4% ± 
1.3%; Glc + AR-C155858 = 68.5% ± 2.2%; p = 0.06; n = 3 nerves; Figure 21A-B) as indicated also by 
the respective CAP waveforms (Figure 22). ATP/CAP ratios strongly deviated from the 1:1 ratio 
observed in the presence of glucose alone when lactate metabolism was impaired (Figure 21C-D). 
Collectively, these results strengthen the conclusion that generation of pyruvate/lactate is required 
by spiking axons of white matter to fuel ATP production. 
 
Figure 22. Example of CAP traces before and after high frequency stimulation (HFS) of optic nerves in the presence of 
inhibitors of lactate metabolism. 
Optic nerves were incubated in ACSF containing 3.3 mM glucose in the absence of inhibitors (A) or in the presence of 
either 20 mM D-lactate (B) or 10 µM AR-C155858 (C). Shown are mean CAP waveforms (n = 3 nerves for each condition) 
prior to high frequency stimulation (“baseline”; dashed lines) or at the end of the 2.5 min HFS (100 Hz) period (solid lines). 
Grey areas indicate SEM. 
 
 
3.7 ATP and CAP monitoring in Slc16A1het optic nerves 
The direct impact of the oxidative production of lactate and pyruvate on axonal ATP 
homeostasis but not on conduction, as demonstrated by MCT/LDH inhibition during HFS, 
encouraged us to study the role of glial MCT1 in vivo. We crossbred ThyAT animals with the 
amyotrophic lateral sclerosis (ALS) murine model Slc16A1het. MCT1 is the most abundant 
pyruvate/lactate transporter in CNS, expressed in oligodendroglia and localized in non-compact 
myelin (Rinholm et al., 2011). Slc16A1het mice develop axonopathy at advanced age (Lee et al., 2012), 
with similar features as Plp1KO mice. In order to compare with ATP/CAP dynamics under MCT/LDH 
pharmacological inhibition, we tested optic nerves from ThyAT- Slc16A1het mice in similar 





Figure 23. Analysis of ATP and CAP during HFS in optic nerves from MCT1+/- mice.  
(A) Western blot of optic nerve lysates showing a reduced expression of MCT1 in Slc16A1het (MCT1het) mice. Coomassie 
staining is displayed as control. (B) Quantification reveals that optic nerves of MCT1het mice contain 46% ± 11% of MCT1 
of wild type littermate controls (n = 5 each for wild type and heterozygous optic nerves). Data in this figure was kindly 
provided by Dr. Kathrin Kusch. 
 
 
The nerves were in fact superfused with 3.3 mM glucose (and subsequently to 6.6 mM lactate) 
while challenged to trains of 16, 50 and 100 Hz stimulations (HFS). We observed only a non-
significant trend towards reduced ATP levels in the optic nerves from ThyAT-Slc16A1het mice under 
the 2.5 min of stimulation (Figure 24). We concluded that a reduced MCT1-expression of 46% ± 11% 
(Figure 23) and the corresponding reduction of oligodendroglial lactate export capacity do not 
significantly impact on axonal energy metabolism, in the short term of HFS, as much as a probably 
more complete blockade of lactate metabolism provided by pharmacological inhibition of 
MCTs/LDH. Young Slc16A1het mice could also have compensatory mechanisms to bypass the reduced 






Figure 24. Analysis of ATP and CAP during HFS in optic nerves from 10 weeks old MCT1+/- mice. 
(A), (B) No statistically significant difference of both CAP and ATP changes are observed between wild type and MCT1-
heterozygous optic nerves incubated in 3.3mM glucose. (D), (E) No ATP or CAP significant difference is observed between 
MCT1het optic nerves and controls superfused with 6.6 mM lactate. The ATP/CAP ratio does not differ significantly between 
wild type and MCT1-heterozygous mice both in glucose (C) and lactate (F). n = 5 for wild type and heterozygous mice, p > 
0.05; Welch’s t-test. 
 
 
3.8 ATP and CAP monitoring in PLP1KO optic nerves 
Since electrical activity at high frequencies poses a metabolic challenge to myelinated nerves, 
the combined monitoring of axonal conductivity and energy metabolism should help understanding 
how the disease affects axonal integrity. X-linked spastic paraplegia type-2 (SPG2) is a human 
neurological disorder, caused by the null mutation of PLP1, an oligodendrocyte-specific gene 
(Schiffmann and Boespflug-Tanguy, 2001) which codes for the homonym protein and a smaller 
peptide DM20. In patients, progressive axonal loss in long myelinated tracts of the spinal cord is 
unexplained, but is recapitulated in Plp1KO mice (Boison & Stoffel, 1994; Klugmann et al., 1997), a 
bona fide SPG2 model (Griffiths et al., 1998; Edgar et al., 2004). Mice lacking PLP/DM20 show 
secondary molecular changes, among these the absence of SIRT2 (Werner et al., 2007) present in the 
non-compact myelin and potential axonal NAD+/NADH sensor (Gruenenfelder, Thomson, Penderis, 
& Edgar, 2011). Lack of SIRT2 might represent the first hint of a link between SPG2 and an impaired 




Figure 25. Optic nerves prepared from PLPKO mice, model of spastic paraplegia type-2, show axonal impairment at 10 weeks 
of age. 
(A) Electron microscopic image of a high-pressure frozen optic nerve of a 10 week old PLPKO animal showing axonal 
swellings and accumulation of transported vesicles at the node of Ranvier. Scale bar: 0.5μm. The image was kindly 
provided by Dr. Wiebke Möbius. (B) Confocal image of an acutely recorded optic nerve from a ThyAT x PLPKO - mouse clearly 
showing axonal swellings (red arrowheads). Shown is the YFP channel of the ATP-sensor. Scale bar: 10 μm. (C) Evoked 
response after supramaximal stimulation: CAP waveforms from PLPKO (red trace) and PLPCTRL (black trace) are shown. (D) 
Intensity-voltage plots from PLPKO and PLPCTRL optic nerves indicate an overall loss of conduction (32.2 ± 9.8%). (E) 
Normalized intensity-voltage plots show no significant change in the excitability of the responding axons in PLPKO. Optic 
nerves from 10 weeks old animal were used (n = 5 for panel C-E). 
 
 
Moreover, given the prominent role of oligodendrocytes in contributing directly to axonal 
energy metabolism (Funfschilling et al., 2012; Lee et al., 2012), we asked whether SPG2 mice exhibit 
an underlying defect of axonal ATP homeostasis contributing to a later axonal degeneration. As 
expected, CNS myelination of PLPKO mice appeared grossly normal (not shown), while by electron 
microscopy of myelinated axons the local accumulation of cargo within axons could be observed (I. 
Griffiths, 1998) (Figure 25A). These occasional axon swellings were also observed by acute confocal 
imaging of the axoplasmic ATP-sensor (Figure 25B). 
Optic nerves from PLPKO-ThyAT mice were functionally challenged ex vivo by electrical 
stimulation using HFS and RAMP (Figure 25C-F and Figure 26C, respectively) and glucose deprivation 
(Figure 26D). During HFS both ATP levels and CAPs decreased more strongly in Plp1 mutant nerves 
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(PLPKO) than in wildtype controls, both in the presence of glucose and lactate as exogenous energy 
substrate (ATP levels at 50 Hz were reduced to 68.1% ± 2.7% and 52.1% ± 3.6% in Plpwt and PlpKO 
with glucose, and to 66.9% ± 5.2% 39.0% ± 5.9% in Plpwt and PlpKO with lactate, p < 0.05; n = 3 and 
4 nerves for Plpwt and PlpKO; Figure 26A-B). Interestingly, no significant difference of ATP levels was 
observed during stimulation at the highest frequency suggesting that a lower limit of ATP had been 
reached (Figure 26A-B).  
 
 
Figure 26. ATP and CAP responses in PLPKO optic nerves subjected to high frequency stimulation (HFS) with glucose or 
lactate as main substrate. 
(A),(B) Comparison of the remaining ATP at the end of HFS, between PLPKO and Ctrl optic nerves incubated in aCSF 
containing 3.3mM glucose (A) and 10 mM lactate (B); n = 3 for each genotype. (C), (D) Comparison of the remaining CAP 
at the end of HFS, between PLPKO and PLPCtrl optic nerves incubated in aCSF containing 3.3 mM glucose (C) or 10mM 
lactate (D); n = 3 for each genotype. 
The dashed lines in panels C-F at 1.0 show CAP size or ATP levels at 0.1Hz stimulation frequency. Asterisks in C-F indicate 
statistically significant differences as indicated (*p < 0.05, ** p < 0.01, *** p < 0.001; Welch’s t-test). 
Optic nerves from 10 weeks old animal were used; n = 3 optic nerves per genotype. Error bars indicate SEM. 
 
 
Using the same experimental conditions and 3.3 mM glucose as substrate, optic nerves from 
Plp1KO-ThyAT were also tested during RAMP stimulation (Figure 27). RAMP stimulation lasted for 7.8 
min and covered 8 steps frequencies from 1 to 100 Hz. ATP measurement showed variability in optic 
nerves from PlpKO, and at the end of the stimulation no significant difference was found (Figure 27A 
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and 27B; ATP at the end of the RAMP stimulation was reduced to 63.0% ± 3.2% and 74.9% ± 10.0% 
in Plpwt and PlpKO). CAP measurements were more consistent between conditions showing a 
prominent loss of conduction in PlpKO (14.7% ± 4.3% of remaining CAP) in comparison to Plpwt (42.6% 
± 1.9% of CAP signal remaining at the end of the RAMP; Figure 27, bottom panels). The ATP and CAP 
signal rate change calculated for each given frequency reflected the overall decay, indicating 25 Hz 
as the frequency at which the CAP signal started diverging between PlpKO and controls (Figure 27B 
bottom panel).  
 
Figure 27. Quantification of ATP and CAP signals in PLPKO optic nerves subjected to increasing frequency stimulation 
(RAMP, 1-100 Hz). 
(A) In presence of 3.3 mM glucose in the circulating aCSF, ATP (on top) and CAP (on bottom) responses to RAMP 
stimulation of PLPKO axons (orange/ gray respectively for ATP and CAP) compared to control axons (red/black), show 
conduction blocks arising at higher frequencies in PLPKO axons but no significant difference in ATP kinetics.  
(B) ATP (top) and CAP (bottom) signals in PLPwt (dark gray boxplot for CAP and red for ATP) and PLPKO (light gray boxplot 
for CAP and orange for ATP) were evaluated during the last 15 s of RAMP (maximum stimulation at 100 Hz) giving the 
total signal decayed during this stimulation paradigm. (C) Rates of ATP (top) and CAP (bottom) decay is calculated at each 
stimulation frequency. 
Significant differences between genotypes are indicated by the asterisks as indicated (*p < 0.05, ** p < 0.01, *** p < 
0.001; Welch’s t-test).  
 
 
To better understand the white matter metabolic state of Plp1KO, optic nerves were finally 
exposed to glucose deprivation. Under GD the axonal demand for ATP is not altered by frequent 
depolarization however the lack of substrates’ supply likely interferes with its constant production. 
During exposure to GD, axonal ATP and CAP decayed simultaneously. However, the velocity of decay 
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of ATP in Plp1KO optic nerves was significantly reduced in comparison to controls. Moreover, ATP 
recovery after glucose reperfusion was found to be significantly greater in PlpKO than Plp
wt axons (p 
= 0.0079, 86.1% ± 1.5% and 60.67% ± 1.9%, respectively; Figure 28A and 28C upper panel). ATP and 
CAP were also found to decay with significantly slower kinetics in Plp1KO optic nerves (Figure 28A 
and 28B) but the conduction was then restored with similar rate and extent in both genotypes after 




Figure 28. Quantification of ATP and CAP signals in PLPKO optic nerves subjected to glucose deprivation (GD).   
(A) The calculated rate of signal decay following glucose deprivation shows ATP (top) and CAP (bottom) signals decaying 
slower in PLPKO axons than controls and an improved ATP overall recovered signal in PLPKO (orange trace) after glucose is 
reintroduced in the aCSF. (B) The maximal rates of signal decay is calculated during GD for ATP (top) and CAP (bottom) 
for PLPKO (orange/gray) and controls (red/black). (C) The maximal rates of signal recovery following glucose reperfusion 
is calculated for ATP (top) and CAP (bottom) for PLPKO (orange/gray) and controls (red/black). 
Significant differences between genotypes are indicated by the asterisks as indicated (*p < 0.05, ** p < 0.01, *** p < 




Maintaining the ex vivo optic nerve perfectly stable under the objective during combined 
confocal imaging and electrophysiology could be challenging in. However, we could smooth 
eventual noise and compensate for small drifts along each imaging axis by averaging channel 
intensities of entire frames. By doing so, we obviously average ATP transients and CAP recordings in 
potentially metabolically different fibers. The results provide an averaged response of all tens of 
thousands fibers that compose the optic nerve, clamped between the suction electrodes (Figure 6A). 
However, we noticed while calculating the ratiometric images of the baseline condition (with normal 
glucose and oxygen supply) large caliber fibers had higher ratios compared to smaller fibers (Figure 
6E). Consequently, the approximation represented by averaging intensities from entire frames blurs 
possible different ATP responses belonging to these different populations of fibers. Consequently, 
we aimed to retrieve this information and cluster the analysis according to fiber diameter.  
The relevance of fiber diameter can be seen in Slc16A1het mice, where small caliber fibers 
seem to pay the price of a reduced expression of the monocarboxylate transporter-1 (Lee et al., 
2012). To cluster the analysis of PLPKO ATP responses to RAMP and GD according to fiber size, we 
developed an ImageJ macro to discriminate fiber size according to intensity. The criteria is based on 
the assumption that larger fibers contains a higher amount of ATeam1.03YEMK fluorescent molecules. 
After X-Y registration, the script applies a threshold to the images. The thresholded stacks (mask) are 
then used to generate ROIs (see methods and appendix §2 for details). With this method we could 
create two categories based on the fiber diameter: large fibers (identified by ROIs with diameter ≥ 
1.5 μm, 2.2 ± 0.4 μm on average) and small fibers (all fibers where ROIs didn’t satisfy the criteria of 
diameter ≥ 1.5 μm). Thus the ThyAT-PLPKO imaging dataset was re-analyzed (Figure 29). The analysis 
showed that the previously detected increase in recovery following GD and glucose reperfusion was 
mainly present in PLPKO small caliber fibers (Figure 29A, blue trace) and large caliber fibers didn’t 
account for this recovery-boost (Figure 29B). During GD, all PLPKO caliber fibers showed a quicker 
recovery, anticipating that of PLPwt axons. During RAMP stimulation it is shown how ATP in small 
fibers is depleted more rapidly and to a larger extent than in large fibers (circa 20% difference; Figure 
29C-D). However no major difference was noticed between genotypes during this stimulation 




Figure 29. Further analysis of ATP in PLPKO optic nerves subjected to RAMP/GD, using a FIJI-macro to separate 
ATeam1.03YEMK fluorescence in large and small fibers.  
(A), (B) Exposure to glucose deprivation of PLPKO optic nerves produces similar ATP decays in small (A) and large caliber 
axons (B). Recovered signal is enhanced, regardless of size, in all PLPKO fibers but max overall recovery is greater only in 
small caliber PLPKO fibers, while appears similar between knockouts and controls in large axons (B, blue and orange traces). 
(C), (D) RAMP stimulation produces larger decays in small axons (C) than in large ones (D), no differences between 
genotypes could be observed. Dataset analyzed here is the same of figure 27. 
 
 
These findings demonstrate that in PLP-deficient mice, during transient GD, axonal ATP can be 
better maintained, probably as a result of compensatory mechanisms (see discussion 4.4). On the 
other hand, electrical stimulation, which directly impact on ATP consumption, shows no relevant 
differences in ATP steady states among genotypes. Conversely, the strong incapability of PLPKO 
stimulated axons to maintain conduction might be explained by a structural defect rather than a 




3.9 Spinal cord in-vivo imaging 
Ex-vivo preparations preserve tissue organization and cell-cell connectivity, thereby 
representing extremely useful tools to investigate CNS metabolism and support. In addition, 
genetically encoded FRET-based reporters provide the necessary temporal and spatial resolution to 
resolve metabolite dynamics in a living system. We have combined two aspects to specifically study 
white matter energy metabolism and metabolic support mechanisms in the context of electrical 
stimulation by isolating optic nerves from transgenic ATP-reporter mice. Isolated optic nerves are 
kept in defined conditions where most experimental parameters are under the experimenter’s control 
(e.g. temperature, amount of substrate, stimulation frequency, etc.). However, in these artificial 
conditions CNS metabolic states are likely very different from the in vivo scenario. Furthermore, long-
term experiments are restricted to the viability time of the acute ex-vivo preparation (< 24 hours for 
optic nerves). Thus, fundamental questions that require long term observations (e.g. “what is the 
metabolic impact of myelin ensheathing on axons?”) cannot be addressed in such system. To test in 
vivo relevance of our previous findings and to continue deepening in the still poorly understood 
territory of white matter metabolism we designed a strategy to study myelinated tracts in vivo in 





Figure 30. Laminectomy and chronic window implant in the spinal cord of a transgenic mouse.  
Illustration of chronic window implant following removal of the lamina pf the 12th thoracic vertebra (Laminectomy); 
Vertebrae T11 to L1 give support and are fixed by flanking steel clamps. A top plate is positioned along with tungsten 
electrodes for evoked CAP recordings. The window is sealed after the space between the CNS tissue and the top 5 mm 
circular coverslip is filled with transparent silicone. The skin is sutured and the implant stabilized with acrylic, providing a 




Most of CNS white matter tracts run deeply into the tissue with few exceptions, therefore, we 
decided to focus the study on the spinal cord (SC) where projecting axons form ascending (sensory) 
pathways run on the top side of the SC tubular formation. These fibers compose the somatosensory 
dorsal column-medial lemniscus tract, which contains the axons of the primary somatosensory 
neurons whose cell soma is found in the dorsal root ganglia. We access this formation by surgically 
removing the lamina of the 12th thoracic vertebra (T12 laminectomy, Figure 30).  
The vertebrae T11 to T13 were held together by steel clamps providing support for a steel 
top-plate. The steel implant carries a 5 mm coverslip on the top-side thereby providing a stable 
chronic window for repetitive imaging (Figure 30, see methods 6.14, and Farrar et al., 2012; Farrar & 
Schaffer 2014). The implant was successfully installed in ThyAT transgenic mice, without electrodes, 
to limit the time of surgery for imaging-only purpose. Imaging was carried at 5 days post-operative 
by acquiring 32 μm z-stacks at 2 μm step intervals. The z-stack max projection showed the in-vivo 
fluorescence of ATeam1.03YEMK in the ascending fibers of the fasciculus gracilis (Figure 31).  
 
 
Figure 31. In vivo imaging of ThyAT spinal cord axons of the fasciculus gracilis (T12) using a chronic window.  
(A) TCSPC-FLIM imaging of the Ateam1.03YEMK in axons of transgenic ThyAT mice. The averaged value measured for 𝛵a-w 
is 2.295  ±  0.008 ns. (B) Z-stack max projection of 30 μm section of in-vivo spinal cord axons expressing ATeam1.03YEMK. 





 ATP is likely the principal molecule in energy metabolism, produced or consumed in 
virtually every metabolic pathway. For a long time, ATP analysis was performed using biochemical 
assays (using e.g. hexokinase enzymatic assay or firefly-luciferase), providing accurate estimates of 
ATP concentration but since these require cell/tissue lysate it was limited to poor cell-specificity, and 
poor spatial and temporal resolution. The emergence of genetically-encoded sensors for ATP 
quantification and the development of imaging techniques overcame these limitations, providing 
cell specificity along with high resolution both in time and space. Several genetically-encoded ATP 
sensors have been described and used in different studies to estimate the cytosolic ATP-
concentration around 1-4 mM (Pathak et al., 2015; Rangaraju et al., 2014), well within the linear range 
of the ATP sensor used in this study. 
 This thesis aimed at understanding white matter metabolism and glial energy support 
contribution, by simultaneously monitoring axonal ATP and CAP recordings as functional readout of 
axonal integrity. This work focuses on optic nerve as white matter model, using an acute ex-vivo 
preparation. Despite missing one important parameter in metabolism, i.e. the active blood flow, this 
preparation has the considerable advantage of allowing precise control over other parameters, such 
as pH, temperature, substrates and electrical stimulation, which are fundamental in metabolism and 
not accessible in vivo. Moreover, unlike in-vitro systems, ex-vivo preparation offers the further 
advantage of preserving CNS structures: this conserved integrity is key to understanding the 
mechanisms of a functional cell-cell interaction. Thus, for the first time to our knowledge, we 
monitored optic nerve CAP and axonal ATP dynamics with very accurate spatial and temporal 
resolution, by taking advantage of neuronal (axonal) expression of the genetically encoded FRET 
sensor for ATP, ATeam1.03YEMK (Imamura et al., 2009), in a transgenic mouse line (ThyAT; Trevisiol et 
al., 2017). Having CAP and ATP as a readout for white matter energy metabolism, we manipulated 
the conditions in which the optic nerve was kept (e.g. firing rate, substrates, pharmacological 
inhibitors, etc.) to understand glial cell contribution in terms of metabolic support to axonal function. 
Following a precise characterization of the ATeam1.03YEMK expression in the CNS and a proof-of-
principle experiment of transient axonal energy loss, we studied I) single metabolic pathway 
inhibition, II) effects of key substrates (e.g. glucose, lactate, ketone bodies, etc.) in maintaining energy 




responses of optic nerve from a mouse model of spastic paraplegia type 2 (HSP or SPG2, i.e. spastic 
gait gene 2) under stress condition, V) ThyAT expression in spinal cord axons in vivo, as tool for 
repetitive ATP-monitoring during long time periods.  
 The following key findings were thus provided by this thesis: I) axonal ATP changes often 
correlate with CAP, decaying in a stimulation-frequency dependent manner; II) lactate metabolism 
contributes to ATP homeostasis in the presence of glucose as the exogenous energy substrate; III) 
recovery rates of ATP after cessation of HFS positively correlate with amplitudes of ATP decrease, 
suggesting short term adaptations of metabolism to match ATP demand; IV) no major difference in 
maintaining energy production is observed between substrates like glucose, lactate and pyruvate, 
even under HFS; V) although ketone bodies, as sole energy substrate, are unable to maintain energy 
production in any condition, ketogenic diet provided a mean of axonal protection after transient 
glucose deprivation as indicated by enhanced CAP recovery in optic nerves; VI) loss of PLP1 in 
oligodendrocytes in a SPG2 mouse model, results in impaired axonal AP conduction during HFS but 
enhanced CAP/ATP homeostasis during glucose deprivation, indicating presence of compensatory 
mechanisms; VII) ThyAT expresses ATeam1.03YEMK in spinal cord axons in vivo and repetitive imaging 
is allowed by a chronic window implant. 
 Our study, by relying on the coupling of electrophysiological recordings of white matter 
tracts of ThyAT mice as axonal ATP reporter, provides a deeper understanding of WM metabolism, 
glial support and myelin.  
 
4.1 Experimental limitations 
 Our experimental approach has some limitations which need to be considered for 
interpretation of the data. It should be noted that ATeam1.03YEMK reports the steady state 
concentration of ATP, which is in function of both production and consumption and therefore 
changes can be measured only if there is an imbalance between rate of ATP production and rate of 
ATP consumption. The transient decay in ATeam1.03YEMK ratio due to, for example, low substrate 
availability can be explained by the impossibility of ATP production in matching its relatively 
unchanged consumption. Therefore, the incomplete recovery of ATP signal after the stressful 
Discussion 
57 
condition of energy loss can be explained by the achievement of a new steady state, different from 
that observed at baseline, as a result of reduced consumption or production (Figure 32). 
 
Figure 32. Concept of ATP steady state  
Measured ATP is the result of a steady state to which two opposite processes contribute: production (via metabolic 
pathways) and consumption (via cellular processes). Consumption of ATP can be enhanced in neurons by electrical 
activity, while ATP production can be blocked by specific metabolic pathway inhibitors or lack of substrates/ oxygen. 
 
 
 Moreover, the correlation between two relative parameters’ changes such as ATP and CAP 
at a given condition might appear controversial given CAP and ATP signals have different origins 
within the optic nerve. On one side, the CAP, evoked by supra-threshold stimulation, measures the 
sum of AP propagation along most of the axons (tens of thousands). In contrast, ATP imaging was 
performed on a single optical plane rather close to the surface of the nerve (within 15-20 μm), which 
typically contained 29 ± 5 axons expressing ATeam1.03YEMK. Despite this apparent incongruence, we 
showed that the relationship between the two parameters is constant over many experiments (Figure 
6E) suggesting that the selection of an imaging plane does not artificially determine the experimental 
outcome. Furthermore, comparison among experiments has been very useful, for example to confirm 
and understand the impact of lactate metabolism on CAP and ATP (Figure 21). 
 On the different nature of CAP and ATP, it has to be taken into account that in absence of 
active blood perfusion in the excised optic nerve ex vivo, the passive diffusion of substrates into the 
nerve poses the axons, and the associated glial cells located in the nerve’s core, in a constant shortage 




scattering properties of a parallel organization of densely packed, highly myelinated axons that 
compose the optic nerve, even using 2-photon laser scanning microscopy, imaging within the core 
of the optic nerve is hardly possible (data not shown). Despite these limitations, our experiments 
present the best estimate of the simultaneous analysis of both parameters possible at the moment. 
Furthermore, the spatial resolution along with the averaging of the ATeam1.03YEMK signal over several 
axons, estimates axoplasmic ATP concentration changes of multiple fibers. At such optimized spatial 
and temporal resolution provided by our experimental setting, possible ATP microdomains caused 
by local ATP production, by mitochondria, or by consumption, e.g. by Na+/K+-ATPase at the plasma 
membrane (Haller, Mironov, & Richter, 2001), are missed. However, the presence of ATP 
microdomains is uncertain as ATP diffusion has been reported to be very fast and formation of ATP 
microdomains is not to be expected (Barros et al., 2013). 
Finally, we considered unspecific changes, e.g. quenching of the FPs, in FRET fluorescence as 
potential artifacts in our measurements. In this regard, the most prominent problem that has been 
reported to our knowledge is yellow FP variants showing pH-dependent fluorescence changes also 
in physiological pH-range (Nagai et al., 2004; Zhao et al., 2011). Since ATeam1.03YEMK is a sensor 
based on CFP-YFP FRET pair, intrinsic changes in the YFP acceptor fluorescence could be wrongly 
interpreted as FRET specific effect. Even though ATeam1.03YEMK has been shown to be almost 
insensitive to changes in pH within the physiological range, likely due to the circular permutation of 
cp173mVenus (Imamura et al., 2009; Surin et al., 2014), we systematically monitored acceptor 
fluorescence upon direct excitation and found only minor changes in cp173mVenus fluorescence 
(Figure 6C-D, Figure 8B, Figure 9B and Figure 15D-F). Although we cannot fully exclude that other 
processes are interfering with other moieties of ATeam1.03YEMK, these results indicate that changes 




4.2 Calibration of ATeam1.03YEMK 
A known caveat for metabolic sensors based on the detection of a target substrate via binding 
proteins is their non-linearity behavior at extreme concentrations above and below their reported Kd. 
ATeam1.03YEMK has an apparent dissociation constant Kd equal to 1.2 mM (Imamura et al., 2009), 
which in practical terms means that the sensor responds in a linear way only for few millimolar units 
of ATP around this value (Figure 3A). At saturation, larger changes in concentrations are required to 
change the FRET ratio by the same amount observed in the linear phase. By calculating normalized-
relative changes in FRET ratio we are prone to systematically underestimate (or, if approaching the 
linear range, overestimate) the calculated change in ATP underlying the ratio. This problem is 
particularly prominent when ATP rates and kinetics are considered. By reporting ATP rates to be 
enhanced following higher stimulation frequencies, we are forced to take the sensor linearity into 
account and make the assumption that at baseline, neuronal/axonal ATP match the values reported 
in the literature and close to the Kd of the sensor (1-4 mM; Rangaraju et al., 2014; Pathak et al., 2015). 
Given this assumption, by fitting the obtained data at HFS, we determined that the changes in ratio 
reflects those of ATP in a quasi-linear way and correlation between rates of ATP are valid. 
Nevertheless, the axonal ATP has never been experimentally assessed in a precise manner and the 
conclusions on ATP kinetics have to be taken with proper precautions.  
Thus, for non-linearity corrections, a precise calibration of the sensor is required. However, the 
lack of transporters and the amount of metabolic pathways involved in the ATP homeostasis makes 
calibration procedures ex-vivo and in-vivo very problematic. Calibration in vitro using single-cell 
would represent a suitable approach, however due to the Rayleigh scattering phenomena, potential 
ratiometric intensity-based calibration curves obtained in cells cannot be applied to more complex 
systems such as acute CNS preparations where the matrix scattering elements contributes to artificial 
alteration in the FRET ratio. We took a different approach which does not rely on intensity 
determination of FRET: FLIM. Using FLIM and cell culture preparations we could describe variation in 
FRET as changes in lifetime 𝛵 as confirmed by the observed transition of 𝛵 in polar plot analysis 
where a pixel-based 2D coordinate transformation of 𝛵 (for software limitation a single exponential 
decay was assumed) along a polar plot representation, displayed two different populations of the 
sensor’s 𝛵 at baseline (ATP) and following ATP washout (no ATP; Figure 33B, lower panel). We initially 




sensor, obtaining positive results (Figure 33C). By transfecting primary astrocytes we attempt to 
reconstruct the calibration curve: unfortunately, using concentrations close to ATeam1.03YEMK 
saturation (e.g. 10 mM, Figure 33D) the 𝛵av-w deviated considerably from its baseline, though closer 
values (or even lower than baseline’s) were expected.  
 
Figure 33. FLIM –TCSPC analysis of ATeam1.03YEMK in cultured cells and calibration.  
(A) Histogram of photons’ arrival at the TCSPC-PMT detector and double exponential fit model, displaying the 
fluorescence decay of ATeam1.03YEMK during baseline condition. (B) Phasor-plot analysis of the lifetimes (assuming mono-
exponential decay) shows lifetime transition from short (baseline, on top) to long (absence of ATP: digitonin 
permeabilization and mitochondrial blockade with N3, bottom).  (C) From left: mseCFP (donor of ATeam1.03YEMK) 
fluorescence transition from short to long lifetime values, when the plasma membrane of transfected HeLa cells is 
perforated by digitonin and ATP leaks out from cytoplasm (0 ATP). 10 mM ATP is then added in the imaging medium to 
saturate the sensor leading to a shortening of the LT (right). (D) Example of average-weighted lifetime (𝛵av-w) transition 




Given it is unlikely astrocytic cytosolic ATP concentration is higher than the supposed 
saturation level of ATeam1.03YEMK we concluded that other processes interfered with the sensor. One 
likely process interfering with the fluorescence properties of the FRET-reporter could be the 
permeabilizing agent itself: both digitonin and aescin contain as many as 17 hydroxy groups per 
molecule which might cross-react with the probe.  
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4.3 Axonal ATP homeostasis and nerve conduction  
 Studying metabolism can be a true challenge given its hierarchical nature: metabolism in 
fact can be seen as a hierarchical organization spanning from single metabolites to entire CNS 
regions, passing through single metabolic pathways. Different techniques and model systems are 
required and should be used for the common aim of unraveling the whole picture (L Felipe Barros et 
al., 2017). The synchronized measurement of ATP as axonal energy state and nerve CAP, as a readout 
for nerve conduction and function, despite focusing on a single model system, covers many of these 
levels and allows for the first time to investigate their temporal and functional correlation in WM.  
 Interference with metabolic pathways of the axon, by withdrawal of substrates (GD), 
inhibition of mitochondrial OX-PHOS (MB) severely compromised axonal ATP as indicated by the 
lowest ratio obtained from ATeam1.03YEMK. The combination of GD and MB mimicked a sudden 
ischemic event and resulted in complete ATP loss. However, time courses of treatments differed: 
during GD, ATP signal began to decay only after 13 min and with a lower rate than after MB, where 
ATP decay was nearly instantaneous. The slower time course for energy loss observed during GD, is 
consistent with the breakdown of glycogen, which can be used as spare fuel (Brown & Ransom, 
2007). We presumed that during MB, glycogen is still present but, in absence of active mitochondria, 
its breakdown by glycolysis only is insufficient to power ATP production in axons as indicated by the 
sudden and very fast decay of ATeam1.03YEMK ratio in the axons. These results suggest that axons 
strongly rely on mitochondria for ATP production. In most of energy-failure paradigms, ATP decrease 
matched CAP’s, indicating a correlation between ATP depletion and conduction failure. Conversely, 
following reperfusion of the optic nerves with control aCSF, ATP signal recovered significantly later 
than CAP (following GD and OGD). ATP signal, unlike CAP’s, is the result of two opposite processes, 
namely production and consumption, and its readout is the sum of both, i.e. the steady-state (see 
above). It is likely that ATP is produced at the beginning of reperfusion but is also immediately 
consumed e.g. for re-establishing ion gradients and consequently, it does not accumulate in the 
axoplasm. The belated onset of ATP recovery observed following OGD and GD, compared to the 
virtually instant rescue observed after MB and MB+GD cessation, can also be explained from the 
point of view of ATP production. While during aglycemia (GD) the nerve can still catabolize all 
available substrates, e.g. glucose, lactate and fatty acids, leading to an eventual depletion of all 




(MB and MB+GD) doesn’t allow this prolonged consumption and eventual depletion. Thus, while 
after glucose reperfusion following GD, glucose needs to reach the axons before it can be 
catabolized, after removal of the inhibitory action on mitochondria respiratory chain, following MB 
and MB + GD, metabolites still present in the axon can be metabolized immediately, in line with the 
quicker ATP recovery detected.  
 We experimentally achieved mitochondrial inhibition by addition of azide or by replacing 
oxygen with nitrogen. Although the mechanism of inhibition should be very similar for azide and 
nitrogen (reversible blockade of cytochrome c oxidase activity) we observed dissimilar dynamics of 
energy loss (MB vs. N2). Whereas 45 minutes of nitrogen (N2) exposure, in presence of glucose didn’t 
cause ATP loss (contrary to expectations, the signal increased), a short 5 minute exposure to 5 mM 
azide, even in presence of glucose, caused complete ATP depletion. We presume that the substitution 
of oxygen with nitrogen (sparging) was incomplete and some dissolved oxygen might still have been 
present when the solution reached the nerve. Despite being provided with nitrogen, the chamber 
was in fact not air-tight. Given the very small volume of aCSF flowing to the nerve (high surface-to-
volume ratio), the lack of air-tightness could have facilitated oxygen to dissolve into the aCSF 
transforming an intended anoxia into a milder hypoxia. The observed relative 20-30% increase in ATP 
signal from baseline, following nitrogen exposure was described both during N2 and OGD. In absence 
of active perfusion of oxygen by blood circulation, aCSF saturation with 95% oxygen is possibly a 
compromise to maintain acute preparations of CNS structure viable ex vivo. Providing oxygen has a 
diffusion gradient towards the nerve core , under normal circumstances of oxygenated aCSF, the 
oxygen levels in the nerve’s core correspond to hypoxic conditions (Mulkey, Henderson, Olson, 
Putnam, & Dean, 2001) while the axons running at the nerve’s periphery are under oxidative stress 
(D’Agostino, Putnam, & Dean, 2007; Mulkey et al., 2001). During hypoxia, the imaged fibers at the 
periphery of the nerve are temporarily released from the oxidative stress induced by the high oxygen 
present at baseline, and normally used to keep acute preparations of CNS structure viable ex-vivo. 
Considering the nature of the recorder ATP (imaged within 20 μm from the surface) and CAP 
(reflecting the conduction of virtually all axons), the presence of a diffusion gradient for oxygen might 
explain the ATP-CAP signal divergence under N2 treatment. The production of superoxide radicals 
are known to interfere directly with the cell energy metabolism at the level of the TCA cycle 
superoxide-sensitive enzymes: aconitase and fumarase (Gardner & Fridovich, 1993). Superoxide 
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might also induce axons and glial cells to activate compensatory mechanisms (e.g. glutathione) that 
require energy (Lu, 2009; Meister & Anderson, 1983). Similarly to N2, an initial 20-30% increase in 
ATP signal was also observed during OGD (combination of N2 and GD; Figure 10C), but this effect 
was quickly overrun by the lack of substrates, setting the decay onset at 12.2  ±  1.0 min for ATP and 
12.0  ±  1.0 min for CAP signal (Figure 10D, lower-right panel). 
 Given the low control on oxygen levels provided by N2, the pharmacological inhibition 
induced by azide provides a better model to study acute ischemic events in ex-vivo preparations. To 
study oxygen impact (normoxia, anoxia, etc.) on WM metabolism, devices that allow a precise control 
on oxygen partial pressure should be employed (Mauleon, Fall, & Eddington, 2012).  
 Axons of the optic nerve are sensory projections of the retinal ganglion cells (RGCs) and, 
under physiological conditions, action potentials are generated in frequencies between 0.1 and 25 
Hz, with most firing rates between 3 and 10 Hz (data obtained for guinea pig; (Koch et al., 2006; 
Perge, Koch, Miller, Sterling, & Balasubramanian, 2009). The axonal ATP of optic nerves superfused 
with 10 mM glucose wasn’t altered by physiological stimulation rates between 1 and 7 Hz (Figure 
12D-E). The stability of the ATP signal under these physiological stimulations suggests that the 
metabolic architecture of the optic nerve is adjusted to maintain ATP constant under normal and 
sustained activity. As soon as the physiological activity threshold was exceeded by the HFS (>15 Hz), 
axonal ATP showed a reversible decline, whose amplitude directly correlated with the rise of the 
stimulation frequency. Even though these supra-physiological stimulation rates are not found in vivo, 
they represent an important tool to understand the metabolic adaptation to increase energy 
requirements by WM. Unlike the described energy failure paradigms, where the energy consumption 
was kept constant by the lack of substrate availability, during HFS the metabolic demand possibly 
increases in a stimulation-dependent fashion. The increase in demand is likely driven by the 
activation of the Na/K ATPase (Attwell & Laughlin, 2001; Johar, Priya, & Wong-Riley, 2014) and is 
accompanied by Ca2+ accumulation in the axon following AP propagation (Lev-Ram & Grinvald, 1987; 
Zhang, Wilson, Williams, & Chiu, 2006): calcium influx regulates glycolysis via Ca2+/calmodulin-
dependent protein kinase (Mieskes, Kuduz, & Soling, 1987) and trigger mitochondrial ATP synthesis 
by increasing malate-aspartate shuttle and pyruvate mitochondrial oxidation (Rueda et al., 2014). The 
idea of metabolic activation concomitant with the increased demand of ATP seems to be supported 




of signal decay achieved at the end of the stimulation. The experimental manipulation of WM energy 
production and consumption has the advantage of providing a better understanding of glial cell 
contribution in terms of energy support to axonal function.  
 To provide a different approach to the study of WM energy homeostasis, we employed 
CAG-GO-ATeam optic nerves in collaboration with Dr. Natsubori at Keio University. GO-ATeam, a 
red-shifted ATP sensor, is expressed globally in all CNS cell types: sparse labeling expression however, 
allowed to visualize single cells in the optic nerve (Figure 18B-D). Electrical stimulation (RAMP) 
showed mild ATP-depletion probably consistent with labeling of a smaller subset of axons than in 
ThyAT (indistinguishable from other cellular processes), however, direct ATP-responses by other cells 
(e.g. pericytes, oligodendrocytes, etc.) cannot be excluded because of the nature of the CAG reporter 
line. The prevalence of cells and processes in CAG-GO-ATeam optic nerves served as a point of 
comparison with axonal specific ATP reporter (ThyAT) nerves. While simultaneous blockade of 
mitochondria and glucose deprivation also depleted ATP very quickly, glucose deprivation in CAG-
GO-ATeam nerves induced a faster affect albeit smaller in amplitude, on ATP loss, than ThyAT axons. 
Intriguing, the recovery from GD obtained by glucose reperfusion gave rise to an instantaneous ATP 
signal rescue in CAG-GO-ATeam. Conversely, in ThyAT optic nerves, the ATP rescue happened only 
after 10 minutes from glucose reintroduction in a similar paradigm. Given the higher specificity for 
axonal ATP provided by Thy1.2 promoter, we hypothesize that either I) axons are possibly less 
glycolytic and have to rely on other cells for support and energy production; II) axons require more 
energy to maintain their structure and function; III) during passive diffusion of substrates, glial cells 
and pericytes in particular are in front position to uptake and oxidize glucose. The first hypothesis is 
supported by the observation that lack of glial cell glycolysis results in neurodegeneration while 
neuronal glycolysis is not required (in drosophila; Volkenhoff et al., 2015; Schirmeier et al., 2016). On 
the second hypothesis, similarly to neurons in gray matter it can be assumed that most of the energy 
expenditure in WM is accounted by the axons (Harris & Attwell, 2012; Laughlin, de Ruyter van 
Steveninck, & Anderson, 1998). However, we cannot exclude coexistence of these three hypothesis 
and to further study metabolic heterogeneity in WM, the observations made in CAG-GO-ATeam and 
ThyAT optic nerves should be extended e.g. with other metabolic reporters/ promoters and by using 
specific metabolic pathway inhibitors. 
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Is lactate the substrate used by glial cells to bridge their metabolism to support energy production 
in axons?  
 Whether neurons, and their axons, prefer glucose or lactate as their main energy substrate 
during rest and activity is still a matter of debate (Díaz-García et al., 2017; Dienel, 2012; J. Hirrlinger 
& Nave, 2014; Luc Pellerin & Magistretti, 2012). Both substrates can sustain CAP propagation in the 
optic nerve and astrocytes metabolize stored glycogen to lactate, during HFS or OGD, to support 
axonal energy homeostasis (Brown et al., 2005, 2003, 2001). We investigated whether, under 
enhanced axonal energy demand forced by HFS, lactate and pyruvate can be utilized by the nerve in 
the same way as glucose i. In line with previous findings (Brown et al., 2001), lactate and pyruvate 
support CAPs similarly as glucose even during HFS. However axonal ATP decayed significantly more 
during HFS when lactate or pyruvate were present as the sole energy substrates. Consistent with this 
result, under glutamate stimulation, ATP production in cultured cerebellar neurons has been shown 
to be well maintained only by glucose (Lange et al., 2015). Nevertheless, our results show that lactate 
derived from glucose oxidation is involved in axonal ATP homeostasis. Under inhibition of 
endogenous lactate metabolism, with D-lactate or by selectively blocking MCT1-2 by AR-C155858, 
ATP reached a significantly lower steady state at the end of HFS, as a result of either increased ATP 
consumption or reduced production (Figure 32). However, MCT1het optic nerves did not show 
significant differences in ATP levels after stimulation at HFS, compared to wild type mice. MCT1het 
mice have only half of the transporter proteins in glial cells and, even though old MCT1het mice show 
axonopathy in small caliber fibers (Lee et al., 2012), the reduced amount of transporters they have, 
or possible compensatory mechanisms, might play a role in maintaining WM energy metabolism 
viable at the studied time point (10 weeks). Thus, the pharmacological inhibition of MCTs and lactate 
metabolism provides a thorough approach to confirm the contribution of endogenous lactate 
production to ATP generation. Direct supply of lactate seems not to be as effective as endogenous 
glucose-derived lactate. Therefore, we suggest that WM organization creates a preferential pathway 
for glucose, the main circulating substrate. This preferential pathway uses GLUT1 transporters facing 
the luminal side to uptake glucose into glial cells which follows rapid hexokinase phosphorylation 
and conversion to lactate. Lactate produced from glucose can probably serve as a local supply, in 
contrast to when it is superfused in the aCSF. This preferential pathway relies also on gap-junction 




very quickly, without the need for rate-limiting MCTs, reaching axons faster. Using our experimental 
setup we could show this higher metabolic power of endogenously-produced lactate in maintaining 
ATP production and the dominant role of glucose in energy production in WM. 
 Glucose is the main carbon source leading to ATP generation in the CNS, however, ketone 
bodies are an important resource during prolonged caloric restriction periods. In absence of glucose, 
our results showed acetoacetate failed to maintain ATP production and conduction in the optic 
nerves, in the presence of β-Hydroxybutyrate (β-HB) as substrate. We hypothesize this was due to 
the rate limiting reaction of acetoacetate conversion into acetyl-CoA that fuels the TCA cycle. This 
limitation was likely due to low expression of mitochondrial SCOT enzymes. Bypassing this rate-
limiting step by inducing ketogenic conditions, which increases  expression of mitochondrial SCOT 
enzymes (Düking et al., unpublished data) or by inducing regulatory modifications on this ketolytic 
enzyme (Turko, Marcondes, & Murad, 2001) failed to maintain axonal ATP and CAP in the presence 
of β-HB as substrate. Strikingly, the recovery of optic nerve conduction, was nearly complete in optic 
nerves from ketogenic diet treated mice after glucose was re-introduced. This finding fits the 
extensive data supporting the neuroprotective effect of a ketogenic diet (Maalouf, Rho, & Mattson, 
2009; Newman & Verdin, 2014, 2017; Rahman et al., 2014). 
 
4.4 Myelin role in controlling ATP homeostasis: PLP mutants 
 Myelin lowers the energetic costs for action potential propagation, but at the same time it 
restricts the axons from accessing extracellular metabolites (J. Hirrlinger & Nave, 2014). To bypass 
this obstacle, oligodendrocytes use myelin sheaths as an active interface that metabolically support 
axons (Nave 2010; Lee et al., 2012; Fünfschilling et al., 2012; Hirrlinger & Nave 2014). What is the 
functional impact on this regulated coupling if myelin stability and function are compromised? We 
addressed this question by crossbreeding the ThyAT reporter mice with mice deficient for the major 
myelin protein PLP, a model mouse line for human spastic paraplegia type 2.  
 Optic nerves from 10 weeks old ThyAT  PLPKO mice were acutely isolated. Although axonal 
degeneration is not reported at this age (Edgar et al., 2004; Griffiths et al., 1998) early signs of white 
matter impairment (i.e. axonal swellings, conduction loss and CAP lag) were observed (Figure 25). 
PLPKO optic nerves were thus challenged with HFS. The results reported a further conduction (CAP) 
impairment from the population of responding fibers (i.e. in which APs could be elicited) indicating 
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an enhanced susceptibility of PLPKO WM. Surprisingly, axonal ATP was barely altered during the 
stimulation and only minor impairments were shown when single frequencies (16, 50 Hz) were used. 
It is possible that during the transient increase in energetic demand triggered by HFS, the axons of 
PLPKO nerves are still well supported by glial cells and myelin instability does not interfere with the 
support mechanisms,. Consequently, the observed conduction impairment in PLPKO nerves could be 
strictly functional, for example due to alteration in K+ channel distribution, as reported for other 
myelin mutant models (Rasband, Trimmer, Peles, Levinson, & Shrager, 1999; Sinha, Karimi-
Abdolrezaee, Velumian, & Fehlings, 2006).  
 We further investigated energy homeostasis in PLPKO mice by exposing the optic nerve to 
a transient period of aglycemia (glucose deprivation, GD). In sharp contrast to the predicted results, 
CAP and the ATP signal from PLPKO optic nerves decayed with slower kinetics than controls during 
the shortage of metabolites, possibly indicating the presence of compensatory mechanisms 
supporting PLP-lacking nerves. In line with this observation, as glucose was restored, PLPKO nerves 
also recovered much more vigorously than controls, outreaching controls in total ATP. An in-depth 
analysis showed small caliber fibers to contribute more substantially than large caliber fibers to this 
observed increase in ATP rescue. Interestingly, small fibers in the optic nerves of PLPKO mice show 
more frequent swellings than larger ones (Griffiths, 1998; Griffiths et al., 1998).  Furthermore, as 
previously discussed, the increase in recovered ATP following an energy deprivation is a result of a 
new steady state and might be conceptually uncoupled from recovery of conductance (similar in 
extent for PLPKO and control nerves) indicating a more efficient mechanism of ATP generation which 
might be the result of a compensatory mechanism. Along these lines, two further observations 
should be considered: I) PLPKO mice show an increase of the GLUT1 and MCT1 transporters within 
myelin (Kusch et al., unpublished), which are found in non-compacted myelin regions at the inner 
and outer tongue in wildtype white matter; II) Non-compacted regions of myelin are more frequent 
in PLPKO animals (Möbius W., unpublished observation). These two findings might underlie an 
increase in the flow of substrates towards the axons and therefore might contribute to the observed 
phenotype. Further supporting this hypothesis, the observed dysregulation of kinase proteins 
involved in glucose metabolism in PLPKO (e.g. PAK1 and PEA-15, linked to regulation of PGM 
(Phosphoglycerate mutase, glycolytic enzyme) and GLUT1/3 insertion in the plasma membrane 




 PLPKO mice develop an early axonal transport deficit with transport cargo, including 
mitochondria, being trapped on the distal side of nodes of Ranvier (Edgar et al., 2004). While myelin 
appears grossly normal at this early stage (as well as at the age of 10 weeks, our current experiments 
timepoint; Griffiths et al., 1998; Griffiths 1998), our findings suggest the presence of compensatory 
mechanisms, acting against a functional impairment and setting a new ATP steady state. During 
axonal action potential propagation, glutamate is released from axons activating NMDA receptors 
on myelin and resulting in Ca2+ signals in myelin and oligodendrocytes (Kriegler & Chiu, 1993; Ileana 
Micu et al., 2007, 2016) Activation of NMDA receptors on oligodendrocytes also increase the 
membrane expression of GLUT1 transporters (Saab et al., 2016). The metabolic targets of Ca2+ signals 
within the oligodendrocytes might include a Ca2+/calmodulin-dependent protein kinase (Mieskes et 
al., 1987), together with regulation of mitochondrial ATP synthesis via enhanced malate-aspartate 
shuttle and pyruvate mitochondrial oxidation (Rueda et al., 2014). This Ca2+ regulated mechanism 
might result in an upregulation of lactate transfer from myelin to axons (Fünfschilling et al., 2012; Lee 
et al., 2012) which would therefore represent a prime candidate to enhance axonal ATP production. 
In conclusion, by monitoring axonal ATP and nerve CAP we could demonstrate the presence of 
energy adaptation mechanisms, mainly in small fibers, in parallel to conduction impairments. The 
CAP impairment could potentially reflect a myelin architectural deficit which is compensated by an 
enhanced flux of metabolites to the nerve. The physical absence of PLP1 in the myelin compartment 
of this mouse model for hSPG2 could in fact lead to myelin and conduction instabilities but also to 
cytosolic channel openings where transporters can be inserted, thereby facilitating the flux of 
metabolites and partially compensating the costs for AP propagation at high rates.  
 This approach for studying WM metabolism has proved to be very sensitive to detect 
mutant oligodendrocytes’ effects on axonal energy metabolism and physiology, months before the 
onset of axonal loss and spastic paraplegia clinical symptoms. To unravel the complete pathological 
impact of PLP1 mutation on axonal metabolism, further analysis should be considered, for example 
aiming at blocking specific axonal support pathways or at visualizing additional metabolite fluxes 




4.5 Conclusions  
Our approach combines confocal axonal ATP imaging in a new transgenic mouse line with 
electrophysiology of CAPs in acutely isolated optic nerves. Such approach represents a novel method 
to assess energy homeostasis in correlation to the ability of electrical signal propagation along white 
matter tracts. This new technical approach allowed us to provide insights about energy metabolism 
in white matter. Moreover we demonstrated that CAP and the axonal energy status are not intimately 
correlated as previously assumed and a more complex interaction has to be considered. As 
disturbances of energy metabolism or glial support contributes to numerous CNS diseases, including 
spastic paraplegia investigated in this work, this new approach will allow to investigate metabolic 
dysregulations that precede or are concomitant with the degeneration process. Based on these 
insights, new therapeutic strategies might be designed aiming at preserving the axonal energy 





We combined metabolic imaging and nerve electrophysiology to generate a novel approach for 
studying metabolism and its implication in neuronal function. This new technical approach provides 
an advancement in the study of white matter metabolism and its energy balance by promoting the 
understanding of the complex metabolic connectivity within myelinated fiber tracts. The strength of 
this approach resides in its coverage of several complexity levels in the hierarchic structure of 
metabolism: from the single metabolite to the pathways involved in its production within and among 
cells, by using specific pathway inhibitors. It allows studying metabolites with unprecedented 
resolution in time and space. However, this approach can have certain limitations when substrate 
concentrations need to be quantified. Therefore, a reasonable alternative is fluorescence lifetime 
measurements using 2-photon laser-scanning microscopy (i.e. FLIM). Contrary to the intensity based 
approach used in this thesis, FLIM is insensitive to phenomena such as wavelength-dependent light 
scattering or bleaching. Therefore, together with proper calibration of metabolic sensors, FLIM can 
provide absolute readouts for metabolites allowing a more precise comparison between mutants 
and wildtype animals or between different regions of white and gray matter. 
The use of ex-vivo preparations presents certain limitations as well. Two of these limitations are 
important in the assessment of metabolism: I) the lack of active blood perfusion which, as discussed, 
leads to non-linear phenomena like the passive diffusion of substrates, metabolites and gas across 
the tissue; II) the limited time window in which the preparation can be considered viable before 
intrinsic degenerative phenomena begin (i.e. Wallerian degeneration for white matter). To overcome 
these limitations, it is necessary to extend from ex-vivo observations to an in-vivo system where 
imaging and electrophysiology can be unceasingly performed over a prolonged period of time. 
Unfortunately, CNS white matter tracts, by running deeply within the tissue, give scarce accessibility 
to conventional optical systems. However, optical access to the spino-cortical white matter tracts 
using a single surgical procedure has been described (Farrar et al., 2012; Farrar & Schaffer, 2014). In 
this thesis, we demonstrate the feasibility of assessing the metabolic state of spino-cortical white 
matter in vivo using FRET. This preparation can be combined with electrophysiological recordings of 
CAP and with viral vector technology, offering an experimental platform that supports ex-vivo 
observations. Moreover, it can help understand white matter vascular coupling to glial cells and 




experimentally extends the limited time window that ex-vivo preparations provide, allowing the study 
of acute demyelination and oligodendrocyte remyelination, their role in axonal energy budget, and 
their impact on axonal functionality and viability.  
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6 Material and Methods 
 
6.1 Solutions 
All master solutions were pH adjusted to 7.4 at the experimental temperature using HCl or 
NaOH solutions following gas (carbogen/ nitrogen)-equilibration. 
 
6.1.1 aCSF 
aCSF solution was used to superfused the optic nerves in the incubation chamber. aCSF was 
prepared by mixing 2X stock solutions A (NaCl, KCl) and B (NaH2PO4, NaHCO3, MgSO4) kept at 4 °C. 
CaCl2 was then added from a 4 M stock solution (i.e. 2000 dilution) and glucose, sucrose and other 
substrates and drugs were finally added. The aCSF master solution was warmed to 37 °C and gassed 
with carbogen mixture (95% O2 / 5% CO2) for about 1 hour before pH was adjusted and final solutions 
mixed separately. For lactate and other Na-salts compounds whose final concentration exceeded 1 
mM, Na+ was reduced in the stock solution to keep its concentration constant. In case the drug (e.g. 
AR-C155858) was diluted from DMSO stock, control solutions were created by adjusting DMSO 
volume. The composition of the aCSF master solution was: 
 
 mM MW (g∙mol-1) mOsm 
NaCl 126 58.44 252 
KCl 3 74.55 6 
NaH2PO4 1.25 137.99 2.5 
NaHCO3 26 84.01 52 
MgSO4 2 246.48 4 
CaCl2 2 147.02 6 
Substrate 10 - 10 
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6.1.2 AP buffer 
AP buffer was used for perfusion of mixed neuro-glia culture. AP buffer is an HEPES-based 
imaging medium. The master solution was prepared by mixing: 
 mM MW (g∙mol-1) mOsm 
HEPES 20.0 238.31 20.0 
CaCl2 1.8 147.02 5.4 
MgCl2 1.0 203.3 3.0 
KCl 5.4 74.56 10.8 
NaCl 110.0 58.44 220.0 
Na2HPO4 0.8 177.99 2.4 
Substrate 20.0 - 20.0 
 
 
CaCl2 was added from a 4 M stock (2222.22 fold dilution) before pH adjustment to 7.4 using NaOH 
solution. Finally, substrates (e.g. glucose, sucrose) and drugs were all added separately from powder 
or stock solutions at the beginning of each experiment. For lactate and other Na-salts compounds 
whose final concentration exceeded 1 mM, Na+ was reduced in the stock solution to keep its final 
concentration constant (110 mM). In case the drug (e.g. ouabain) was diluted from DMSO stock, 
control solutions were created by adjusting DMSO volume. 
 
6.1.3 AT imaging medium 
AT imaging medium was used for the calibration of Ateam1.03YEMK in HeLa cells and primary 
astrocytes. pH is kept constant by HEPES, carbonate as well as phosphate buffering. The master 
solution was prepared by mixing two 2x stock solution (1 = NaCl, KCl, HEPES, NaH2PO4, NaOH; 2 = 
MgSO3, NaHCO3, Na2HPO4) in equal amounts. CaCl2 was added separately from a 4 M stock (2222.22 
dilution factor). NaOH is included in the master solution in the attempt to balance the acidic pH 
created by HEPES and account for the extra Na+ introduced. The final master solution was: 
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 mM MW (g∙mol-1) mOSm 
NaCl 91.77125 58.44 183.5425 
NaHCO3 17.856 84.007 35.712 
HEPES 20 238.3012 20 
KCl 5.366 74.5515 10.732 
MgSO4∙7H2O 0.811 246.4755 1.622 
NaH2PO4∙H2O 0.906 137.99 1.812 
Na2HPO4∙2H2O 0.2265 177.99 0.6795 
CaCl2∙2H2O 1.8 147.02 5.4 
Substrate 20 - 20 
NaOH 15.5 39.9971 15.5 
 
AT imaging medium was warmed to 37 °C or RT depending on the experimental temperature 
before pH was adjusted to 7.4 using HCl solution. Appropriate substrates and drugs were added to 
the final solution mixture. Na+ and DMSO were adjusted in the control solution accordingly.  
 
6.2 Transgenic mice 
Animals were bred in the animal facility of the Max-Planck-Institute for Experimental Medicine 
and treated in accordance with the German Protection of Animals Act (TSchG §4 Abs. 3) and with the 
guidelines for the welfare of experimental animals issued by the European Communities Council 
Directive 2010/63/EU. Mice were housed in a 12h/12h light dark cycle with access to food and water 
ad libitum. The transgene construct was assembled in pTSC (P. G. Hirrlinger et al., 2005) containing 
Thy1.2 promoter sequences. The plasmid pDR-GW AT1.03YEMK containing the open reading frame of 
the ATP-sensor ATeam1.03YEMK (Imamura et al., 2009) was obtained from Wolf Frommer (via 
Addgene; plasmid #28004). The open reading frame of ATeam1.03YEMK was subcloned into the XhoI 
restriction site of pTSC using PCR. The linearized transgene was injected into fertilized mouse oocytes 
of the C57BL/6J mouse strain. Transgenic founders were identified using PCR based genotyping on 
genomic DNA isolated from tail tips (see section 6.2.3 and 6.2.4). 
CAG-GO-ATeam mice were transferred from the department of neuropsychiatry at the Keio 
University School of Medicine in Tokyo (Japan) to our lab in Göttingen and kept in the quarantine of 
the animal facility until experiments were performed.   
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6.2.1 Determination of copy number 
Mouse genomic DNA was isolated from tail biopsies of four C57BL/6J and six ThyAT-mice 
with Invisorb® Spin Tissue Mini Kit according to the manufacturer’s instructions (Stratec Biomedical, 
Birkenfeld, Germany). Short FAM-labeled hydrolysis probes (UPL) were used for qPCR reactions 
(Roche Diagnostics GmbH, Mannheim, Germany). Primers and the UPL-probe were designed by 
ProbeFinder version 2.50 for Mouse (Roche Diagnostics; Primer Thy1s: TGCCGGTGTGTTGAGCTA; 
Thy1as: TGGTCCTGTGTTCATTGCTG; UPL 60; amplicon 73 bp). The genomic sequence of Nrg1 was 
used to calibrate for the amount of DNA (Primer Nrg1s: GGCTATAATGCTAACACAGTCCAA; Nrg1as: 
AGTGGATCGTAACAACACTGTCA; UPL 38; amplicon 61 bp) as described (Besser et al., 2015). 10 to 25 
ng of genomic DNA was subjected to qPCR amplification to measuring the amount of Thy1.2 on a 
Light Cycler 480 system (Roche Diagnostics GmbH, Mannheim, Germany) according to the 
manufacturer’s instructions. The copy number of the Thy1.2-ATeam1.03YEMK transgene was calculated 
using the ΔΔCt method compared to wild type mice carrying only the two endogenous allele of the 
Thy1 gene (Besser et al., 2015). This analysis was kindly performed by Grit Marx, Carl-Ludwig-Institute 
for Physiology, University of Leipzig. 
 
6.2.2 Analysis of the sensor expression pattern 
Adult mice were transcardially perfused with 4% formaldehyde solution (PFA, in phosphate 
buffered saline: 137mM NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.5mM KH2PO4, pH 7.4) under deep 
anesthesia. The brain and the eyes were removed and post-fixed for 24 h in the same fixative. 45μm 
thick sections were cut on a vibratome (Leica VT1000 S, Nussloch, Germany) and slices were mounted 
directly after cutting with Vectashield embedding medium (Vectashield HardSet™ Mounting 
Medium, Vector Laboratories, Burlingame, CA, USA). From the eyes retinal whole mounts were 
prepared.  
For imaging of fixed brain slices and retina, confocal images were acquired on a LSM Olympus 
IX71 inverted microscope using an UPlanFL 10x/0.3 objective (Olympus) for overview images (Figure 
3A-C, G) or an UApo/340 40x/1.35 oil objective (Olympus) for detailed images (Figure 3D-F, H), 
respectively. Microscopic images were acquired and processed using Olympus Software Fluoview 
v5.0. ATeam1.03YEMK sensor fluorescence was excited with a 488 nm argon laser and detected through 
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a BA 510-540 nm emission filter (AHF Analysentechnik AG, Tübingen, Germany). For all images, a 
Kalman filter of 2 was used for denoising and images were acquired with 1024 x 1024 resolution 
(pixel size for overview images: 0.9µm; pixel size for detail images: 0.35 µm). Z-stacks comprise 12-
38 singles z-planes for overview images and 30-85 z-planes for detailed images, respectively, with 
distances between each z-plane of 2 µm (overview), 0.5µm (Figure 3D-F) and 0.35µm (Figure 3H). 
Single z-stacks were converted to maximum intensity projections (by using Fiji macro “Flattening 
V2f.ijm”; generously provided by Jens Eilers) and for overview images maximum intensity projections 
of different positions (210 for Figure 3A; 154 for Figure 3B; 160 for Figure 3C; 49 for Figure 3G) were 
stitched by using Fiji software and a Fiji stitching plugin (Preibisch, Saalfeld, & Tomancak, 2009). This 
analysis was in part kindly performed by Dr. Ulrike Winkler, Carl-Ludwig-Institute for Physiology, 
University of Leipzig. 
 
6.2.3 Preparation of mouse genomic DNA 
DNA isolation for transgenic animal identification via PCR genotyping was performed using two 
different and interchangeable methods: 
 
1) NexttecTM Tissue & Cells kit-based genomic DNA isolation  
Nexttec™ Tissue & Cells kit was used to isolate DNA from tail or ear biopsies. Isolation was 
performed according to manufactures protocol. Biopsies were lysed in 300 μl lysis buffer (265 
μl buffer G1, 10 μl buffer G2, 25 μl buffer G3) by vigorous shaking for 60-120 min at 1200 rpm 
and 62 °C. Meanwhile, NexttecTM cleanPlate96 were equilibrated with 350 μl Prep buffer for 
5 min at RT and centrifuged for 1 min at 350 G. 120 μl of the lysates were loaded onto the 
columns and centrifuged at 750 G for 1 min into fresh tubes. Lysates were diluted 1:5 in 
ddH2O. 1 μl of the lysate was used in genotyping PCR reactions. 
2) Chloroform DNA extraction 
DNA was isolated from tail or ear biopsies using 400 μl of extraction buffer (0.5% SDS, 0.1 M 
NaCl, 0.05 M Tris (pH 8.0), 3 mM EDTA), added directly into each tube containing the biopsy. 
In addition, 75 μl of 8 M potassium acetate (sterile-filtered; pH not adjusted), and 400 μl 
chloroform were added. The solution was mixed by vortexing for approximately 10 s, until a 
cloudy appearance was obtained. Samples were then centrifuged (5415 D Eppendorf) for 
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10 min at 4 °C (750 G). 200 μl of the supernatant containing the genomic DNA were 
transferred to a new tube and precipitated chloroform waste was kept under fume cupboard 
and properly discarded. 400 μl 100% ethanol were added, and the samples were mixed by 
inverting the tubes. Subsequently, samples were centrifuged for 10 min at RT (maximum 
speed). The supernatant was completely removed and the pellets were air dried for 30-45 
min. Finally, 200 μl Tris buffer (10 mM Tris pH 8.0) were added to resuspend the DNA. Samples 
were vortexed and stored at 4 °C for further analysis. 
 
6.2.4 Genomic DNA analysis by PCR DNA-amplification 
Polymerase chain reaction (PCR) is a multi-step enzymatic amplification of a DNA sequence 
(template) of interest in vitro (Mullis et al., 1986). The reaction cycles through denaturation, 
annealing, and extension of the DNA template sequence using flanking primers, i.e. two short (18-
30 bp) single strand DNA sequences complementary to the 5’-3’ (sense) and 3’-5’ (antisense) regions 
upstream and downstream the sequence of interest. PCR reactions require a thermostable DNA 
polymerase, which is stable at the melting temperature of the double stranded DNA and has an 
optimal activity at around 72 °C. Standard PCR master mixes for genotyping were set up with RedTaq 
polymerase (Sigma) or GoTaq DNA polymerase (Promega) following manufacture’s specification. 
Specific primers for every mouse line were used. 
PCR master mix for RedTaq polymerase: 
 
1.00 μl DNA (100 pg-100 ng) 
0.10 μl sense primer (50 pM) 
0.10 μl antisense primer (50 pM) 
2.00 μl dNTP mix (2 mM) 
2.00 μl 10x RedTaq buffer 
0.80 μl RedTaq polymerase (1 U/μl) 
14.00 μl ddH2O 
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PCR master mix for GoTaq polymerase: 
 
1.00 μl DNA (100 pg-100 ng) 
0.10 μl sense primer (50 pM) 
0.10 μl antisense primer (50 pM) 
2.00 μl dNTP mix (2 mM) 
4.00 μl 5x GoTaq buffer 
0.15 μl GoTaq polymerase (5 U/μl) 
12.65 μl ddH2O 
 
6.2.5 Primers 
Primers were designed based on the template sequence information using the DNAStar™ 
LaserGene SeqBuilder software, and OligoAnalyzer 3.1 (http://eu.idtdna.com/calc/analyzer). 
Oligonucleotides were synthesized in-house at the AGCTlab (AGCTLab@em.mpg.de) of the Max-
Planck-Institute of Experimental Medicine.  
Sense primer for ThyAT:  
5’-TCTGAGTGGCAAAGGACCTTAGG-3’ 
Antisense primer for ThyAT: 
5’- CGCTGAACTTGTGGCCGTTTACG-3’  
Sense primer for PLP 
5’-TTG GCG GCG AAT GGG CTG AC-3’ 
Antisense primer #1 
5’-GGA GAG GAG GAG GGA AAC GAG-3’ 
Antisense primer #2  
5’-TCT GTT TTG CGG CTG ACT TTG-3’ 
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6.2.6 PCR programs for genotyping 
ThyAT: 
 95 °C 03:00 
{60 °C 00:30 
72 °C 00:30 
95 °C 00:30}35 
60 °C 00:30 
72 °C 05:00 
4 °C II 
[Expected bp product: 247bp].  
 
PLPKO: 
95 °C 03:00 
{56 °C 00:30 
72 °C 01:00 
95 °C 00:30}36 
56 °C 02:00 
72 °C 10:00 
4 °C II 
[Expected bp products: 300 bp (absence of PlpKO) and 150 bp (Plpwt). Heterozygote animals should 
be recognized by the presence of both products]. 
 
6.3 Ketogenic diet 
After one-off overnight food-restriction, the mice were fed ad libitum with fat-enriched diet 
(Ssniff Spezialdiäten GmbH: Ketogenic HF diet #E15149) for 30 days before the final ex-vivo 
experiment was performed. The high-fat food contained 79.2% Fat, 8.4% proteins, 4.4% ash 
(minerals), 4.3% fibers and 2.4% carbohydrates, carrying about 7.5 kcal/g, i.e. approximately 3.5 
kcal/g more than the normal chow. Control mice were kept on the regular high-carbohydrate food-
pellet and didn’t undergo starvation. 
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6.4 Blood measurement of glucose and ß-hydroxybutyrate 
To monitor the efficacy of ketogenic diet in enhancing blood ketone levels we withdrew blood 
samples from mice that were kept on ketogenic diet and control mice once a week for 4 weeks. After 
the mice were secured in a restrainer, the tail was wiped several times with 80% ethanol solution and 
their tail vein was punctured to obtain blood samples. Glucose and ß-hydroxybutyrate were 
measured from the blood sample, using Freestyle Precision blood sugar monitor (Abott Diabetes 
Care, Wiesbaden, Germany). BW of mice was also assessed at the same time of blood withdrawal. 
 
6.5 Mixed myelinating co-cultures 
The preparation was adapted from Thomson et al., 2006, Thomson et al., 2008. ThyAT mice 
were mated with C57BL6/N mice. Following confirmed-plugging procedure, defined as embryonic 
day 0.5 (E0.5), embryos were collected on embryonic day 13.5 (E13.5). The spinal cord was dissected 
and enzymatically dissociated by addition of 0.25% trypsin (Invitrogen). Enzymatic activity was 
stopped by further addition of plating medium (50% DMEM, 25% horse serum, 25% Hank's balanced 
salt solution without Ca2+, Mg2+) containing 2.5 μg/ml DNAse I (Sigma). Cells were then dissociated 
into cell suspension by triturating through 20- and 23-gauge needles and spun at 800 rpm for 5 min 
in 15 ml tubes. The pellet was resuspended in 1-2 ml of plating medium. Cells were initially plated at 
a density of 1.5 ∙ 104 cells/100 μl onto poly-L-lysine (in boric acid buffer, pH 8.4)-coated coverslips, 
which were then placed into a 35-mm Petri dish. The cells were left to adhere for 2–3 h in a humidified 
atmosphere of 5% CO2 at 37 °C, after this time 200 μl of differentiation medium was added. This 
medium contained DMEM (4.5 mg/l glucose), 10 mg/ml biotin, 0.5% hormone cocktail (1 mg/ml 
apotransferrin, 20 mM putrescine, 4 μM progesterone and 6 μM selenium), 50 nM hydrocortisone 
and 10 μg/ml insulin (all reagents from Sigma). Cultures were maintained by replacing half of the 
medium with fresh medium three times per week. After 12 d in culture, cells were fed with 
differentiation medium with reduced concentration of insulin (0.2 μg/ml). Cultures were maintained 
for 25 days and cells were imaged between day in vitro DIV 26 and DIV 28. 
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6.6 HeLa cell line culture 
For preliminary FLIM-imaging experiments, human cervical cancer cells (HeLa) were used. HeLa 
cells were kindly provided by Prof. Dr. Luis Pardo at MPI-EM as frozen stocks. Astrocytes were isolated 
by differential adhesion following dissociation from cerebral cortices of P0-2 rat pups as described 
previously (Barros et al., 2009; McCarthy and de Vellis, 1980). All cells were maintained at 37 ⁰C and 
7.5% CO2 in their respective culturing media based on Dulbecco’s modified Eagle’s medium (Gibco, 
DMEM 1 g/L glucose [HeLa] or 4.5 g/L glucose [astrocytes], without glutamine) and supplemented 
with 10% fetal bovine serum (Gibco), 1% L-glutamine (Gibco GlutaMAX), and 1% antibiotics 
(penicillin-streptomycin, Gibco). 
All cells were seeded at 2.0 ∙ 104. Depending on their density, HeLa cells and primary astrocyte 
were transfected, 24-72 hours after seeding, with (per coverslip/reaction): 530 ng AT1.03YEMK plasmid 
DNA, diluted in 53 µl Opti-MEM by using 1.6 µl of Lipofectamine 2000 transfection reagent 
(Invitrogen) . 
 
6.7 Optic nerve preparation and electrophysiological recordings 
For optic nerve experiments mice were used in an age of 8 to 12 weeks. Optic nerves were 
excised from decapitated mice, placed into an interface Brain/Tissue Slice (BTS) chamber system 
(#65-0073; Harvard apparatus) and continuously superfused with artificial cerebrospinal fluid (aCSF). 
The perfusion chamber was continuously aerated by a humidified gas mixture of carbogen (95% O2/ 
5% CO2) and experiments were performed at 37°C. The temperature in the chamber was maintained 
constant at 37 °C using a feedback-driven temperature controller (model TC-10, NPI electronic) 
connected to a temperature probe (TS-100-S; NPI electronic) inserted in the BTS incubation chamber.  
The signal from a custom-made recording suction electrode was sent to an headstage (Heka 
Elektronik) and subsequently amplified 200 or 500 times, low-pass filtered at 30 kHz (defined by the 
preamplifier), and acquired at 100 kHz using an HEKA EPC9 double-patch clamp amplifier (Heka 
Elektronik). The signal amplification was obtained using serial amplification, by the Ext 10-2F amplifier 
module (10 fold; NPI electronic) and by the low-noise voltage preamplifier SR560 (20-50 fold 
amplification; Stanford Research System). The reference channel was recorded by an aCSF-filled glass 
capillary next to the recording suction electrode, in contact with the bathing aCSF. All glass capillaries 
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were purchased at World Precision Instruments (1.5 mm, #1B150-6). The suction electrodes were 
prepared by manually bending the glass capillaries on a Bunsen burner flame to an approximate 
angle of 40°. The opening was then adjusted to optic-nerve diameter by melting and polishing the 
tip of the glass capillary on the flame. Finally, 0.25 mm chlorided silver-wire (WPI) was inserted in the 
suction electrodes and solder to a gold pin to be connected to the battery anode and cathode wires 
(stimulation) and to the headstage (recording). Both suction electrodes were stabilized using heat-
shrinking tubes and attached to the arms of two micromanipulators (Luigs & Neumann) that helped 
driving the electrodes to the optic nerve, laying inside the BTS incubation chamber. The optic nerve 
orientation in the suction electrodes followed the physiological sensory propagation, with the 
stimulated end being always at the proximal side (i.e. near retina) and the recorded end at the distal 
side (i.e. near the optic chiasm). The stimulating electrode, connected to the battery (Stimulus Isolator 
385; WPI), delivered a supramaximal stimulus of 0.75 mA to the nerve evoking compound action 
potentials (CAP). The recording electrode was connected to the EPC9 amplifier.  
The CAP, elicited by the maximum stimulation of 0.75 mA, was recorded at baseline stimulation 
frequency at 0.1 Hz. During HFS a burst-stimulation was applied, the burst consisted of 100 stimuli 
at the given frequency (16, 50 or 100 Hz), separated by 460 ms, during which the CAP response was 
recorded; HFS overall duration was kept constant at 150 seconds, independent of the frequency. 
RAMP stimulation consisted of 8 subsequent steps at 1, 4 (continuous), 7, 15, 25, 50, 75 and 100 
(burst-like) Hz stimulation for a total duration time of 7.8 min. CAP recovery from HFS and RAMP 
was monitored at 0.2 Hz for 7.5 min.  
 
6.8 Optic nerve imaging 
Live imaging of ThyAT and GO-ATeam optic nerves was performed using an up-right confocal 
laser scanning microscope (Zeiss LSM 510 META/NLO) equipped with an Argon laser and a 63x 
objective (Zeiss 63x IR-Achroplan 0.9 W). The objective was immersed into the aCSF superfusing the 
optic nerve. Theoretical optical sections of 1.7 μm over a total scanned area of 66.7 μm x 66.7 μm 
(512 x 512 pixels) of the optic nerve were obtained every 10.4 s in three channels for ThyAT. GO-
ATeam signal was acquired over a larger area of 133.3 μm x 133.3 μm (512 x 512 pixels)  For ThyAT 
the recorded channels are referred to as CFP (band pass 470-500 nm), FRET and YFP (long pass 530 
nm). CFP and FRET channels were obtained by collecting photons using two PMT-detectors upon 
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458 nm excitation. Acceptor (YFP) fluorescence was obtained by excitation at 514 nm. For GO-ATeam 
the three channels are referred to as GFP (band pass 500-550 nm), FRET and OGR (band pass 565-
615 nm). GFP and FRET channels were obtained after excitation at 488 nm and ORG following 
excitation at 543 nm. 
The two excitation-scan events are referred to as “tracks”. Track scan time was set at 1.3182 s 
for all experiment, as result of pixel dwell time equal to 2.5143 µs and two-line scan averaging.  
 
6.9 aCSF based solutions for optic nerve CAP/ ATP recording  
Optic nerves were superfused by aCSF containing (in mM): 124 NaCl, 3 KCl, 2 CaCl2, 2 MgSO4, 
1.25 NaH2PO4, and 23 NaHCO3. aCSF was continuously bubbled with carbogen (95% O2 / 5% CO2). 
aCSF control (or standard) solution is prepared with 10 mM glucose (Fluka BioChemika). Glucose was 
substituted with the appropriate energy substrates as indicated in each experiment. For glucose 
deprivation (GD), glucose was removed from the aCSF and substitute by sucrose (Merck Millipore) 
to maintain the correct osmolarity. For mitochondrial blockage (MB), aCSF containing 10 mM glucose 
was supplemented with 5 mM sodium azide (Merck Millipore). For the combination of MB + GD, 
glucose was substituted by sucrose and 5 mM sodium azide was added. For different  
For HFS, aCSF was supplemented with different substrates and/or concentration. Glucose was 
used at three concentrations: 10 mM, 3.3 mM and 2 mM, and to maintain osmolarity constant sucrose 
was added accordingly (e.g. for 3.3 mM glucose aCSF, 6.7 mM sucrose were added). L-lactate and 
pyruvate (Sigma-Adrich) were used at 10 mM. Inhibitors of lactate metabolism were added to a basal 
concentration of glucose of 3.3 mM: the MCT1 inhibitor AR-C155858 (Med Chem Express) was used 
at 10 μM and all solutions were adjusted for DMSO (in which AR-C155858 was dissolved); sodium D-
lactate (Sigma-Aldrich) was used at 20 mM in a low sodium (104 mM Na) aCSF control solution. In 
the HFS (16 Hz) stimulation using acetoacetate as energy substrate, glucose and sucrose (10 mM 
each, in the control solution) were replaced by 20 mM acetoacetate (sigma). For the ketone-body 
incubation the control solution had, in addition, 10 mM sucrose and was supplemented with 
glycogen phosphorolysis and debranching inhibitors 30 μM1,4-Dideoxy-1,4-imino-D-arabinitol 
hydrochloride (DAB, Sigma), 30 μM 1-Deoxynojirimycin Hydrochloride (DNJ, Santa Cruz Biotech). 
Glucose and sucrose (10 mM each) were then replaced by 20 mM B-Hydroxybutyrate (Sigma).  
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6.10 Coverslip preparation 
In order to fit cell preparation into the custom-made perfusion chamber for live-cell imaging, 
30 mm diameter coverslips (Thermo Fisher Scientific, #1.5; 0.17 ± 0.01 mm thickness) were used. To 
restrict the cell plating to the field of view of the chamber, the coverslips were endowed with a Ø 13 
mm silicone rings which reduced the plating surface to 132.73 mm2. Coverslips were treated with 
consecutive washes in nitric acid, distilled water and ethanol before the silicone rings were attached 
by negative vacuum pressure obtained by ethanol evaporation. Coverslips were successively 
autoclaved and coated with 10x poly-L-lysine in boric acid buffer before transfer into 35 mm petri 
dishes and usage. Cells were maintained in 250-300 µl of their respective culturing medium 
 
6.11 Solutions for ThyAT neuronal ATP imaging 
Primary ATeam1.03YEMK expressing neurons in mixed cultures from ThyAT E13.5 embryos were 
imaged between day 26th and day 28th. Cells were pre-incubated for about 30 minutes to allow 
adaptation to the imaging AP buffer medium (in mM): HEPES 20.0, CaCl2 1.8, MgCl2 1.0, KCl 5.4, NaCl 
110.0, Na2HPO4 0.8, glucose/lactate 20.0. For K
+ and Na+ stimulation NaCl and KCl components of 
the medium were changed to reach the reported concentrations (K+: 1 or 20 mM; Na+: 146.6 or 165.6 
mM). For glutamate stimulation 100 μM glutamate (Sigma) and 100 μM glycine (Sigma) were used. 
Ouabain (Sigma, 7.3 mg/mL in DMSO) was used to block Na/K ATPase at 100 μM and other solutions 
were consequently corrected for DMSO (1 μL per mL). Iodoacetic acid (AppliChem) was used as 
GAPDH inhibitor (i.e. glycolysis blocker (Schmidt & Dringen, 2009) at 1 mM. Azide (Merck) was used 
at 5 mM to inhibit ATP synthesis in the mitochondria (Bowler, Montgomery, Leslie, & Walker, 2006). 
  




Figure 34. Custom perfusion chamber for cell 
imaging.  
A thin volume of liquid constantly perfuses the 
cells by flowing between the bottom coverslip 
and the fixed coverslip on the chamber’s lid. 
The perfusion chamber is a closed system 




6.12 Solutions for FLIM calibration 
The cells were put into a custom-built perfusion chamber (figure 34) connected to a gravity 
flow perfusion system (model VC-3/VM-8, ALA Scientific) 24-36 hours after transfection. The 
culturing medium was exchanged with imaging medium (in mM): NaCl 91.171, NaHCO3 17.856, 
HEPES 20.000, KCl 5.366, MgSO4 0.811, NaH2PO4 0.906, Na2HPO4 0.227, CaCl2 1.800 30-60 min before 
each imaging session to allow cells to adapt to the medium. The pH of the imaging medium was 
adjusted using 5 M NaOH solution to 7.40 at room temperature. To achieve cell permeablization and 
ATP calibration, the following components were added to the imaging medium in different 
combination as specified in each calibration step: 6 µM digitonin/escin (Sigma-Aldrich), 5 mM azide 
(NaN3, Merck KGaA), 25 mM sucrose (Merck KGaA), 25 mM glucose (Merck KGaA) 250 µM ouabain 
(Sigma-Aldrich), and ATP (ATP Na2 Sigma-Aldrich, variable concentrations).  
 
6.13 FLIM imaging 
Images were taken with an upright 2-photon microscope (TriM Scope II, LaVision BioTec). For 
excitation of the fluorophores a Titanium:Sapphire tunable laser (Chameleon Vision II, Coherent) was 
used. The excitation wavelength was set at 840 nm and emitted photons were collected via a 20 X 
objective (W Plan-Apochromat 20x/ 1.0 DIC CG = 0.17 M27 75 mm, FWD = 1.7 mm; Zeiss #421452-
9880-000) using a band-pass filter 485/20 nm to monitor donor fluorescence only. Imaging was done 
at nominal laser intensity 1.8%, EOM 100%, unless otherwise noted. The laser has a pulse length of 
140 fs and a repetition rate of 78 MHz, which limits the duration of a single measurement to a 
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maximum of 12.8 µs. The actual measurement length is 11.95 ns. Images were taken a pixel dwell 
time of 9.21 ns. Line averaging of 3 was used.  
The emitted photons were directed by a silver mirror via the band-pass filter 485/20 to a 16 
channel PMT-array for time-correlated single-photon counting (TCSPC) (FLIM X16 TCSPC detector, 
LaVision BioTec). The FLIM detector has a total counting rate of 76 MHz with a dead time of 5.5 ns 
(per channel). The nominal temporal bin size in the histogram is 80 ps. The temporal resolution of 
the detector electronics was determined to be ∼ 110 ps (full-width half-maximum of IRF). The IRF 
was measured taking advantage of the second harmonic generation (SHG) phenomena through 
excitation at 840 nm of dextrose crystals (sugar cubes) in order to generate a very fast SHG signal, 
recorded at half-wavelength (BP filter 420/10 nm). The imaging parameters were kept constant in all 
other measurements (unless otherwise noted). In order to avoid pile-up effects, which are responsible 
for introducing artefactual shortening of the measured lifetime due to a combination of increased 
number of events (photons) happening during detector dead-time, we followed the manufacturer 
recommendation and kept the MAX count/ pixel dwell time ratio ≤ 35. Preliminary tests were 
performed with a Rhodamine-101 sample, in order to compare 𝛵 to the benchmark value of 4.0 ns 
(value measured at the LaVision setup was 3.9 ns). 
For ratiometry the mirror was replaced by a 495 nm beam splitter. The signal was directed onto 
two gallium arsenide phosphide photomultiplier tubes (GaAsP PMT) which recorded the YFP and CFP 
signals, respectively.  
All FLIM-imaging experiments were performed at room temperature, unless differently noted. 
 
6.14 In vivo imaging 
6.14.1 Anesthetisia and pain management during the postoperative phase 
For surgical procedure we used a completely reversible anesthesia (in German: 
Vollantagonisierbare Anästhesie or VAA). VAA combines three different drugs with some overlapping 
sedative effects, in the attempt to reduce undesired side effects: Medetomidine, Midazolam and 
Fentanyl (MMF; Fleischmann et al., 2016). Medetomidine is an α2-adrenoreceptor agonist, produces 
dose-dependent sedation and analgesia: the stimulation of α2-adrenoreceptor in the CNS leads to 
GABA release and decreased release of acetylcholine. The analgesic potency of medetomidine is 
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caused by an inhibition of the spinal nociceptive reflexivity. Midazolam is a member of the substance 
group of the benzodiazepines. It has an anxiolytic and relaxing effect, and it blocks convulsion. 
Fentanyl is a strong opioid agonist providing very potent but short analgesic effects. With the 
exception of metamizol, all anesthetics and drugs were prepared by mixing each active 
pharmaceutical ingredient (API) in sterile saline solution (i.e. excipient, 0.9% NaCl) to reach 1 ml of 
volume per 100 g of body weight (BW). After the BW of the mouse was assessed (typically between 
20-30 g), MMF was injected IP at 0.1 μl per 10 g. MMF was prepared according to the following 
scheme: 
 
API mg/ml stock dosage mg per 100 gr BW μl/ 100 g BW 
Fentanyl 0.05 0.005 100.000 
Midazolam 5 0.5 100.000 
Medetomidine 1 0.05 50.000 
0.9% NaCl   750.000 
 
MMF anesthesia can be antagonized by atipamezole and flumazenil (AF). Atipamezole 
displaces medetomidine from the α2-adrenoreceptor, thus antagonizing its effects. Similarly, 
flumazenil is a highly selective antagonists of GABAA receptors, and is used to reverse benzodiazepine 
(midazolam) effects. Finally, naloxone has an antagonistic effect on opioid receptors, it was 
prepared for mice that could show side effects due to fentanyl overdose (e.g. respiratory depression). 
AF was injected at 0.1 μl per 10 g of BW at the end of the surgical procedure. It was mixed as follows: 
  
API mg/ml stock dosage mg per 100 gr BW μl/ 100 g BW 
Atipamezole 5 0.25 50.000 
Flumazenil 0.1 0.05 500.000 
Naloxone 0.4 0.12 300.000 
0.9% NaCl  to 1 mL 450.000 
0.9% NaCl (Naloxone) to 1 mL 150.000 
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Buprenorphine is a partial opiate agonist, and was also administered to the mice at the end 
of the surgical procedure via IP injection to provide acute pain relief in the postop. Buprenorphine 
has a duration of action in the range of 24 hours. Buprenorphine was mixed as follows: 
 
API mg/ml stock dosage mg per 100 gr BW μl/ 100 g BW 
Buprenorphine 0.33 0.01 30.303 
0.9% NaCl   969.697 
 
Metamizol was given to the mice as pain killer for 3 days after the surgery. A solution 0.2 % 
glucose and 5 g/L of metamizol was prepared to replace the drinking water, as well as to soak the 
food-pellet into a petri dish positioned on the bottom of the cage. The solution in the water bottle 
and the food were replaced daily.  
 
API mg/ml stock 
dosage mg per 100 mL 
0.2% glc solution 
 
Metamizol 500 500 
1 mL in 99 mL of 11.2 
mM glc solution sterile 
 g ∙ mol-1 Concentration in dH2O g/L 
Glucose(H2O) 198.17 11.21 mM  2.2222 
 
The mice were kept on a moist tissue placed on top of a polyester heating foil (Conrad 
electronics) during the surgery and the temperature was monitored via a thermometer probe placed 
between the animal and the heated plate. To track the anesthesia, animal’s heart rate, breathing, 
arterial oxygen saturation and pulse distension were also monitored via the oximeter MouseOx Plus 
(Starr Life Sciences Corp.).  
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6.14.2 Surgery  
After IP injection with MMF the animal’s reflexes were tested via tail and paw pinch every 3-
5 minutes from the moment the animal fell asleep. After no reflex could be observed the animal was 
injected with 1 mL of saline solution IP. The mouse was shaved in the dorsal area and the skin was 
dabbed with paper-tissue soaked with 80% ethanol. The mouse’s vital parameter were continuously 
monitored via the oximeter after being transferred on a heated plate. After the incision, the muscles 
and the transverse ligaments were separated from the side of the three thoracic vertebrae T11-T13. 
Two steel clamps were then positioned on the side of the exposed vertebrae and T12 laminectomy 
was performed using a micro-drill (World Precision Instruments) equipped with a carbide spherical 
ball mill 0.5 mm diameter (#1/4 Circuitmedic). The steel top plate was then anchored to the side bars 
with steel screws. The hollow space between the spinal cord tissue and the top plate was filled with 
transparent silicone (Kwik-Sil, World Precision Instruments #600022). A 5 mm round coverslip 
(Thermofisher) was rapidly placed on top of the silicone to provide a flat imaging surface. The skin 
above and below the implant was sutured using non-absorbable silk (Silkam DS12, B. Braun 
#0762067). The steel implant was sealed to the skin using self-curing dental acrylic. At the end of the 
procedure the mouse was injected with AF and buprenorphine and placed in a new cage to recover 
and monitored for the following week. 
 
6.14.3 Imaging 
Imaging was performed at the upright 2-photon microscope (TriM Scope II, LaVision BioTec). 
Following MMF anesthesia the mice were placed on a custom holder which locks the steel implant 
on the top plate. The holder was transferred on a custom chamber heated via a self-adhesive 
polyester heating foil (Conrad Electronic) attached to a 12V power supply. The chamber was in turn 
locked on a custom stage that replaced the manufacturer’s one. The holder was adjusted on the z-
axis to position the mouse at the correct distance between the objective and the heated chamber. 
The holder was made to coarsely rotate around the x-axis and the y-axis to best position the implant 
in the center of the objective. Fine x-y movements were obtained by the motorized x-y table. The 
mouse body-core was lifted from the chamber and the front and rear limbs were fixed to the steel 
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holder via rubber bands to distribute the weight. The chamber was finally closed by three Plexiglas 
walls that helped to keep the heath confined around the animal.  
For excitation of the fluorophores a Titanium:Sapphire tunable laser (Chameleon Vision II, 
Coherent) was used. The excitation wavelength was set at 840 nm and emitted photons were 
collected via a 20X objective (W Plan-Apochromat 20x/ 1.0, FWD = 1.7 mm) and separated by their 
λ with a 495 nm beam splitter which reflected with a 45˚ angle the λ ≤ 495 nm. The separated light-
beam were then directed towards two gallium arsenide phosphide photomultiplier tubes (GaAsP 
PMTs) which recorded the YFP and CFP signals. CFP signal was further filtered by a CFP 485/20 BP 
filter positioned in front of the detector. Unless differently noted, images were acquired using a pixel 
size of 0.494 μm and dwell time of 9.29 μs.  
 
6.15 Data analysis  
6.15.1 CAP 
Optic nerve function was monitored quantitatively as the area under the supramaximal CAP. 
CAP responses were acquired using an HEKA EPC9 double-patch clamp amplifier (Heka Elektronik), 
following 200 or 500 fold amplification and low pass filtering at 30 KHz (defined in the preamplifier). 
All the waveforms were converted using the PatchMaster software (provided by the manufacturer) 
into ‘.mat’ format and loaded into a custom script where CAP area is calculated as the area under the 
waveform (AUW) and plotted against time (cf. appendix §1). The integration of AUW is done in a 
range of approximately 1.5 ms, defined by the beginning of the response (typically at 0.2 ms after 
the stimulus artifact) and by the lowest point that marked the end of the second peak of the curve, 
characteristic of the optic nerve evoked CAP. The CAP area is considered to be proportional to the 
total number of excited axons and represents a convenient and reliable means of monitoring optic 
nerve axon function (Saab et al., 2016; Stys, Ransom, & Waxman, 1991). Data were normalized to the 
mean obtained during the initial 15 min (defined as baseline, i.e. no experimental condition applied). 
Results from several nerves were pooled, averaged, and plotted against time. 
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6.15.2 ATP 
The relative amount of ATP in the optic nerve was calculated in two steps. Initially, the mean 
intensity of FRET and donor (CFP for ATeam1.03YEMK and GFP for GO-ATeam) channel were extracted 
from the imaging time-series (in Fiji-ImageJ) and the ratio F/C or F/G was calculated. All fibers visible 
in the field of view were included with in the analysis without any prior selection. The ratio (F/C or 
F/G) was then normalized to zero using the F/C or F/G value obtained by application of MB + GD at 
the end of each experiment, i.e. by depleting all axons from ATP. Furthermore, F/C and F/G values 
obtained during baseline recordings in 10 mM glucose at the beginning of each experiment were 
set to one. In order to separate the ATeam1.03YEMK signal of small and large caliber fibers a custom 
macro for FIJI was used (cf. appendix §2): the macro generates a processed time-series stack to first 
increase the intensity signal-to-noise by consecutively: multiply all the available channel, remove 
outliers, smooth and finally apply a gaussian-blur filtering. The newly generated time-series is then 
used to align all images using the ‘Register Virtual Stack Slices’ and ‘Transform Virtual Stack Slices’ 
FIJI plugins (ImageJ plugins are available at: http://imagej.net/Register_Virtual_Stack_Slices and 
http://imagej.net/Transform_Virtual_Stack_Slices). The registered stack is then thresholded based on 
the average stack-intensity and used as a mask to separate, in each channel, the large and small 
axons. Intensities are then calculated and imported in excel to further process the signals by 
calculating the FRET/CFP normalized ratio as described above.  
 
6.15.3 ATP & CAP parameters 
For GD, MB, Β-HB, HFS, RAMP and MB + GD conditions, m coefficients for the slope-
intercepts at the point of maximal change of the ATeam1.03YEMK signal were used to calculate the 
CAP and ATP rate per second, during the initial decay and the recovery following either reperfusion 
with aCSF containing 10 mM glucose or following return to baseline stimulation at 0.2 Hz. The time 
of the start of decay/recovery of the ATP and CAP curves were defined as the first time-point at which 
the slope-intercept of the signal was above a threshold value based on the standard deviation 
calculated at the baseline. For HFS, RAMP analysis three parameters were considered for both CAP 
and ATP: 1) the overall amplitude obtained by averaging the data at the time points within the last 
15 s of the stimulation 2) the rate of initial decay defined within the 45 seconds that followed the 
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beginning of the stimulation 3) the rate of recovery defined within the 60 seconds that followed the 




Single-time-point measurements were saved as .tif image stacks with the third axis 
representing TCSPC time: each stack contained 109 images, each representing single temporal bins 
that described the fluorescence decay. In order to subtract background, the third axis of each stack 
was squeezed (projected) into a 2D plane and then thresholded to remove background noise and 
high-intensity signals correlated to lifetime shortening due to pile-up. The thresholded stacks were 
converted to 8-bit masks of 0/255 value. For each given timepoint the 3D data containing TCSPC 
information, was multiplied by the corresponding mask. These operations were performed via a 
custom-made Fiji macro (cf. appendix §3-4). The background-cleared image stacks were finally 
uploaded into MATLAB® where we used a MATLAB script modified from that kindly provided by Dr. 
Ingo Gregor (Georg-August-Universität Göttingen, Enderlein group) which applies a deconvolution 
algorithm and was modified to iterate through the entire time-series and through several ROIs 
obtained and saved as x, y coordinates using ImageJ (cf. appendix §4). At each time point and for 
each ROI, the script applies a double-exponential decay scheme. The script outputs the amplitude-




∑ 𝐴𝑖 ∙ 𝜏𝑖
⁄  
and plotted against time.  
 
6.16 Western blot and quantification 
Optic nerve lysate preparation 
A total protein preparation of MCT1het optic nerves was prepared by homogenizing both 
optic nerves including the chiasma in 500 µl RIPA-buffer (150 mM NaCl, 50 mM Tris/HCl, pH 6.8, 1% 
[v/v] Triton X-100, 0.5% [w/v] sodiumdeoxycholate, 0.5% [w/v] SDS and Roche complete protease 
inhibitor (Roche)) using a Precellys 24 homogenizer (Bertin technologies) equipped with Soft tissue 
homogenizing CK14 tubes (Bertin technologies) by 3 cycles at 6500 rpm for 10 s with intermittent 
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cooling of the samples on ice. Debris was removed by centrifugation for 5 min at 17000 G at 4 °C 
and samples were frozen at -80 °C prior to analysis. Mice were analyzed at an age of eight weeks. 
Protein concentration was determined using the DC Protein assay (Biorad) according to the 
manufacturer’s instructions.  
Western blot analysis was kindly performed by Dr. Kathrin Kusch - Neurogenetics 
department, Max-Planck Institute for Experimental Medicine. 
 
6.16.1 Immunoblotting 
Immunoblotting was performed as described before (Werner et al., 2007). Briefly, 20µg 
protein sample in sample buffer containing 2%[w/v] LDS, 0.5%[v/v] Triton X-100 and 0.5%[w/v] 
sodiumdeoxycholate were separated on 12% polyacrylamide-SDS-gels in Laemmli-buffer. For 
immunoblotting, proteins were blotted onto polyvinylidene difluoride membranes (PVDF, Roche), 
blocked with 5% [w/v] skim milk in TBST (150mM NaCl, 10mM Tris/HCl, pH 7.4, 0.05%[v/v] Tween 20) 
and incubated with primary antibodies diluted in the same solution for 48h at 4°C. After washing 
with TBST, blots were incubated with horse radish peroxidase coupled secondary antibodies 
(Dianova), washed with TBST and developed by enhanced chemiluminescence (Western Lightning 
ECL, Perkin Elmer) using a luminescence imager (Intas). The antiserum specific for MCT1 was raised 
in rabbit using a synthetic peptide located at a conserved intracellular loop of MCT1 (SLC16a1; NH2-
CDANTDLIGGSPKGEKL-CONH2). Antibodies were purified by affinity chromatography to the 
immunizing peptide and used in a final concentration of 180 pg/ml. For quantification of MCT1 
amount, 16-bit tiff images obtained from the luminescence imager were analyzed in ImageJ by 
densitometry using the “gels” plugin. Signal intensities for MCT1 were normalized to mean signal 
intensity for MCT1 of the wild type samples. 
To determine equal protein loading, gels prepared with the same samples were stained with 
colloidal coomassie. Briefly, gels were fixed subsequent to electrophoresis in 50% [v/v] ethanol, 10% 
[v/v] acetic acid for 1h at room temperature, washed twice in distilled water for 15min and stained 
with colloidal coomassie (0.08% [w/v] Coomassie Brilliant Blue G250, 1.6% [v/v] ortho-phosphoric 
acid, 8% [w/v] ammonium sulfate, 20% [v/v] methanol] over night at room temperature. Gels were 
washed several times in distilled water and documented using a transmitted light scanner.  
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Immunoblot analysis was kindly performed by Dr. Kathrin Kusch - Neurogenetics department, 
Max-Planck Institute for Experimental Medicine. 
 
6.17 Electron microscopy 
PLPKO mice were sacrificed by cervical dislocation and their optic nerves carefully removed. The 
nerves were cut in half and placed in an aluminum specimen carrier submerged in a solution of 20% 
PVP (polyvinylpyrrolidone, MW = 10`000 from Sigma) in PBS. After adjusting the level of liquid in the 
carrier, a second carrier was placed on top as a lid. Then the complete assembly was immediately 
transferred into the high-pressure-freezer (HPM100, Leica, Vienna, Austria) and frozen with liquid 
nitrogen. Subsequent freeze-substitution was carried out using a Leica AFS II (Leica, Vienna, Austria) 
as follows: Samples were first kept in tannic acid (0.1% in acetone) at –90 °C for 100h, washed with 
acetone (4 x 30 min, –90 °C), and then transferred into OsO4 (EMS; 2% in acetone, -90 °C). The 
temperature was raised from –90 °C to –20 °C in increments of 5 °C/h, then kept unaltered at –20 °C 
for 16 hours, and then raised from –20 °C to +4 °C in increments of 10 °C/h. Then samples were 
washed with acetone (3 x 30 min at 4 °C), allowed to adjust to room temperature (1 hour), and finally 
transferred into Epon (Serva) (50% Epon in acetone for 3 hours, 90% Epon in acetone for 18 hours, 
100% Epon for 6 hours). The samples were placed in an embedding mold and polymerized (60 °C, 
24 hours). Ultrathin sections (50 nm) were cut using a Leica Ultracut S ultramicrotome (Leica, Vienna, 
Austria) and stained with an aqueous solution of 2% uranyl acetate (Merck, Darmstadt, Germany). 
The sections were viewed in a LEO EM 912AB electron microscope (Zeiss, Oberkochen, Germany) and 
pictures were taken with an on-axis 2048x2048-CCD-camera (TRS, Moorenweis, Germany).  
Transmission electron microscopy imaging was kindly performed by Dr. Wiebke Möbius - 
Neurogenetics department, Max-Planck Institute for Experimental Medicine. 
 
6.18 Presentation of data 
All data are presented either as mean ± SEM. or as stripe plots showing all data points and the 
mean (line within the plot). If not indicated otherwise in the figure legends, data was statistically 
evaluated using Welch’s t-test and assuming a normal distribution (* p<0.05; ** p<0.01; *** p<0.001). 
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6.19 Analysis scripts 
Scripts to analyze data were written in MATLAB® as well as in ImageJ (FIJI). The scripts were used 
to process and analyze the CAP (MATLAB, appendix §1), the ATeam1.03YEMK FRET-LSM imaging 
timeseries (ImageJ, appendix §2) and the FLIM data (ImageJ and MATLAB®, appendix §3-4). The 
MATLAB script to analyze FLIM data was modified from the one kindly provided by Dr. Ingo Gregor 
(Third Institute of Physics – Enderlein Lab). 
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7.1 Appendix §1 – MATLAB script for CAP processing and analysis  
The script processes .mat files generated in Patchmatster as exported waveforms-timeseries (from 
.dat raw data) 
 
clear all; clc  
[FileName,PathName] = uigetfile('*.mat','Select the MATLAB code file');  
S = load(fullfile(PathName,FileName)); 
    prompt={'Enter value for signal amplification used: '}; 
    name = 'Amplification';  
    defaultans = {'200'}; 
    amplif = inputdlg(prompt,name,[1 40],defaultans); 
    Mag = sprintf('%s*', amplif{:});  
    Mag = sscanf(Mag, '%f*');  
fig1=figure('Name','CAP waveforms',... 
    'Color', [0.99 0.99 0.99],... 
    'Position', [380 180 1280 720],... 
    'Units', 'pixels'); 
for f = fieldnames(S)' 
    i = S.(f{1}); 
    u = horzcat((i(:,1)-i(1,1))*1.00e+3,i(:,2).*(1000/Mag));  
    plot(u(:,1),u(:,2)); 
    hold on; 
end 
title('CAP'); 
xlabel('time [ms]');  
ylabel('\muV');  
datacursormode on; 
dcm_obj = datacursormode(gcf);  
set(dcm_obj,'Enable','on');  
disp('select range for offset with TWO datatips on the waveform, then press ENTER') 
pause; 
c_info = getCursorInfo(dcm_obj); 
    if length(c_info) == 2 
        offset = 
sort(vertcat(c_info(1).Position(1,1),c_info(2).Position(1,1)),'ascend')'; 
        off1 = offset(1,1); 
        off2 = offset(1,2); 
    else disp('WARNING!! not enough/too many datatips inserted: will assign default 
values 0.1 and 0.9 for offset'); 
        off1 = 0.1; 
        off2 = 0.9; 
        pause 
    end 
datacursormode off; 
hold off 
for f = fieldnames(S)' 
    i = S.(f{1}); 
    u = horzcat((i(:,1)-i(1,1))*1.00e+3,i(:,2).*(1000/Mag)); 
    r = horzcat(u(:,1),u(:,2)-mean(u(min(find(u(:,1)> 
off1&u(:,1)<off2)):max(find(u(:,1)>off1&u(:,1)<off2)),2))); 
    r(:,2) = sgolayfilt(r(:,2),4,23); 
    plot(r(:,1),r(:,2)); 
    hold on; 
end 
datacursormode on; 
dcm_obj = datacursormode(gcf);  
set(dcm_obj,'Enable','on');  
disp('select range for CAP Area Analysis, then press ENTER') 
pause; 




range = sort(vertcat(c_info2(1).Position(1,1),c_info2(2).Position(1,1)),'ascend')'; 
left = range(1,1); 
right = range(1,2); 
if c_info2(1).Position(1,1)>c_info2(2).Position(1,1); 
    xcap = c_info2(1).Target.XData; 
    ycap = c_info2(1).Target.YData; 
else 
    xcap = c_info2(2).Target.XData; 
    ycap = c_info2(2).Target.YData; 
end 
hold on 
xauc = [xcap(xcap>=left&xcap<right); xcap(xcap>=left&xcap<right); 
xcap(xcap>left&xcap<=right); xcap(xcap>left&xcap<=right)]; 
yauc = [zeros(1,length(xauc)); ycap(xcap>=left&xcap<right); ycap(xcap>left&xcap<=right); 
zeros(1,length(xauc))]; 




f = fieldnames(S)'; 
t0 = S.(char(f(1,1)))(1,1); 
h = 1; 
for f = fieldnames(S)'  
    i = S.(f{1});  
    x1=(i(:,1)-i(1,1)).*1000;   
    cap_time(h)=(i(1,1)-t0)/60;  
    y1=i(:,2).*(1000/Mag); 
    R.(f{1}) = horzcat(x1,y1); 
    cap_range=x1(x1>=left&x1<=right); 
    cap_area(h)=trapz(cap_range,y1(x1>=left&x1<=right)); 
    h = h+1; 
end 
dcm_obj = datacursormode(gcf);  
set(dcm_obj,'Enable','on');  
disp('select range for CAP amplitude-latency Analysis, then press ENTER') 
pause; 
c_info3 = getCursorInfo(dcm_obj); 
range0 = sort(vertcat(c_info3(1).Position(1,1),c_info3(2).Position(1,1)),'ascend')'; 
left0 = range0(1,1); 
right0 = range0(1,2); 
    if c_info3(1).Position(1,1)>c_info3(2).Position(1,1); 
        xcap0 = c_info3(1).Target.XData; 
        ycap0 = c_info3(1).Target.YData; 
    else 
        xcap0 = c_info3(2).Target.XData; 
        ycap0 = c_info3(2).Target.YData; 
    end 
h = 1; 
for f = fieldnames(R)' 
    i = R.(f{1});  
    x2=i(:,1);  
    y2=i(:,2); 
    cap_range=x2(x2>=left0&x2<=right0); 
    cap_amplitude(h)=max(y2(x2>=left0&x2<=right0)); 
    cap_latency(h)=mean(x2(y2==max(y2(x2>=left0&x2<=right0)))); 
    h = h+1; 
end 
xauc0 = [xcap0(xcap0>=left0&xcap0<right0); xcap0(xcap0>=left0&xcap0<right0); 
xcap0(xcap0>left0&xcap0<=right0); xcap0(xcap0>left0&xcap0<=right0)]; 
yauc0 = [zeros(1,length(xauc0)); ycap0(xcap0>=left0&xcap0<right0); 
ycap0(xcap0>left0&xcap0<=right0); zeros(1,length(xauc0))]; 
p0 = patch(xauc0,yauc0,[.1 1 .3],'FaceAlpha','.2','EdgeColor','none'); 
cap_time = cap_time'; 
cap_area = cap_area'; 
cap_amplitude = cap_amplitude'; 
cap_latency = cap_latency'; 
  
fig2=figure('Name','CAP Area',... 
    'Color', [0.99 0.99 0.99],... 
    'Position', [100 100 1280 720],... 
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    'LineWidth',.1,... 
    'MarkerEdgeColor',[1 0 0],... 
    'MarkerFaceColor',[.9 .3 .3]); 
sz =50; 
scatter(cap_time,cap_amplitude,sz,'filled','o',... 
    'LineWidth',.05,... 
    'MarkerEdgeColor',[0 1 1],... 
    'MarkerFaceColor',[.3 .9 .9]); 
sz =50; 
scatter(cap_time,cap_latency,sz,'filled','s',... 
    'LineWidth',.05,... 
    'MarkerEdgeColor',[1 0 1],... 
    'MarkerFaceColor',[.9 .3 .9]); 
dot_operator = char(8901); 
legend('CAP Area','CAP Amplitude','CAP Latency','Location','best') 
title('CAP Analysis'); 
xlabel('time [min]'); 
ylabel(strcat('\muV',dot_operator,'ms     ',' - ','     \muV    ',' - ','   ms')); 
file = strcat(PathName,strtok(FileName,'.'),'.xlsx'); 
strange = strcat(num2str(range(1,1)),'_ms_',num2str(range(1,2)),'_ms'); 








7.2 Appendix §2 – ImageJ Macro for FRET ATP analysis on ROI basis  
The script processes FRET data as .lsm hyperstacks (three channels, timeseries). ROIs are generated 
around large structures (large axons for ThyAT) and small structures (complementary-ROIs, small 
axons for ThyAT) 
 
function convert2NaN(filename) { 
 h = getHeight(); 
 w = getWidth();  
 for (n=1; n<=nSlices; n++) { 
  setSlice(n); 
  for (y = 0; y < h; y++){  
   for ( x = 0; x < w;  x++){  
    p = getPixel(x,y);  
     if (p == 0.0){ setPixel(x,y,NaN); }  
    }  
   } 
  } 
}; 
run("Set Measurements...", "mean redirect=None decimal=3"); 
path = File.openDialog("Select a File"); 
open(path); 
setLocation(1110, 10); 
dir = File.getParent(path)+"//"; 
fileName = File.getName(path); 
title = File.nameWithoutExtension;  
run("Split Channels"); 
Dialog.create("Substack range"); 
 setLocation(900,10);  




 Dialog.addNumber("end:", 650); 
 Dialog.show(); 
 img_start = Dialog.getNumber(); 
 img_end = Dialog.getNumber(); 
substack = "slices="+img_start+"-"+img_end; 
 
selectWindow("C1-"+fileName); 
 run("Make Substack...", substack); 
 rename("FRET_"+"("+substack+")"); 
 subdir1= dir + "/" + title + "_FRET//";  
 File.makeDirectory(subdir1);  
 run("Image Sequence... ", "format=TIFF save=["+subdir1+"]"); 
 close("C1-"+fileName); 
 run("Remove Outliers...", "radius=2 threshold=0 which=Bright stack"); 
 run("Remove Outliers...", "radius=2 threshold=0 which=Dark stack"); 
selectWindow("C2-"+fileName); 
 run("Make Substack...", substack); 
 rename("CFP_"+"("+substack+")"); 
 subdir2= dir + "/" + title + "_CFP//";  
 File.makeDirectory(subdir2);  
 run("Image Sequence... ", "format=TIFF save=["+subdir2+"]"); 
 close("C2-"+fileName); 
 run("Remove Outliers...", "radius=2 threshold=0 which=Bright stack"); 
 run("Remove Outliers...", "radius=2 threshold=0 which=Dark stack"); 
selectWindow("C3-"+fileName); 
 run("Make Substack...", substack); 
 rename("YFP_"+"("+substack+")"); 
 subdir3= dir + "/" + title + "_YFP//";  
 File.makeDirectory(subdir3);  
 run("Image Sequence... ", "format=TIFF save=["+subdir3+"]"); 
 close("C3-"+fileName) 
 run("Remove Outliers...", "radius=2 threshold=0 which=Bright stack"); 
 run("Remove Outliers...", "radius=2 threshold=0 which=Dark stack"); 
imageCalculator("Multiply create 32-bit stack", 
"FRET_"+"("+substack+")","CFP_"+"("+substack+")"); 
imageCalculator("Multiply create 32-bit stack", "Result of 
FRET_"+"("+substack+")","YFP_"+"("+substack+")"); 





  run("16-bit"); 
  run("Enhance Contrast", "saturated=1.90"); 
  run("Remove Outliers...", "radius=2 threshold=100 which=Bright stack"); 
  run("Remove Outliers...", "radius=2 threshold=1 which=Dark stack"); 
  run("Smooth", "stack"); 
  run("Despeckle", "stack"); 
  run("Gaussian Blur...", "sigma=2 stack"); 
  run("Remove Outliers...", "radius=5 threshold=1 which=Bright stack"); 
  run("Remove Outliers...", "radius=5 threshold=1 which=Bright stack"); 
  setMinAndMax(0, 1200); 
 subdir4= dir + "/" + title + "_stack4align//";  
 File.makeDirectory(subdir4);  
 run("Image Sequence... ", "format=TIFF save=["+subdir4+"]"); 
 close("stack4align_"+"("+substack+")"); 
 subdir5= dir + "/" + title + "_stackAligned//";  
 File.makeDirectory(subdir5); 
 subdir6= dir + "/" + title + "_Align_transform//"; 
 File.makeDirectory(subdir6); 
  run("Register Virtual Stack Slices", "source=["+subdir4+"] 
output=["+subdir5+"] feature=Rigid registration=[Translation          -- no deformation                      
] advanced shrinkage save initial_gaussian_blur=1.60 steps_per_scale_octave=4 
minimum_image_size=32 maximum_image_size=256 feature_descriptor_size=8 
feature_descriptor_orientation_bins=8 closest/next_closest_ratio=0.92 
maximal_alignment_error=16 inlier_ratio=0.05 feature_extraction_model=Rigid 
registration_model=[Translation          -- no deformation                      ] 
interpolate"); 
  close(getTitle()); 
  run("Image Sequence...", "open=["+subdir5+"] sort");  
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  run("Convert to Mask", "method=IsoData background=Dark calculate black"); 
  rename("8bit_large_fibers"); 
  run("Z Project...", "projection=[Max Intensity]"); 
   rename("Particles_ROIs"); 
    run("Analyze Particles...", "size=10-Infinity add"); 
    roiManager("Select All"); 
    roiManager("Combine"); 
    run("Make Inverse"); 
    roiManager("Add"); 
    selectWindow("Particles_ROIs"); 
    run("Select All"); 
    roiManager("Add"); 
   close(); 
  selectWindow("8bit_large_fibers"); 
  run("Divide...", "value=255 stack");  
   rename("MASK_large_fibers"); 
   MASK_large_fibers = getTitle() 
  run("Duplicate...", "duplicate");  
  run("Multiply...", "value=255 stack"); 
  run("Convert to Mask", "method=Default background=Light calculate black"); 
  run("Divide...", "value=255 stack"); 
   rename("MASK_small_fibers"); 
   MASK_small_fibers = getTitle() 
 subdir7= dir + "/" + title + "_FRET_aligned//";  
 File.makeDirectory(subdir7); 
 subdir8= dir + "/" + title + "_CFP_aligned//";  
 File.makeDirectory(subdir8); 
 subdir9= dir + "/" + title + "_YFP_aligned//";  
 File.makeDirectory(subdir9); 
 run("Transform Virtual Stack Slices", "source=["+subdir1+"] output=["+subdir7+"] 
transforms=["+subdir6+"]"); 
   close(getTitle()); 
   run("Image Sequence...", "open=["+subdir7+"] sort"); 
    FRET_align_stack = getTitle(); 
    imageCalculator("Multiply create 32-bit stack", 
FRET_align_stack, MASK_large_fibers); 
     convert2NaN(getTitle); 
      rename("FRET_large_fibers"); 
       nROIs = roiManager("count"); 
        for (n=0;n<nROIs;n++){ 
         roiManager("Select", n); 
         roiManager("Rename", 
"FRET_ROI_"+(n+1)); 
        } 
       roiManager("Select", nROIs-2); 
       roiManager("Rename", "FRET_remain_ROIs"); 
       roiManager("Select", nROIs-1); 
       roiManager("Rename", 
"FRET_All_large_fibers"); 
       roiManager("Select All"); 
       roiManager("Multi Measure"); 
       filename0 = subdir7 + "FRET_large_fibers"; 
      saveAs("Tiff", filename0); 
       roiManager("Show All with labels"); 
       roiManager("Select All"); 
       roiManager("Associate", "false"); 
       roiManager("Centered", "false"); 
       roiManager("UseNames", "true"); 
       run("Flatten", "slice"); 
       filename0ROI = subdir7 + "FRET_ROIs"; 
       saveAs("Tiff", filename0ROI); 
      close(); 
      close("FRET_large_fibers.tif"); 
      roiManager("Select All"); 
      roiManager("Save", filename0ROI+".zip"); 
    imageCalculator("Multiply create 32-bit stack", 
FRET_align_stack, MASK_small_fibers); 
     convert2NaN(getTitle); 
      rename("FRET_small_fibers"); 




      roiManager("Rename", "FRET_All_small_fibers"); 
      roiManager("multi-measure measure_all one 
append"); 
      filename1 = subdir7 + "FRET_small_fibers" 
      saveAs("Tiff", filename1); 
      close(); 
    close(FRET_align_stack); 
 run("Transform Virtual Stack Slices", "source=["+subdir2+"] output=["+subdir8+"] 
transforms=["+subdir6+"]"); 
   close(getTitle()); 
   run("Image Sequence...", "open=["+subdir8+"] sort"); 
    CFP_align_stack = getTitle() 
    imageCalculator("Multiply create 32-bit stack", 
CFP_align_stack, MASK_large_fibers); 
     convert2NaN(getTitle); 
      rename("CFP_large_fibers"); 
        for (n=0;n<nROIs;n++){ 
         roiManager("Select", n); 
         roiManager("Rename", 
"CFP_ROI_"+(n+1)); 
        } 
       roiManager("Select", nROIs-2); 
       roiManager("Rename", "CFP_remain_ROIs"); 
       roiManager("Select", nROIs-1); 
       roiManager("Rename", 
"CFP_All_large_fibers"); 
       roiManager("Select All"); 
       roiManager("multi-measure measure_all one 
append"); 
       filename2 = subdir8 + "CFP_large_fibers"; 
      saveAs("Tiff", filename2); 
       roiManager("Show All with labels"); 
       roiManager("Select All"); 
       roiManager("Associate", "false"); 
       roiManager("Centered", "false"); 
       roiManager("UseNames", "true"); 
       run("Flatten", "slice"); 
       filename2ROI = subdir8 + "CFP_ROIs"; 
       saveAs("Tiff", filename2ROI); 
      close(); 
      close("CFP_large_fibers.tif"); 
      roiManager("Select All"); 
      roiManager("Save", filename2ROI+".zip"); 
    imageCalculator("Multiply create 32-bit stack", 
CFP_align_stack, MASK_small_fibers); 
     convert2NaN(getTitle); 
      rename("CFP_small_fibers"); 
      roiManager("Select", nROIs-1); 
      roiManager("Rename", "CFP_All_small_fibers"); 
      roiManager("multi-measure measure_all one 
append"); 
      filename3 = subdir8 + "CFP_small_fibers" 
      saveAs("Tiff", filename3); 
      close(); 
    close(CFP_align_stack); 
 run("Transform Virtual Stack Slices", "source=["+subdir3+"] output=["+subdir9+"] 
transforms=["+subdir6+"]"); 
   close(getTitle()); 
   run("Image Sequence...", "open=["+subdir9+"] sort"); 
    YFP_align_stack = getTitle() 
    imageCalculator("Multiply create 32-bit stack", 
YFP_align_stack, MASK_large_fibers); 
     convert2NaN(getTitle); 
      rename("YFP_large_fibers"); 
        for (n=0;n<nROIs;n++){ 
         roiManager("Select", n); 
         roiManager("Rename", 
"YFP_ROI_"+(n+1)); 
        } 
       roiManager("Select", nROIs-2); 
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       roiManager("Rename", "YFP_remain_ROIs"); 
       roiManager("Select", nROIs-1); 
       roiManager("Rename", 
"YFP_All_large_fibers"); 
       roiManager("Select All"); 
       roiManager("multi-measure measure_all one 
append"); 
       filename4 = subdir9 + "YFP_large_fibers"; 
      saveAs("Tiff", filename4); 
       roiManager("Show All with labels"); 
       roiManager("Select All"); 
       roiManager("Associate", "false"); 
       roiManager("Centered", "false"); 
       roiManager("UseNames", "true"); 
       run("Flatten", "slice"); 
       filename4ROI = subdir9 + "YFP_ROIs"; 
       saveAs("Tiff", filename4ROI); 
      close(); 
      close("YFP_large_fibers.tif"); 
      roiManager("Select All"); 
      roiManager("Save", filename4ROI+".zip"); 
      
    imageCalculator("Multiply create 32-bit stack", 
YFP_align_stack, MASK_small_fibers); 
     convert2NaN(getTitle); 
      rename("YFP_small_fibers"); 
      roiManager("Select", nROIs-1); 
      roiManager("Rename", "YFP_All_small_fibers"); 
      roiManager("multi-measure measure_all one 
append"); 
      filename5 = subdir9 + "YFP_small_fibers" 
      saveAs("Tiff", filename5); 
      close(); 
    close(YFP_align_stack); 









7.3 Appendix §3 – ImageJ macro for initial processing of FLIM data 
The script processes FLIM data as .tif stacks separated by timepoint. 
 
function mask_FLIM(input, output1, output2, filename) { 
 run("Bio-Formats Windowless Importer", "open=["+input+"//"+filename+"]"); 
 run("Duplicate...", "duplicate"); 
 duplicateImg = getTitle(); 
     run("Convert to Mask", "method=Otsu background=Dark calculate black"); 
  run("Z Project...", "projection=[Max Intensity]"); 
  run("Despeckle"); 
  run("Remove Outliers...", "radius=1 threshold=0 which=Bright"); 
  run("Remove Outliers...", "radius=2 threshold=0 which=Dark"); 
  //....! 
    run("Divide...", "value=255"); 
 run("Save", "save=["+output1+filename+"]"); 
 mask = getTitle(); 
 imageCalculator("Multiply create 32-bit stack", duplicateImg, mask); 
 run("Save", "save=["+output2+filename+"]"); 
 run("Close All"); 
}; 




 run("Bio-Formats Windowless Importer", "open=["+input+"//"+filename+"]"); 
 h = getHeight(); 
 w = getWidth();  
 for (n=1; n<=nSlices; n++) { 
  setSlice(n); 
  for (y = 0; y < h; y++){  
   for ( x = 0; x < w;  x++){  
    p = getPixel(x,y);  
     if (p == 0.0){ setPixel(x,y,NaN); }  
    }  
   } 
  } 
 run("Save", "save=["+output+filename+"]"); 
 run("Close"); 
}; 
path = File.openDialog("Select a File"); 
 setLocation(1110, 10) 
 dir = File.getParent(path); 
 fileName = File.getName(path); 
 title = File.nameWithoutExtension; 
 list = getFileList(dir); 
  subdir1= dir + "/" + title + "_Mask//";  
  subdir2= dir + "/" + title + "_Results//"; 
  File.makeDirectory(subdir1);  
  File.makeDirectory(subdir2); 
for (k = 0; k < list.length; k++) { 
 mask_FLIM(dir, subdir1, subdir2, list[k]); 
} 
 
7.4 Appendix §4 – MATLAB script for FLIM analysis on ROI basis 
The script requires 1) system IRF, 2) a .csv file generated in ImageJ, containing the x-y coordinates of 
the ROI, 3) FLIM data as .tif stacks separated by timepoint. 
 
clear all; close all 
workdir = pwd; 
[name1,PathData] = uigetfile({'*.tif','tif-image'},'select reference FLIM stack and 
folder...'); 
[name2,PathIRF] = uigetfile({'*.tif','tif-image'},'Select IRF stack and folder...'); 
[name3,PathROI] = uigetfile({'*.csv','ROI'},'select ROI csv file generated in FIJI'); 
filename = strsplit(name1,'.'); 
t_res = 0.25; 
h = waitbar(0,'starting analysis...','Name','FLIM Analysis progress','Position',[20 30 
270 50],'Unit','pixels','Color','c'); 
filePattern = fullfile(PathData, '\*.*'); 
ImageFiles = dir(filePattern); 
ListOfImageNames = {}; 
    for Index = 1:length(ImageFiles) 
        baseFileName = ImageFiles(Index).name; 
        [folder, name, extension] = fileparts(baseFileName); 
        extension = upper(extension); 
        switch lower(extension) 
            case {'.tif'} 
                ListOfImageNames = [ListOfImageNames baseFileName]; 
        end 
    end 
im_info = imfinfo([PathData name1]); 
im_w = im_info(1).Width;  
im_h = im_info(1).Height;  
im_num = numel(im_info);  
filePattern2 = fullfile(PathROI, '\*.*'); 
AllFiles = dir(filePattern2); 
ListOfROINames = {}; 
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ROI_names = {}; 
    for Index = 1:length(AllFiles). 
        baseFileName = AllFiles(Index).name; 
        [folder, name, extension] = fileparts(baseFileName 
        extension = upper(extension); 
        switch lower(extension) 
            case {'.csv'} 
                ListOfROINames = [ListOfROINames baseFileName]; 
                ROI_names = [ROI_names name]; 
        end 
    end 
  
cd(PathROI); 
Mask_3D = zeros(im_w,im_h,length(ListOfROINames),'uint16'  
for iii = 1:length(ListOfROINames)  
    nameROI=char(ListOfROINames(iii)); 
    ROIxy = csvread(nameROI,1,1);  
    ROIx = ROIxy(:,2)+1; 
    ROIy = ROIxy(:,1)+1;  
    Mask = zeros(im_w, im_h, 1,'uint16'); 
    indexes = sub2ind([im_w, im_h], ROIx, ROIy 
    Mask(indexes) = 1; 
    Mask_3D(:,:,iii) = Mask; 
    figure('Name',ROI_names{iii},'NumberTitle','off');  
    imagesc(Mask_3D(:,:,iii))     
end 
  
for i = 1:length(ROI_names) 
    Amplitude_ext.(ROI_names{i}) = [];    
    Tau_ext.(ROI_names{i}) = []; 
    Tau_weight.(ROI_names{i}) = []; 
    Tau_mean_weight.(ROI_names{i}) = []; 
end 
  
im_info = imfinfo([PathIRF name2]); 
im_w = im_info(1).Width; 
im_h = im_info(1).Height; 
im_num = numel(im_info); 
  
IRF = zeros(im_w, im_h, im_num,'uint16'); 
for l = 1:im_num 
    IRF(:,:,l)=imread([PathIRF name2],'Index',l); 
end 
IRF  = squeeze(sum(sum(IRF))); 
nbin = numel(IRF); 
IRF = reshape(IRF,nbin,numel(IRF)/nbin); 
IRF = mean(IRF,2); 
T = 1e9/84e6;  
dt = T/nbin; 
tau = ((1:nbin)-0.5).*dt; 
figure_2 = figure; 




    name1=char(ListOfImageNames(ii)); 
    perc = round(ii/size(ListOfImageNames,2),2)*100; 
    waitbar(perc/100,h,sprintf('%d%% completed...',perc)) 
    if strcmp(name2,name1)==0 
  
    FLIMData = zeros(im_w, im_h, im_num,'uint16');  
        for l = 1:im_num 
            FLIMData(:,:,1)=imread([PathData name1],'Index',l);  
        end 
  
    for ri = 1:size(Mask_3D,3) 
        Mask_roi = Mask_3D(:,:,ri);  
        for mi = 1:size(FLIMData,3) 
            Data{ri}(:,:,mi) = FLIMData(:,:,mi).*Mask_roi;  




         
        Data = squeeze(sum(sum(Data{ri}))); 
        nbin = numel(Data); 
        T   = 1e9/84e6; 
        dt  = T/nbin; 
        tau = ((1:nbin)-0.5).*dt; 
  
        figure(figure_2); 
        hold on 
        semilogy(tau,Data,'x') 
  
        tau = [0.1 1]; 
        tau = tau(:)'/dt; 
        m   = numel(tau); 
        lim = [zeros(1,m) 10.*ones(1,m)]; 
        lim_min = lim(1:m)./dt; 
        lim_max = lim(m+1:end)./dt; 
        p   = nbin; 
        tp  = (1:p)'; 
        y = Data(:); 
        t = 1:numel(y); 
        c = 0; 
        x   = exp(-(tp-1)*(1./tau))*diag(1./(1-exp(-p./tau))); 
        irs = IRF(rem(rem(t-floor(c)-1, p)+p,p)+1); 
        z = Convol(irs, x); 
        z = [ones(size(z,1),1) z]; 
        A = lsqnonneg(z,y); 
        % close all 
        param = [c; tau']; 
        paramin = [-1/dt lim_min]; 
        paramax = [ 1/dt lim_max]; 
  
        tmp = param; 
        err = 0; 
        for casc=1:10 
            [ts, s] = min(err); 
            r0 = tmp(:, s); 
            for sub=1:10 
                rf = r0.*[(2.^(1.2*(rand(3,1)-0.5)./casc))]; 
                tmp(:,sub) = Simplex('lsfit', param, paramin, paramax, [], [], IRF(:), 
y(:), p); 
                c    = tmp(1,sub); 
                tau  = tmp(2:m,sub)'; 
                x    = exp(-(tp-1)*(1./tau))*diag(1./(1-exp(-p./tau))); 
                irs  = (1-c+floor(c))*IRF(rem(rem(t-floor(c)-1, p)+p,p)+1) + (c-
floor(c))*IRF(rem(rem(t-ceil(c)-1, p)+p,p)+1); 
                z = Convol(irs, x); 
                z = [ones(size(z,1),1) z]; 
                z = z./(ones(nbin,1)*sum(z)); 
                A = lsqnonneg(z,y); 
                z  = z*A; 
                err(sub) = sum((y-z).^2./abs(z))/(nbin-m); 
            end 
        end 
  
        param = mean(tmp(:,err==min(err)),2); 
  
        [param, dparam] = Simplex('lsfit', param, paramin, paramax, [], [], IRF(:), y(:), 
p); 
  
        c    = param(1); 
        dc   = dparam(1); 
        tau  = param(2:length(param))'; 
        dtau = dparam(2:length(param)); 
  
        x   = exp(-(tp-1)*(1./tau))*diag(1./(1-exp(-p./tau))); 
        irs = (1-c+floor(c))*IRF(rem(rem(t-floor(c)-1, p)+p,p)+1) + (c-
floor(c))*IRF(rem(rem(t-ceil(c)-1, p)+p,p)+1); 
        z = Convol(irs, x); 
        z = [ones(size(z,1),1) z]; 
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        z = z./(ones(nbin,1)*sum(z)); 
        A = lsqnonneg(z,y); 
        zz = z.*(ones(size(z,1),1)*A'); 
        z  = z*A; 
        dc = dt*dc; 
  
        chi = sum((y-z).^2./abs(z))/(nbin-m); 
  
        t   = dt*t; 
        tau = dt*tau'; 
        c   = dt*c; 
        offset = zz(1,1); 
        A(1) = []; 
         
        figure(counts_residuals); 
        hold on 
        subplot('position',[0.1 0.35 0.8 0.55]) 
        plot(t,log10(y),'+k') 
        plot(t,log10(irs),':b'); 
        plot(t,log10(z)); 
        v = axis; 
        v(1) = min(t); 
        v(2) = max(t); 
        axis(v); 
        xlabel('Time / ns'); 
        ylabel('Log Count'); 
        s = sprintf('COF = %3.3f   %3.3f', c, offset); 
        text(max(t)/2,v(4)-0.05*(v(4)-v(3)),s); 
        s = ['Amp = ']; 
        for i=1:length(A) 
            s = [s sprintf('%1.3f',A(i)/sum(A)) '   ']; 
        end 
        text(max(t)/2,v(4)-0.12*(v(4)-v(3)),s); 
        s = ['tau = ']; 
        for i=1:length(tau) 
            s = [s sprintf('%3.3f ns',tau(i)) '   ']; 
        end 
        text(max(t)/2,v(4)-0.19*(v(4)-v(3)),s); 
        subplot('position',[0.1 0.1 0.8 0.15]) 
        plot(t,(y-z)); 
        v = axis; 
        v(1) = min(t); 
        v(2) = max(t); 
  
        axis(v); 
        xlabel('time / ns'); 
        ylabel('residuals'); 
        s = sprintf('%3.3f', chi); 
        text(max(t)/2,v(4)-0.1*(v(4)-v(3)),['\chi^2 = ' s]); 
        set(gcf,'units','normalized','position',[0.01 0.05 0.98 0.83]) 
        clear Data; 
         
        Amplitude = A./sum(A); 
  
        Amplitude_ext.(ROI_names{ri}) = [Amplitude_ext.(ROI_names{ri}) Amplitude]; 
        Tau_ext.(ROI_names{ri}) = [Tau_ext.(ROI_names{ri}) tau]; 
  
    end  
    else 
        disp('IRF image not taken') 
    end  
end  
 
time = [0:t_res:(length(ListOfImageNames)-1)*t_res]'; 
  
for ji = 1:length(ROI_names) 
    Tau_weight.(ROI_names{ji}) = [Tau_weight.(ROI_names{ji}) 
Amplitude_ext.(ROI_names{ji}).*Tau_ext.(ROI_names{ji})]; 







Tau_AWLT = []; 
for ji = 1:length(ROI_names); 
    Tau_AWLT = [Tau_AWLT (Tau_mean_weight.(ROI_names{ji}))']; 
end 
  
figure_2 = figure('Name','Lifetime','NumberTitle','off','Color', [0.99 0.99 0.99],... 
    'Position', [100 100 1280 720],... 
    'Units', 'pixels'); 
    plot(time,Tau_AWLT) 
    title(strrep(filename{1},'_','\_')) 
    xlabel('time min'); ylabel('Lifetime nsec') 
    legend(ROI_names); legend('Location','best'); legend('boxoff'); 
    set(gca,'fontsize',12) 
     
Tau_AWLT = vertcat(ROI_names,num2cell(Tau_AWLT)); 





{ Function lsfit 
 
function err = lsfit(param, irf, y, p) 
 
n = length(irf); 
t = 1:n; 
tp = (1:p)'; 
c = param(1); 
tau = param(2:length(param)); tau = tau(:)'; 
x = exp(-(tp-1)*(1./tau))*diag(1./(1-exp(-p./tau))); 
irs = (1-c+floor(c))*irf(rem(rem(t-floor(c)-1, n)+n,n)+1) + (c-floor(c))*irf(rem(rem(t-
ceil(c)-1, n)+n,n)+1); 
z = Convol(irs, x); 
z = [ones(size(z,1),1) z]; 
A = lsqnonneg(z,y); 
z = z*A; 
  




{ Function Simplex 
 
function [x, dx, steps] = Simplex(fname, x, xmin, xmax, tol, steps, varargin) 
x = x(:); 
if nargin<5 
    tol = 1e-10; 
if nargin<4 
        xmax = Inf*ones(length(x),1); 
        if nargin<3 
            xmin = -Inf*ones(length(x),1); 
        end 
    end 
elseif isempty(tol) 
tol = 1e-5; 
end 
if nargin<6 
    steps = []; 
end 
if isempty(xmin)  
    xmin = -Inf*ones(size(x));  
end 
if isempty(xmax)  
    xmax = Inf*ones(size(x));  
end 
xmin = xmin(:); 
xmax = xmax(:); 
xmax(xmax<xmin) = xmin(xmax<xmin); 
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x(x<xmin) = xmin(x<xmin); 
x(x>xmax) = xmax(x>xmax); 
xfix = zeros(size(x)); 
tmp = xmin==xmax; 
xfix(tmp) = xmin(tmp); 
mask = diag(~tmp); 
mask(:, tmp) = []; 
x(tmp) = []; 
xmin(tmp) = []; 
xmax(tmp) = []; 
  
if isa(fname,'function_handle') 
    fun = fname; 
    evalstr = 'fun'; 
else 
    evalstr = fname; 
end 
evalstr = [evalstr, '(mask*x+xfix']; 
if nargin>6 
    evalstr = [evalstr, ',varargin{:}']; 
end 
evalstr = [evalstr, ')']; 
  
n = length(x); 
if n==0  
    x = xfix; 
    dx = zeros(size(xfix)); 
    steps = 0; 
    return 
end 
if isempty(steps) 
    steps = 200*n; 
end 
  
xin = x(:); 
%v = 0.9*xin; 
v = xin; 
v(v<xmin) = xmin(v<xmin); 
v(v>xmax) = xmax(v>xmax); 
x(:) = v; fv = eval(evalstr);  
for j = 1:n 
    y = xin; 
    if y(j) ~= 0 
        y(j) = (1 +.2*rand)*y(j); 
    else 
        y(j) = 0.2; 
    end 
    if y(j)>=xmax(j) 
        y(j) = xmax(j); 
    end 
    if y(j)<=xmin(j) 
        y(j) = xmin(j); 
    end 
    v = [v y]; 
    x(:) = y; f = eval(evalstr); 
    fv = [fv f]; 
end 
[fv, j] = sort(fv); 
v = v(:,j); 
count = n+1; 
  
% Parameter settings for Nelder-Meade 
alpha = 1; beta = 1/2; gamma = 2; 
  
% Begin of Nelder-Meade simplex algorithm 
while count < steps 
    if 2*abs(fv(n+1)-fv(1))/(abs(fv(1))+abs(fv(n+1))) <= tol 
        break 





    % Reflection: 
    vmean = mean(v(:, 1:n),2); 
    vr = (1 + alpha)*vmean - alpha*v(:, n+1); 
    x(:) = vr; 
    fr = eval(evalstr);  
    count = count + 1;  
    vk = vr; fk = fr; 
  
    if fr < fv(1) && all(xmin<=vr) && all(vr<=xmax) 
        % Expansion: 
        ve = gamma*vr + (1-gamma)*vmean; 
        x(:) = ve; 
        fe = eval(evalstr); 
        count = count + 1; 
        if fe < fv(1) && all(xmin<=ve) && all(ve<=xmax) 
            vk = ve; fk = fe; 
        end 
    else 
        vtmp = v(:,n+1); ftmp = fv(n+1); 
        if fr < ftmp && all(xmin<=vr) && all(vr<=xmax) 
            vtmp = vr; ftmp = fr; 
        end 
        % Contraction: 
        vc = beta*vtmp + (1-beta)*vmean; 
        x(:) = vc; 
        fc = eval(evalstr);  
        count = count + 1; 
        if fc < fv(n) && all(xmin<=vc) && all(vc<=xmax) 
            vk = vc; fk = fc; 
        else 
            % Shrinkage: 
            for j = 2:n 
                v(:, j) = (v(:, 1) + v(:, j))/2; 
                x(:) = v(:, j); 
                fv(j) = eval(evalstr);  
            end 
            count = count + n-1; 
            vk = (v(:, 1) + v(:, n+1))/2; 
            x(:) = vk; 
            fk = eval(evalstr);  
            count = count + 1; 
        end 
    end 
    v(:, n+1) = vk; 
    fv(n+1) = fk; 
    [fv, j] = sort(fv); 
    v = v(:,j); 
end 
  
x = v(:,1); 
dx = abs(v(:,n+1)-v(:,1)); 
x = mask*x + xfix; 
dx = mask*dx; 
if count>=steps 
    disp(['Warning: Maximum number of iterations (', int2str(steps),') has been 
exceeded']); 
else 
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